




(86) Date de dépôt PCT/PCT Filing Date: 2014/08/08
(87) Date publication PCT/PCT Publication Date: 2015/02/12
(45) Date de délivrance/Issue Date: 2017/08/29
(85) Entrée phase nationale/National Entry: 2016/02/02
(86) N° demande PCT/PCT Application No.: US 2014/050446
(87) N° publication PCT/PCT Publication No.: 2015/021448
(30) Priorité/Priority: 2013/08/08 (US61/863,888)

(51) Cl.Int./Int.Cl. *A61B 17/34* (2006.01),
A61M 5/178 (2006.01)
(72) Inventeurs/Inventors:
CABRERA AQUINO, JOSE GUSTAVO, MX;
SEGURA PACHECO, BIANCA ANGELICA, MX;
GERKEN, STEVEN, US;
MASTERSON, STEVEN, US
(73) Propriétaire/Owner:
GLOBAL BIO THERAPEUTICS, INC., US
(74) Agent: SMART & BIGGAR

(54) Titre : DISPOSITIF D'INJECTION POUR INTERVENTIONS PEU INVASIVES ET SES UTILISATIONS
(54) Title: INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF



(57) Abrégé/Abstract:

Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

12 February 2015 (12.02.2015)



WIPO | PCT



(10) International Publication Number

WO 2015/021448 A3

(51) International Patent Classification:

A61B 17/34 (2006.01) A61M 5/178 (2006.01)

(21) International Application Number:

PCT/US2014/050446

(22) International Filing Date:

8 August 2014 (08.08.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/863,888 8 August 2013 (08.08.2013) US

(71) Applicant: GLOBAL BIO THERAPEUTICS USA, INC. [US/US]; 4370 La Jolla Village Drive, Suite 400, San Diego, CA 92122 (US).

(72) Inventors: CABRERA AQUINO, Jose, Gustavo; Cerrada De Guadalajara No. 4 Casa 7, Del Thalpan, CP. 14260 (MX). SEGURA PACHECO, Blanca, Angelica; Retorno 8 De Fray Servando #10, Col. Jardin Balbuena, Mexico, D.F., C.P. 18900 (MX). GERKEN, Steven; 202 Lindsey Lane, Encinitas, CA 9024 (US). MASTERSON, Steven; 1350 Specialty Drive, Suite A, Vista, CA 92081 (US).

(74) Agents: SEIDMAN, Stephanie, L. et al.; Mckernna Long & Aldridge LLP, 4435 Eastgate Mall, Suite 400, San Diego, CA 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

21 May 2015

(54) Title: INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF




FIG. 1B

(57) Abstract: Provided herein is an injection device that can be used in minimally invasive procedures, such as laparoscopic surgeries, for direct administration of a fluid, such as a therapeutic, to a target tissue or organ.



WO 2015/021448 A3

51205-159

- 1 -

INJECTION DEVICE FOR MINIMALLY INVASIVE PROCEDURES AND USES THEREOF

RELATED APPLICATIONS

Benefit of priority is claimed to U.S. Provisional Application No. 61/863,888,
5 filed August 8, 2013, entitled "Injection Device for Minimally Invasive Procedures and Uses
Thereof."

This application is related to United States Patent Application Serial No. 14/455,865,
filed the same day herewith, entitled "Injection Device for Minimally Invasive Procedures and
Uses Thereof," which claims priority to U.S. Provisional Application No. 61/863,888.

10 This application is related to United States Patent Application Serial No. 14/455,871,
filed the same day herewith, and International PCT Application No. PCT/US2014/050441,
filed the same day herewith, each entitled "Clamp Device for Minimally Invasive Procedures
and Uses Thereof," both of which claim priority to U.S. provisional Application No.
61/863,903, filed August 8, 2013, entitled "Clamp Device for Minimally Invasive Procedures
15 and Uses Thereof."

This application also is related to U.S. Application Serial No. 13/815,206, filed
February 7, 2013, and International PCT Application No. PCT/US13/25234, filed February 7,
2013, each entitled "Compartmentalized Method of Nucleic Acid Delivery and Compositions
and Uses Thereof," both of which claim priority to U.S. Provisional Application Serial No.
20 61/633,287, filed February 7, 2012, entitled "Compartmentalized Method of Nucleic Acid
Delivery and Compositions and Uses Thereof."

FIELD OF THE INVENTION

Provided herein is an injection device that can be used in minimally invasive
25 procedures, including surgeries such as laparoscopic surgeries, for direct administration of a
fluid, such as a therapeutic, to a target tissue or organ.

- 2 -

BACKGROUND

Many medical procedures, including minimally invasive procedures, can require direct injection of a fluid, such as a therapeutic, to a target tissue. Such procedures can require that the needle is inserted through a port at a distance far from the operator. This can create safety concerns, since it can be easy to puncture non-target tissues and/or to inadvertently puncture or pierce through tissues or organs with the needle. Thus, there is a need for injection devices that can be used in minimally invasive procedures that overcome these problems.

REFERENCE NUMERALS LIST

The following list indicates the terms used and the corresponding reference numerals. Reference to each should be made with respect to the description below and the accompanying Drawings.

60, 60' or 60'' – laparoscopic injection device

71 or 71' – needle sheath controller

710 – needle sheath controller housing

711 – positioner

711a – positioner – forward position

711b – positioner – intermediate position

711c – positioner – rearward position

712 – lock and release element

713 – connection member

715 – distal sheath stop

716 – proximal sheath stop

717 – controller lumen

72, 72' or 72'' – needle sheath

72a – needle sheath – sheathed position

72b – needle sheath – transitional position

72c – needle sheath – unsheathed position

720 – proximal portion of the needle sheath

723 – needle sheath lumen

724 – visibility window

725 – visibility window

- 3 -

- 726 – open cavity
- 73 or 73' – needle sheath distal tip
- 733 – needle channel
- 76 – needle groove
- 5 81 – injection needle
- 82 – coupling member
- 83 – injection tube
- 84 – needle hub
- 85 – needle coupler
- 10 900a – standard syringe – detached position
- 900b – standard syringe – connected position
- 910 – dockable syringe
- 910a – dockable syringe – undocked position
- 910b – dockable syringe – docked position
- 15 91, 91' or 91'' – syringe barrel
- 92, 92' or 92'' – plunger
- 920 – auxiliary plunger
- 93 – Luer fit adaptor
- 94 – syringe barrel base
- 20 95 or 95' – plunger head
- 951 – plunger adaptor
- 96 – syringe adaptor lining
- 960 – plunger rest cavity
- 961 – barrel dock
- 25 962 – barrel rest cavity
- 963 – barrel dock

SUMMARY

- Provided herein are injection devices used for direct injection of a fluid, such
- 30 as a therapeutic, to a target site of a subject, such as a target tissue or organ. The injection device can be used in minimally invasive procedures, such as surgeries and other procedures, for example in laparoscopic surgery. Also provided herein is a

- 4 -

method and uses to use the injection devices, including in medical applications to treat diseases and conditions. As provided herein, the injection device includes a) a syringe barrel, in which the syringe barrel provides a fluid reservoir; b) a plunger configured to be controlled by the operator of the device and to move within the syringe barrel for loading and releasing fluid from the fluid reservoir in the syringe barrel; c) an injection needle that is operably coupled to the syringe barrel providing a fluid pathway for fluid contained in the syringe barrel to be injected into a target tissue when the plunger is depressed; d) an elongate sheath, which includes an internal lumen that contains the injection needle and having a distal tip that contains an opening for the injection needle, in which the sheath is movable around the injection needle; and e) a controller for positioning the sheath, which includes a housing, including at least a first and second stop to control exposure of the injection needle and that are provided within the housing at a predetermined distance from each other; a central lumen in the housing including a connection member, in which the connection member is configured to be movable in the central lumen in the housing and is coupled to the sheath, in which the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath; and a positioner mounted within the housing configured to move forward towards the distal end of the controller and rearward towards the proximal end of the controller, between the stops in the housing, in which the positioner is operatively connected to the connection member to guide movement of the connection member in the same direction, whereby movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose the injection needle inside the lumen of the sheath, and movement of the positioner rearward towards the proximal end engages the second stop and moves the sheath to expose no more than a predetermined length of the distal tip of the injection needle through the opening in the injection needle for injection into the tissue.

In examples of any of the injection devices herein, the elongate sheath has a sufficient length and width to reach an organ through an endoscopic port. For example, the elongate sheath generally has a length from its proximal to distal end of from or from about 200 mm to 600 mm and a diameter of from or from about 2 mm to 15 mm, and typically a length from its proximal to distal end of from or from about

- 5 -

250 to 400 mm and a diameter of 4 mm to 12 mm. For example, the elongate sheath has a length from its proximal to distal end of at least or about at least 300 mm and a diameter of at least or about at least 5 mm, 6 mm, 7 mm, 8 mm, 9 mm or 10 mm.

In examples of any of the injection devices herein, the predetermined length of the distal tip of the injection needle is generally 1 mm to 10 mm, 2 mm to 8 mm, 4 mm to 6 mm or 2 mm to 3 mm, and typically less than 10 mm, 9 mm, 8 mm, 7 mm, 6 mm, 5 mm, 4 mm, 3 mm, 2 mm or less. For example, the predetermined length is less than 5 mm.

In examples of any of the injection devices herein, the injection device can include at least 3 stops, 4 stops or 5 stops, in which the second stop is the most proximal stop and the first stop is the most distal stop and the other stop or stops are positioned between the first stop and the second stop; and each stop is positioned at a predetermined distance from adjacent stop or stops to control exposure of the needle to different predetermined lengths, in which the second stop controls exposure of the needle its longest predetermined length, whereby the positioner can move between the adjacent stops to engage with the stop to expose different predetermined lengths of the injection needle. Generally, the predetermined distance between stops is substantially the same as the predetermined length of the exposed injection needle.

In examples of any of the injection devices herein, the positioner can include a lock and release element that is configured in the positioner to engage the positioner with the stops. Typically, the lock and release element is a spring that provides an upward force against the positioner and a downward force against the connection member to lock the positioner into the stop, and is capable of being compressed to release the positioner from the stop.

In examples of any of the injection devices herein, the injection needle typically is 5 mm to 40 mm in length, and 25 gauge to 34 gauge, 25 gauge to 30 gauge or 26 gauge to 28 gauge. For example, injection needle is or is about 27 gauge.

In examples of any of the injection devices herein, the syringe barrel can be either proximal or distal to the controller.

In particular examples of the injection devices provided herein, the syringe barrel is proximal to the controller and is operably coupled to the injection needle by an injection tube, in which: the injection tube includes a proximal and a distal end, in

- 6 -

which the proximal end is connected to the syringe barrel and the distal end connected to the injection needle; and the controller is configured to hold the injection tube and includes an opening at the proximal end so that the injection tube extends out of the controller to connect to the syringe barrel. In particular examples, the syringe barrel is
5 configured to be connected to the injection tube so that the syringe barrel is detachable from the device. The syringe barrel can be connected to the injection tube, which includes a hub on its proximal end that is compatible with an adaptor on the distal end of the syringe barrel, and the hub of the injection tube connects to the adaptor of the syringe barrel.

10 In particular examples herein, the injection tube is fixed in the controller; the connection member in the controller includes a recess by which the injection tube is routed to pass from the controller into the sheath at the junction where the connection member is coupled to the sheath; and the connection member is movable around the injection tube. In some examples, the injection tube is connected directly to the
15 injection needle. In other examples, the injection tube is connected indirectly to the injection needle via a coupler, the coupler having a proximal and distal end, the proximal end connected to the distal end of the injection tube and the distal end connected to the proximal end of the injection needle. The injection tube and injection needle can be the same gauge or a different gauges. In particular examples provided
20 herein, the injection tube has a larger outer diameter than the injection needle; the injection needle can be 25 gauge to 34 gauge, 25 gauge to 30 gauge or 26 gauge to 28 gauge; and the injection tube can be 15 gauge to 25 gauge or 20 gauge to 25 gauge. For example, the injection needle is or is about 27 gauge and the injection tube is or is about 21 gauge.

25 In examples of any of the injection devices herein, the sheath can be opaque or transparent. In some examples of the injection devices provided herein, the coupler is opaque or transparent. In particular examples, the sheath is opaque; the coupler is transparent; and the sheath includes a window configured in the sheath to view the coupler.

30 In examples of any of the injection devices herein, the injection device can include a) a syringe barrel, in which the syringe barrel provides a fluid reservoir; b) a plunger configured to be controlled by the operator of the device and to move within

- 7 -

the syringe barrel for loading and releasing fluid from the fluid reservoir in the syringe barrel; c) an injection needle that is operably coupled to the syringe barrel providing a fluid pathway for fluid contained in the syringe barrel to be injected into a target tissue when the plunger is depressed, in which: the injection needle is operably

5 coupled to the syringe barrel by an injection tube, the injection tube includes a proximal and a distal end, the proximal end connected to the syringe barrel and the distal end directly or indirectly connected to the injection needle; the injection needle is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm; and the injection tube has a larger diameter than the injection needle that is has a smaller

10 diameter than 25 gauge and is connected to the syringe barrel; d) an elongate sheath, which includes an internal lumen that contains the injection tube and injection needle and having a distal tip that contains an opening for the injection needle, in which the sheath is movable around the injection needle; and e) a controller for positioning the sheath, in which the controller is distal to the syringe barrel and plunger and which

15 includes: a housing, including at least a first and second stop to control exposure of the injection needle and that are provided within the housing at a predetermined distance from each other; a cavity for the injection tube and an opening at the proximal end so that the injection tube extends out of the controller to connect to the syringe barrel, in which the injection tube is fixed in the controller; a central lumen in

20 the housing which includes a connection member, in which: the connection member in the controller includes a recess by which the injection tube is routed to pass from the controller into the distal lumen of the sheath at the junction where the connection member is coupled to the sheath; the connection member is configured to be movable in the central lumen in the housing around the injection tube and is coupled to the

25 sheath, in which the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath; and a positioner mounted within the housing configured to move forward towards the distal end of the controller and rearward towards the proximal end of the controller, between the stops in the housing, in which the positioner is

30 operatively connected to the connection member to guide movement of the connection member in the same direction, whereby movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose

- 8 -

the injection needle inside the lumen of the sheath, and movement of the positioner rearward towards the proximal end engages the second stop and moves the sheath to expose no more than a predetermined length of the distal tip of the injection needle through the opening in the injection needle for injection into the tissue

5 In some examples provided herein, the total length of the injection tube and injection needle is as long as the controller and sheath. For example, the total length of the injection tube and injection needle can be 100 mm to 600 mm or 200 mm to 400 mm.

10 In some examples of the injection device provided herein, the syringe barrel is positioned distal to the controller and the internal lumen of the sheath includes the syringe barrel in its distal end; and the syringe barrel is configured in the lumen so that the sheath is movable around the syringe barrel. In particular examples, the sheath encloses the syringe barrel. In particular examples, the sheath can include a window to view the syringe barrel. In particular examples, the sheath includes an
15 open cavity that includes the syringe barrel, where the open cavity of the sheath includes a lining that is configured in the sheath so that the sheath is movable around the lining; and the syringe barrel is mounted into the lining in the open cavity. In some examples, the open cavity extends the length of the sheath. The sheath can be enclosed at its proximal end and provides a conduit for the plunger and the open
20 cavity is present at the distal end of the sheath.

 In some examples provided herein, the plunger is extended to engage with the syringe barrel in the distal end of the lumen of the sheath and arranged so that the plunger is movable through the controller and within the lumen of the sheath.

25 In some examples provided herein, the plunger is longer than the sheath and has a length that is from or from about 100 mm to 600 mm or 200 mm to 500 mm.

 In some examples provided herein, the plunger is operably connected to an auxiliary plunger provided in the lumen of the sheath; and the plunger is extended to engage with the auxiliary plunger in the lumen of the sheath and arranged so that the plunger is movable through the controller and sheath and the auxiliary plunger is
30 movable through the sheath and configured to move within the syringe barrel, whereby depressing the plunger depresses the auxiliary plunger into the syringe barrel releasing fluid from the fluid reservoir in the syringe barrel and pulling back on the

- 9 -

plunger pulls back on the auxiliary plunger to load fluid into the fluid reservoir in the syringe barrel. In particular examples, the plunger includes an adaptor at its distal end to connect to the proximal end of the auxiliary plunger. The sheath can include an open cavity which includes a detachable syringe; and the detachable syringe includes the syringe barrel, the auxiliary plunger having a distal end configured to be movable in the syringe barrel and a proximal end coupled to the plunger, and the injection needle that is operably coupled to the syringe. The open cavity of the sheath can include a lining that is configured in the sheath so that the sheath is movable around the lining; and the detachable syringe is mounted into the lining in the open cavity. In particular examples, the controller is configured to hold the plunger so that the plunger is movable within the controller, and the controller that includes: an opening at its proximal end to receive the plunger; and a recess in the connection member of the controller by which the plunger is routed to pass from the controller into the lumen of the sheath at the junction where the connection member is coupled to the sheath, in which the plunger and connection member move independently with respect to each other.

In some examples provided herein, the injection device includes a) a syringe barrel, in which the syringe barrel provides a fluid reservoir; b) an extended plunger configured to be controlled by the operator of the device and coupled to an auxiliary plunger to move within the syringe barrel for loading and releasing fluid from the fluid reservoir in the syringe barrel, whereby depressing the plunger depresses the auxiliary plunger into the syringe barrel releasing fluid from the fluid reservoir in the syringe barrel and pulling back on the plunger pulls back on the auxiliary plunger to load fluid into the fluid reservoir in the syringe barrel; c) an injection needle that is operably coupled to the syringe barrel providing a fluid pathway for fluid contained in the syringe barrel to be injected into a target tissue when the plunger is depressed, in which the injection needle is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm; d) an elongate sheath, which includes an internal lumen that contains the plunger, the auxiliary plunger, the syringe barrel and the injection needle and having a distal tip that contains an opening for the injection needle, in which: the sheath is enclosed at its proximal end and provides a conduit for the plunger, in which the plunger is movable through the sheath; the sheath includes an open cavity at the

- 10 -

distal end, the open cavity which includes the auxiliary plunger, syringe barrel and injection needle, in which: the open cavity of the sheath includes a lining that is configured in the sheath so that the sheath is movable around the lining; the auxiliary plunger, syringe barrel and injection needle are mounted into the lining in the open cavity; and the auxiliary plunger, syringe barrel and injection needle are detachable as a unit from the open cavity; the sheath is movable around the plunger, auxiliary plunger, syringe barrel and injection needle; and e) a controller for positioning the sheath, which includes: a housing, including at least a first and second stop to control exposure of the injection needle and that are provided within the housing at a predetermined distance from each other; an opening at its proximal end to receive the plunger and which includes a cavity configured to hold the plunger so that the plunger is movable within the controller; a central lumen in the housing including a connection member, in which: the connection member includes a recess by which the plunger is routed to pass from the controller into the distal lumen of the sheath at the junction where the connection member is coupled to the sheath, in which the plunger and connection member move independently with respect to each other; the connection member is configured to be movable in the central lumen in the housing and is coupled to the sheath, in which the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath; and a positioner mounted within the housing configured to move forward towards the distal end of the controller and rearward towards the proximal end of the controller, between the stops in the housing, in which the positioner is operatively connected to the connection member to guide movement of the connection member in the same direction, whereby movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose the injection needle inside the lumen of the sheath, and movement of the positioner rearward towards the proximal end engages the second stop and moves the sheath to expose no more than a predetermined length of the distal tip of the injection needle through the opening in the injection needle for injection into the tissue.

30 In some examples provided herein, the injection device includes a) a syringe barrel, in which the syringe barrel provides a fluid reservoir; b) an extended plunger configured to be controlled by the operator of the device to move within the syringe

- 11 -

barrel for loading and releasing fluid from the fluid reservoir in the syringe barrel; c) an injection needle that is operably coupled to the syringe barrel providing a fluid pathway for fluid contained in the syringe barrel to be injected into a target tissue when the plunger is depressed, in which the injection needle is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm; d) an elongate sheath, which includes an internal lumen that contains the plunger, the syringe barrel and the injection needle and having a distal tip that contains an opening for the injection needle, in which: the sheath is enclosed to provide a conduit for the plunger, in which the plunger is movable through the sheath; the sheath includes an a window to view the syringe barrel; the sheath is movable around the plunger, syringe barrel and injection needle; and e) a controller for positioning the sheath, which includes: a housing, including at least a first and second stop to control exposure of the injection needle and that are provided within the housing at a predetermined distance from each other; an opening at its proximal end to receive the plunger and including a cavity configured to hold the plunger so that the plunger is movable within the controller; a central lumen in the housing including a connection member, in which: the connection member includes a recess by which the plunger is routed to pass from the controller into the distal lumen of the sheath at the junction where the connection member is coupled to the sheath, in which the plunger and connection member move independently with respect to each other; the connection member is configured to be movable in the central lumen in the housing and is coupled to the sheath, in which the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath; and a positioner mounted within the housing configured to move forward towards the distal end of the controller and rearward towards the proximal end of the controller, between the stops in the housing, in which the positioner is operatively connected to the connection member to guide movement of the connection member in the same direction, whereby movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose the injection needle inside the lumen of the sheath, and movement of the positioner rearward towards the proximal end engages the second stop and moves the sheath to expose no more than a

- 12 -

predetermined length of the distal tip of the injection needle through the opening in the injection needle for injection into the tissue.

In examples of any of the injection devices herein, the syringe barrel can be transparent and configured to hold 0.2 mL to 10 mL of fluid, 0.5 mL to 5 mL of fluid
5 or 0.5 to 2 mL of fluid. For example, the syringe barrel holds at least or about at least or about 1 mL of fluid. The syringe barrel can be disposable or is re-usable.

In examples of any of the injection devices herein, the device can be disposable or is re-usable. The device is for delivering a therapeutic to an organ or tissue. The therapeutic can be a biologic, chemotherapeutic or gene therapy agent. For
10 example, the therapeutic is a small molecule drug, prodrug, protein, peptide, DNA, RNA, virus, antibody, organic molecule, saccharide, polysaccharide, lipid and combinations or conjugates thereof.

Also provided herein is a method of directly administering a fluid to a tissue or an organ in a subject during a minimally invasive procedure, which includes: inserting
15 any of the injection devices provided herein into a port or cannula configured to provide access to the tissue or organ during the minimally invasive procedure; and depressing the plunger to inject the fluid into the tissue. Methods provided herein include providing the device for inserting into the port with the positioner moved forward towards the distal end to engage with the first stop to move the sheath to
20 enclose the injection needle inside the lumen of the sheath; and prior to depressing the plunger, moving the positioner rearward toward the proximal end to engage the second stop to move the sheath to expose the injection needle. In any of the methods provided herein, the tissue or organ is selected from among liver, brain spinal cord, pancreas, heart, skin, kidney, lung, blood vessel, bone, muscle, uterus, cervix,
25 prostate, urethra, and intestine.

In any of the methods provided herein, the fluid is a composition including a therapeutic, which can be a biologic, chemotherapeutic or gene therapy agent. In any of the methods provided herein, the composition is a pharmaceutical composition.

In any of the methods provided herein, the therapeutic is a small molecule
30 drug, prodrug, protein, peptide, DNA, RNA, virus, antibody, organic molecule, saccharide, polysaccharide, lipid and combinations or conjugates thereof. For example, the therapeutic can be a gene therapy agent, a chemotherapeutic agent, an

- 13 -

analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, and antiarthritics agent, an anti-fungal agent, an antihypertensive agent, antipyretic agent, an anti-parasite agent, an
 5 antihistamine agent, an alpha-adrenergic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchi dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a beta-adrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a
 10 hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, an alcohol, or a sleep
 15 inducer. The therapeutic can be a polypeptide selected from among an enzyme, a hormone, a coagulation or clotting factor, a cytokine, a growth factor or active portion thereof, an antibody or antigen binding portions of antibodies, an angiogenesis modulator, an immunomodulator, a pain modulator, a receptor or active portion thereof, a transport protein, a regulatory protein, an antigen or an allergen.

20 In any of the methods provided herein, the therapeutic can be a nucleic acid molecule for gene therapy, and the nucleic acid molecule can encode a polypeptide. The encoded polypeptide can be an enzyme, a hormone, a coagulation or clotting factor, a cytokine, a growth factor or active portion thereof, an antibody or antigen binding portions of antibodies, an angiogenesis modulator, an immunomodulator, a
 25 pain modulator, a receptor or active portion thereof, a transport protein, a regulatory protein, an antigen and an allergen. For example, the encoded polypeptide can be adenosine deaminase, cystic fibrosis transmembrane conductance regulator (CTFR), galsulfase, laronidase, N-acetylgalactosamine 6-sulfatase, phenylalanine ammonia lyase, acid alpha glucosidase, imiglucerase, alglucosidase alpha, thyrotropin, growth
 30 hormone, insulin, thyroid hormone, erythropoietin (EPO), interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-7, interferon- α (IFN- α), IFN- β , IFN- γ , tumor necrosis factor (TNF), IL-12, IL-18, Fms-Related Tyrosine Kinase 3 (flt3), neuropilin-2 (NP2), bone

- 14 -

morphogenic protein (BMPs), epidermal growth factor (EGF), erythropoietin (EPO),
 fibroblast growth factor (FGF), granulocyte colony stimulating factor (G-CSF),
 granulocyte macrophage colony stimulating factor (GM-CSF), hepatocyte growth
 factor (HGF), insulin-like growth factor (IGF), platelet derived growth factor (PDGF),
 5 transforming growth factor α or β , vascular endothelial growth factor (VEGF),
 epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR),
 FGFR antagonist (sFGFR) transforming growth factor receptor (TGFR), vascular
 endothelial growth factor receptor (VEGFR), plasminogen activator, urokinase,
 Factor VIII, Factor IX, von Willebrand factor, growth hormone, metalloproteinase
 10 thrombospondin motifs 1 (METH-1), METH -2, tryptophanyl-tRNA synthetase
 (TrpRS) fragments, proliferin-related protein, prolactin fragment, pigment epithelium-
 derived factor (PEDF), vasostatin, angiostatin, endostatin, kininostatin, fibrinogen-E
 fragment, thrombospondin, tumstatin, canstatin, restin, soluble fms-like tyrosine
 kinase-1 (sFlt-1), soluble vascular endothelial growth factor receptors (sFlk), soluble
 15 Neuropilin 1 (sNRP1), Interferon gamma-induced protein 10 (IP-10), Platelet factor 4
 (PF-4), Gro-beta, soluble Ephrin type-B receptor 4 (sEphB4), sephrinB2, IGF-1,
 herpes simplex virus thymidine kinase (HSV-TK), carboxypeptidase G2 (CPG2),
 carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450),
 deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase
 20 (PNP), thymidine phosphorylase (TP), varicella zoster virus thymidine kinase (VZV-
 TK), xanthine-guanine phosphoribosyl transferase (XGPRT),
 Aspartylglucosaminidase, α -Galactosidase A, Palmitoyl Protein Thioesterase,
 Tripeptidyl Peptidase, Lysosomal transmembrane protein, cysteine transporter, Acid
 ceramidase, acid α -L-fucosidase, protective protein/cathepsin A, acid β -glucosidase or
 25 glucocerebrosidase, acid β -galactosidase, iduronate-2-sulfatase, α -L-Iduronidase,
 galactocerebrosidase, acid α -mannosidase, acid β -mannosidase, arylsulfatase B,
 arylsulfatase A, N-Acetylgalactosamine-6-sulfate sulfatase, N-Acetylglucosamine-1-
 phosphotransferase, Acid sphingomyelinase, Niemann-Pick disease, type C1 (NPC-
 1), β -Hexosaminidase B, Heparan N-sulfatase, α -N-Acetylglucosaminidase (NaGlu),
 30 Acetyl-CoA: α glucosaminide N-acetyltransferase, N-Acetylglucosamine-6-sulfate
 sulfatase, β -Glucuronidase, acid lipase, neprilysin, the insulin-degrading enzyme
 insulysin, thimet oligopeptidase, calbindin D28, parvalbumin, hypoxia induced factor

- 15 -

1-alpha (HIF1-alpha), sirtuin-2 (SIRT-2), survival motor neuron protein-1 (SMN-1), SMN-2, glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNF), low density lipoprotein receptor (LDLR), lipoprotein lipase (LPL), Alpha-1-Antitrypsin (AAT), UDP-glucuronyl-transferase (UGT), UGT1A1, glucose-6
 5 phosphatase, phosphoenolpyruvate-carboxykinase, galactose-1 phosphate uridyl transferase, phenylalanine hydroxylase, branched chain alpha-ketoacid dehydrogenase, fumarylacetoacetate hydrolase, methylmalonyl-CoA mutase, ornithine transcarbamylase, argininosuccinic acid synthetase, adenosine deaminase, hyposanthine guanine phosphoribosyl transferase, biotinidase, beta-
 10 glucocerebrosidase, beta-glucuronidase, porphobilinogen deaminase (PBGD) or p53.

In any of the methods provided herein, the nucleic acid molecule can be a therapeutic nucleic acid molecule that encodes a therapeutic product, whereby delivery of the nucleic acid molecule effects treatment of a disease or condition. The disease or condition can be an arthritis, chronic pain, HIV-related AIDS,
 15 atherosclerosis, restenosis, inherited enzyme deficiency, inherited immune deficiency, cancer, a retrovirus infection, hemophilia, diabetes, a muscular dystrophy, a cardiovascular disorder, cystic fibrosis, a neurodegenerative disorder, trauma, pain, sickle cell anemia, autoimmune disease, inflammatory disease, and hypertension. In particular examples, the nucleic acid encoded polypeptide can be a Factor VIII for the
 20 treatment of hemophilia A; a Factor IX for the treatment of hemophilia B; an insulin gene for treatment of type I diabetes mellitus; an alpha-1-antitrypsin (AAT) for the treatment of alpha-1-antitrypsin (AAT) deficiency; a hemochromatosis protein (HFE) for treatment of hemochromatosis; a copper-transporting ATPase 2 for treatment of Wilson's disease; UDP glucuronosyltransferase 1A1 (UGT1A1) for the treatment of
 25 Crigler-Najjar syndrome type I; ornithine transcarbamylase (OTC) for the treatment of ornithine transcarbamylase deficiency, type II; low density lipoprotein receptor (LDLR) for the treatment of familial hypercholesterolemia; fibrinogen alpha (FGA), beta (FGB) or gamma (FGB) for the treatment of afibrinogenemia; glucose-6-phosphate- α for the treatment of glycogen storage disease (GSD) type Ia; G6PT for
 30 the treatment of GSD type Ib; acid- α -glucosidase for the treatment of GSD type II (Pompe); α -L-iduronidase for the treatment of mucopolysaccharidosis (MPSI); sulphamidase for the treatment of MPS IIIA; α -N-acetylglucosaminidase (NaGlu) for

- 16 -

the treatment of MPS IIIB; β -glucuronidase for the treatment of MPS VII; α -galactosidase A for the treatment of Fabry disease; glucocerebrosidase for the treatment of Gaucher's disease; acid sphingomyelinase for the treatment of Niemann-Pick syndrome; phenylalanine hydroxylase for the treatment of phenylketonuria;

5 TIMP antagonist or anti-HSC molecules for the treatment of liver fibrosis; anti-ROS molecules for the treatment of liver ischemia reperfusion injury; amyloid-beta degrading enzyme neprilysin, the insulin-degrading enzyme insulysin, or thimet oligopeptidase for the treatment of Alzheimer's disease; insulin growth factor-1 (IGF-1), calbindin D28, parvalbumin, HIF1-alpha, SIRT-2, VEGF, SMN-1, SMN-2, GDNF

10 or ciliary neurotrophic factor (CNF) for the treatment of Amyotrophic Lateral Sclerosis (ALS); galactose-1 phosphate uridyl transferase for the treatment of galactosemia; branched chain alpha-ketoacid dehydrogenase for the treatment of maple syrup urine disease; fumarylacetoacetate hydrolase for the treatment of tyrosinemia type 1; methylmalonyl-CoA mutase for the treatment of methylmalonic

15 acidemia; argininosuccinic acid synthetase for the treatment of citrullinemia; hyposanthine guanine phosphoribosyl transferase for the treatment of Gout and Lesch Nyan syndrome; beta-glucuronidase for the treatment of Sly syndrome; peroxisome membrane protein 70 kDa for the treatment of Zellweger syndrome, enfuvirtide for the treatment of Human immunodeficiency virus (HIV) infection; adenosine

20 deaminase (ADA) for the treatment of combined immunodeficiency disease (SCID); CFTR for the treatment of cystic fibrosis; porphobilinogen deaminase (PBDG) for the treatment of acute intermittent porphyria; interferon-beta for the treatment of multiple sclerosis; lipoprotein lipase for the treatment of lipoprotein lipase deficiency (LPLD), p53 for the treatment of cancer; and glutamic acid decarboxylase (GAD) for the

25 treatment of Parkinson's Disease.

For example, the nucleic acids molecules can encode a protein for treatment of a cancer. For example, the cancer can be a solid tumor, including, but not limited to, breast cancer, melanoma, head and neck cancer, colon cancer, renal carcinoma and sarcoma. Such cancers can be treated with any molecule that inhibits angiogenesis.

30 Hence, a nucleic acid molecule can encode a protein that inhibits angiogenesis, including, but not limited to, endostatin, angiostatin, vasculostatin, thrombospondin-1, tissue inhibitor of metalloprotease (TIMP), soluble vascular endothelial growth factor

- 17 -

(VEGF) receptor and vasostatin (calreticulin fragment). Such anti-angiogenic agents also can be used in the treatment of other angiogenic diseases or conditions, such as ocular diseases.

In any of the methods provided herein, the nucleic acid molecule can encode a polypeptide that increases muscle production in an animal, increases hair production in an animal, increases wool production in an animal, increases growth of an animal, or is involved in nutrient synthesis or utilization. For example, the encoded polypeptide can be: a polypeptide that increases muscle production in an animal that is a myostatin inhibitor; a polypeptide that increases growth in an animal that is a growth hormone, IGF-1, a growth hormone releasing factor or chicken Ski; or a polypeptide that is involved in nutrient synthesis or utilization that is a serine transacetylase and o-acetylserine sulphydrylase. In particular examples, the myostatin inhibitor is follistatin.

In any of the methods provided herein, the nucleic agent molecule can be a DNA molecule, a RNA molecule, or an aptamer. For example, the nucleic acid molecule can be a microRNA, a small interfering RNA, a ribozyme or an antisense nucleic acid. The nucleic acid can be delivered in a vehicle, which can be lipid vesicle, a virus or a microorganism. For example, the lipid vesicle can be a liposome or micelle. In other examples, the vehicle is a virus, and the virus can be an adenovirus, an adeno-associated virus (AAV), a retrovirus, a vaccinia virus or a herpes simplex virus. The retrovirus can be a lentivirus. In particular examples, the virus is an adenovirus, and the adenovirus can include a deletion in an E1, E2a, E2b, E3, or E4 coding region and have a serotype of adenovirus type 2 or adenovirus type 5. In some of the examples of methods provided herein, the amount of virus administered can be from or from about 10 to 1×10^{12} particles, 10 to 1×10^6 particles, 1×10^3 to 1×10^{12} particles, 1×10^6 to 1×10^{10} particles, or 1×10^7 to 1×10^9 particles; or is or is from or from about 10 to 1×10^{12} pfu, 10 to 1×10^6 pfu, 1×10^3 to 1×10^{12} pfu, 1×10^6 to 1×10^{10} pfu, or 1×10^7 to 1×10^9 pfu; or less than 1×10^{12} particles, 1×10^{11} particles, 1×10^{10} particles, 1×10^9 particles, 1×10^8 particles, 1×10^7 particles, 1×10^6 particles, 1×10^5 particles, 1×10^4 particles, 1×10^3 particles or less; or is less than 1×10^{12} pfu, 1×10^{11} pfu, 1×10^{10} pfu, 1×10^9 pfu, 1×10^8 pfu, 1×10^7 pfu, 1×10^6 pfu, 1×10^5 pfu, 1×10^4 pfu, 1×10^3 pfu or less.

- 18 -

In any of the methods provided herein, the subject can be a mouse, rat, cow, pig, sheep, goat, horse and human. For example, subject can be a human child under the age of 18 or is a human fetus.

In any of the methods provided herein includes removing the device from the port, in which prior to removing the device from the port, the positioner is moved forward towards the distal end to engage with the first stop to move the sheath to enclose the injection needle inside the lumen of the sheath.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.

FIGS. 1A and 1B illustrate a standard syringe injection device. **FIG. 1A** shows a perspective view of an exemplary embodiment of an injection device containing a standard syringe at the proximal end of the device. **FIG. 1B** illustrates connection of the syringe barrel to the needle sheath controller .

FIG. 2 shows a perspective view of an exemplary embodiment of an integrated syringe injection device in which a syringe barrel is integrated into the needle sheath lumen at the distal end of the device.

FIG. 3 shows a perspective view of an exemplary embodiment of a dockable syringe injection device in which a syringe containing an auxiliary plunger, barrel and injection needle are adapted to be docked onto a syringe adaptor within the needle sheath lumen at the distal end of the device

FIGS. 4A-C illustrate the movement of the needle sheath of the injection device between the sheathed and unsheathed position as controlled by the positioner. **FIG. 4A** is a birds-eye view showing the positioner positioned towards the distal end so that the needle sheath is in the sheathed position. **FIG. 4B** is a birds-eye view showing the positioner in an intermediate or middle position with the needle sheath in the transitioning position moving between the sheathed and unsheathed position. **FIG. 4C** is a birds-eye view showing the positioner position towards the proximal end so that the needle sheath is in the unsheathed position.

FIG. 5 is an enlarged sectional view of the needle sheath controller of the device depicted in FIG. 1A and 1B.

- 19 -

FIG. 6 is an enlarged sectional view of the needle sheath controller of the device depicted in FIG. 2.

FIG. 7 is an enlarged sectional view of the needle sheath controller of the device depicted in FIG. 3.

5 **FIGS. 8A-8B** show an enlarged sectional view of the tip of the needle sheath in the device shown in FIG. 1A and 1B. **FIG. 8A** shows the needle sheath in the sheathed position. **FIG. 8B** shows the needle sheath in the unsheathed position.

10 **FIGS. 9A-9D** show enlarged perspective views of the needle sheath in the device shown in FIG. 1A and 1B. **FIG. 9A** illustrates the needle sheath in the sheathed position in a windowless needle sheath shaft. **FIG. 9B** illustrates the needle sheath in the unsheathed position in a windowless needle sheath shaft. **FIG. 9C** illustrates the needle sheath in the sheathed position in a needle shaft with a visibility window. **FIG. 9D** illustrates the needle sheath in the unsheathed position in a needle shaft with a visibility window.

15 **FIGS. 10A-10D** illustrate enlarged views of the device shown in FIG. 2. **FIG. 10A** is a sectional view of the needle sheath in the sheathed position. **FIG. 10B** is a sectional view of the needle sheath in the unsheathed position. **FIG. 10C** is a perspective view of the needle sheath in the sheathed position. **FIG. 10D** is a perspective view of the needle sheath in the unsheathed position.

20 **FIGS. 11A-11D** illustrate enlarged views of the device shown in FIG. 3. **FIG. 11A** is a perspective view of the distal end of the device illustrating the syringe adaptor cavity and the syringe adaptor with the dockable syringe in the undocked position. **FIG. 11B** is a perspective view of the distal end of the device, with the dockable syringe docked onto the syringe adaptor and the needle sheath in the sheathed position. **FIG. 11C** is a perspective view of the distal end of the device, with the dockable syringe docked onto the syringe adaptor and the needle sheath in the unsheathed position. **FIG. 11D** is a perspective view of the distal end of the device, with the dockable syringe docked onto the syringe adaptor, the needle sheath in the unsheathed position and the dockable syringe plunger in the depressed position.

30 Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings. For parts which are similar but not the same as parts originally specified with a given number, a prime (') of the original numbers is used.

51205-159

- 20 -

A lowercase reference numeral (*e.g.* a, b, etc.) refers to the same part but in different positions or states.

DETAILED DESCRIPTION

A. Definitions

5 B. Injection Device

1. Standard Injection Device

2. Integrated Injection Device

3. Dockable Injection Device

C. Applications and Uses

10 1. Treating Diseases and Disorders

D. Examples

A. DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the same
15 meaning as is commonly understood by one of skill in the art to which the invention(s) belong. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference
20 thereto evidences the availability and public dissemination of such information.

As used herein, reference to a "minimally invasive surgery" or a "minimally
 invasive procedure," also sometimes referred to as endoscopy, refers to any procedure
 (surgical or otherwise) that is less invasive than open surgery used for the same purpose . A
 minimally invasive procedure is carried out through the skin or through a body cavity or
25 anatomical opening. The procedure typically involves use of devices suitable for the
 procedure, such as arthroscopic devices (for joints and the spine) or laparoscopic devices (for
 surgeries of abdomen). Minimally invasive procedures can be carried out with indirect
 observation of the surgical field through an endoscope or

- 21 -

large scale display panel, and can involve manual or remote-control manipulation of instruments. Exemplary of a minimally invasive procedure is laparoscopy. Other minimally invasive procedures include, but are not limited to, refractive surgery, percutaneous surgery, arthroscopic surgery, cryosurgery, microsurgery, keyhole
5 surgery, thoracoscopic surgery, endovascular surgery (such as angioplasty), coronary catheterization, stereotactic surgery, image-guided surgery, and ultrasound guided percutaneous ethanol treatment.

As used herein, "laparoscopy" or "laparoscopic surgery" refers to a minimally invasive surgical procedure in which operations in the abdomen are performed
10 through small incisions. The incisions are typically 5 millimeters (mm) to 20 mm in length. One or several incisions are made, and laparoscopic ports, typically 5 mm to 12 mm in diameter, are inserted into the incisions. Laparoscopic surgical instruments are inserted or withdrawn through the laparoscopic ports.

As used herein, endoscope refers to an instrument that can be introduced into
15 the body to give a view of its internal parts. A "laparoscope" refers to an instrument that can be introduced into the abdomen to give a view of its internal parts.

As used herein, "endoscopic port" refers to a medical appliance inserted into an incision for a minimally invasive procedure that provides a pathway that allows a minimally invasive device to pass through the skin or body cavity. With reference to
20 laparoscopy, a "laparoscopic port" is a medial appliance inserted into an incision for a laparoscopic procedure that provides a pathway that allows a laparoscopic device to pass through the skin into the abdominal cavity.

As used herein, a device for minimally invasive procedures is a device that is sufficiently long and narrow to permit access to a tissue or an organ during minimally
25 invasive procedures.

As used herein, a laparoscopic device is a device that is sufficiently long and narrow to permit access to a tissue or an organ during minimally invasive procedures.

As used herein, injection device refers to a device can that can be used to deliver fluids into the body or its cavities, such as a tissue or an organ or a portion
30 thereof. The device generally contains a hollow barrel or syringe fitted with a plunger and a hollow needle for penetrating the target. For purposes herein, an injection

- 22 -

device is one that can be used for minimally invasive procedures, such as laparoscopic surgeries or procedures.

As used herein, direct injection refers to injections given straight into the target, for example, straight into the tissue or organ or portion thereof.

5 As used herein, an organ or a tissue refers to differentiated parts of the body of a subject that performs a specific function. Tissues generally are a group of specialized cells that group together to form a specialized function. For example, muscle tissue is a specialized tissue that can contract. Organs are made up of tissues that perform a function. Examples of organs, include but are not limited to, the eyes,
10 ears, lungs, liver, kidney, heart, or skin.

As used herein, reference to a “portion of a tissue or an organ” refers to part of a tissue or an organ of the body of a subject. The part can be a region, segment, lobe, section or other part of a tissue or an organ. The portion is one that can be mobilized or isolated separate from the rest of the tissue or organ. It also is a portion that is
15 sufficient to effect delivery of the agent. It is within the skill of one in the art to determine the appropriate size of a portion of a tissue or an organ sufficient to effect delivery of the agent, and it depends upon the particular organ, the indication treated, the dosage, the size of the subject and other parameters. Typically, a portion of a tissue or an organ has a volume of at least about 5 mm³, 10 mm³ or more. For
20 example, the portion can be any area of a tissue or an organ that has a length ranging from 0.5 cm to 25 cm, a height (or thickness) of 0.5 cm to 20 cm and/or a depth from 0.5 cm to 15 cm. As an example, a portion of a liver lobe or segment is one that has a length of 5 cm to 10 cm, a height of 1 cm to 3 cm and a depth (from the tip) of 1.5 cm to 3 cm. Smaller regions or portions are also contemplated so long as the portion is of
25 a sufficient size to deliver a therapeutic or other agent.

As used herein, parenchyma refers to the portions of the tissue and associated cells of an organ that conducts the specific function of the organ and that makes up the bulk of the organ. Hence, the parenchyma is the main underlying functional tissue of an organ. These can include the epithelial tissue, muscle tissue, nervous tissue and
30 associated cells thereof. Parenchyma is distinct from the stroma, which is the connective tissue, blood vessels, nerves and ducts. Hence, parenchyma does not include connective tissue, blood vessels, nerves and ducts. For example, the

- 23 -

parenchyma of the liver includes hepatocytes, the parenchyma of the heart includes cardiac muscle cells such as myocytes, the parenchyma of the kidney includes nephrons. The parenchyma of the skin is the epidermis.

As used herein, "parenchymal cells" refers to the cells that are contained in or
5 that make up the parenchyma of a tissue or an organ. For example, hepatocytes are cells of the main tissue of the liver, which make up 70-80% of the liver's mass. In the lung, 75% of all lung cells are contained in the parenchyma. These include, for example, fibroblasts of the interstitium and epithelial cells that line that alveoli, such as type 1 and type 2 cells (pneumocytes) and brush cells. In the skin, cells found in
10 the parenchyma include epidermal cells such as keratinocytes. One of skill in the art is familiar with the parenchyma of various tissue and organs and cells therein.

As used herein, parenchymal injection refers to administration to the parenchyma of a tissue or an organ.

As used herein, "proximal" with reference to a component of the device or the
15 device refers to the end of the component or the device that is closest to the medical professional operating the device during use of the device. It is understood that the proximal portion need not be the end of the component, but includes the entire portion of the component that is closest to the medical professional operating the device during use of the device.

20 As used herein, "distal" with reference to a component of the device or the device refers to the end of the device furthest from the medical professional during use of the device.

As used herein, "operably" or "operatively" when referring to two components means that the segments are arranged so that they function in concert for their
25 intended purposes, *e.g.*, movement of one component by another component.

As used herein, "engaged" refers to the condition in which two members that are designed to be contacted or connected are physically contacted to connected to each other in a manner in which they are designed to be contacted or connected. For example, an adaptor and a hub, such as Luer connectors, can be engaged when they
30 are physically connected to each other in a manner in which they are designed to be connected. A groove (*e.g.* in sheath stops) and a notch that fits in the groove (*e.g.* in

- 24 -

positioner), can be engaged when they are physically contacted to each other in a manner in which they are designed to be contacted.

As used herein, "male" with reference to a thread (e.g. of a Luer connector) refers to a member that includes a thread on its outer surface.

5 As used herein, "female" with reference to a thread (e.g. of a Luer connector) refers to a connecting member that includes a thread on its inner surface.

As used herein, elongate with reference to the sheath means that the sheath is long in relation to width or diameter. The elongate structure permits use of the device through ports to access the body cavity in minimally invasive procedures, such as
10 laparoscopic procedures or surgeries.

As used herein, extended with reference to the plunger means that the proximal end of the plunger is not in proximity to the syringe barrel, such that the plunger is expanded or increased in length to cover a larger area so that it is able to operably connect with the syringe barrel.

15 As used herein, "substantially the same" with reference to the length of the exposed needle compared to the distance between sheath stops means that the length and distance are for the most part the same or essentially the same, but can differ slightly in a manner that is not significant. For example, the length of the exposed needle and the distance between sheath stops is substantially the same if the length of
20 the exposed needle is longer or shorter than the distance between the sheath stops by no more than 1 mm, and generally less than 1 mm, 0.8 mm, 0.6 mm, 0.5 mm, 0.4 mm or less.

As used herein, sheath stop with reference to the needle sheath controller refers to an opening or groove formed in the controller to cease or halt or prevent the
25 movement of the sheath. The engagement of the sheath with the stops need not be direct, but can be indirect. For example, the sheath can be operably coupled to a component that itself engages with stop. In examples of the device herein, the sheath is connected to a connection member that is connected to a positioner that engages directly with the stop to cease, halt or prevent the movement of the sheath. Hence, the
30 stops lock the sheath from moving. The stops can be positioned at different distances from each other so that the sheath can be movably locked into more than one position (e.g. the sheathed and unsheathed position).

- 25 -

As used herein, "sheathed" or "the sheathed position" with reference to the injection needle means that the sheath is enclosed over the needle so that the sheath is not extended or exposed outside of the blunt end of the sheath.

As used herein, "unsheathed" or "the unsheathed position" with reference to
5 the injection needle means that the distal tip of the needle extended or exposed outside of the sheath, and the sheath does not enclose the distal tip of the needle. The extent by which the distal tip of the needle is unsheathed is dependent on the particular device (e.g. sheath stops).

As used herein, axial force with reference to the plunger refers to force that
10 directly acts on the center axis of an object. The axial force used herein is applied along the longitudinal axis. For example, axial force must be applied to depress or pull back the plunger. Axial force is typically compression force, e.g. depression of a plunger, or a stretching force, e.g. pulling back of a plunger.

As used herein, lumen refers to the inside space of a tubular structure. The
15 tubular structure can have a regular tubular or cylindrical shape, or irregular tubular or cylindrical shape.

As used herein, cavity refers to an empty or hallow space or an opening leading to an empty space within an object.

As used herein, recess refers to an empty or hallow space created by part of an
20 object which is constructed further back from the rest. It can be a hallow space created by walls surrounding the space. For example, a recess can be a groove with openings at one or both ends so that an item can pass through.

As used herein, predetermined length refers to a length that is set by the configuration of the device. Once the device has been constructed and configured, the
25 predetermined length cannot be changed.

As used herein, loading a syringe refers to filling the syringe barrel, the fluid reservoir, with fluid. The syringe barrel is typically loaded or filled by pulling the plunger backward/rearward, toward the proximal end of the device.

As used herein, releasing, dispelling, expelling or ejecting a fluid from the
30 syringe refers to emptying the fluid content of the syringe through the distal end of the syringe by depressing the plunger.

- 26 -

As used herein, lining refers to a separate layer of different material positioned on the inside surface of an object. For example, if a hallow tubular structure has another hallow tubular structure with a slightly smaller diameter fitted on the inside surface, the inner tubular structure is a lining for the outer tubular structure.

5 As used herein, integrated describes a part which is physically enclosed or encased with another part. Integrated parts cannot be separated from the part that encases or encloses the integrated part. With reference to the integrated injection device, the syringe barrel is enclosed or encased by the sheath and cannot be separated from the sheath.

10 As used herein, dockable or detachable describes a part which can be attached, docked, snap-fitted or placed into an adaptor of another part. Dockable parts can be attached docked, snap-fitted or placed into an adaptor in a reversible manner. For example, the part can be undocked or removed, i.e. separated from the part. Hence, the part is not physically bonded to the other part which contains the dock or the
15 adaptor. With reference to the dockable syringe injection device, the syringe can be removed or undocked from the sheath. Likewise, with reference to the standard injection device, the syringe barrel can be detached from the device.

As used herein, dead volume refers to the volume of fluid that is loaded into the syringe barrel but cannot be expelled from the device and remains in the syringe
20 barrel or needle. Factors that influence the amount of dead volume include the length of the needle, the diameter of the needle, and the diameter of the syringe barrel.

As used herein, injection pressure refers to the pressure required to inject the fluid out of the fluid reservoir into the target. Required injection pressure may differ depending on the properties of the composition of the fluid (*e.g.* viscosity), the length
25 of the needle and the target site (*e.g.* hardness).

As used herein, pressure drop refers to the decrease in pressure as fluid flows through the fluid path, due to factors such as drag and frictional effect. Factors that can influence pressure drop include length of the needle, the diameter of the needle, and the viscosity of the fluid. If significant pressure drop occurs, the axial force
30 applied to the plunger does not result in sufficient injection pressure at the needle.

As used herein, a composition refers to any mixture. It can be a solution, a suspension, fluid, powder, a paste, aqueous, non-aqueous or any combination thereof.

- 27 -

As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions. For purposes herein, a fluid generally is injectable.

5 As used herein, a therapeutic refers to an agent, a product, a compound or a composition that is capable of producing a therapeutic effect. The agent, product, compound or composition can comprise small molecule drugs, prodrugs, proteins, peptides, DNA, RNA, viruses, antibodies, organic molecules, saccharides, polysaccharides, lipids and combinations or conjugates thereof. The agent, product,
10 compound or composition can include other pharmaceutically effective agents known in the general art to be of value in treating one or more of the diseases or medical conditions. Exemplary therapeutics are described herein.

As used herein, therapeutic effect means an effect resulting from treatment of a subject that alters, typically improves or ameliorates the symptoms of a disease or
15 condition or that cures a disease or condition. A therapeutically effective amount refers to the amount of a composition, molecule or compound which results in a therapeutic effect following administration to a subject.

As used herein, "genetic therapy" or "gene therapy" involves the transfer of a nucleic acid molecule, such as heterologous DNA to certain cells, target cells, of a
20 mammal, particularly a human, with a disorder or condition for which such therapy is sought. The DNA is introduced into the selected target cells in a manner such that the heterologous DNA is expressed and a therapeutic product encoded thereby is produced. Alternatively, the heterologous DNA can in some manner mediate expression of DNA that encodes the therapeutic product, it can encode a product, such
25 as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy also can be used to deliver nucleic acid encoding a gene product to replace a defective gene or supplement a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid can encode a therapeutic compound (e.g. a growth factor inhibitor thereof, or a
30 tumor necrosis factor or inhibitor thereof, such as a receptor therefor), that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a therapeutically useful time. The heterologous DNA encoding

- 28 -

the therapeutic product can be modified prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof.

As used herein, nucleic acid molecule refers to single-stranded and/or double-stranded polynucleotides, such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), as well as analogs or derivatives of either RNA or DNA. Also included in the term “nucleic acid” are analogs of nucleic acids such as peptide nucleic acid (PNA), phosphorothioate DNA, and other such analogs and derivatives. Nucleic acids can encode gene products, such as, for example, polypeptides, regulatory RNAs, microRNAs, small inhibitory RNAs (siRNAs) and functional RNAs. Hence, nucleic acid molecule is meant to include all types and sizes of DNA molecules including siRNA, aptamers, ribozymes, complementary DNA (cDNA), plasmids and DNA including modified nucleotides and nucleotide analogs.

As used herein, a therapeutic nucleic acid is a nucleic acid molecule that encodes a therapeutic or is capable of producing a therapeutic effect. The product can be nucleic acid, such as a regulatory sequence or gene, or can encode a protein that has a therapeutic activity or effect. For example, therapeutic nucleic acid can be a ribozyme, antisense, double-stranded RNA, a nucleic acid encoding a protein and others.

As used herein, “vehicle” refers to the agent or conduit, such as vector or construct, that contains a nucleic acid molecule for gene therapy and that facilitates entry of the nucleic acid molecule into cells and/or expression thereof. Hence, the vehicle containing the nucleic acid is the delivered agent that is administered to a subject and that contains the nucleic acid molecule packaged therein or associated therewith. Examples of vehicles include, but are not limited to, a virus, virus-like particles, mini-circles, a plasmid or vector, a liposome and/or nanoparticle. For example, a vehicle can include a lipid-based or other polymer-based composition, such as liposome, micelle or reverse micelle, that is associated with a nucleic acid molecule or other agent, such as a non-viral vector or virus provided herein, for delivery into a host subject. The uptake of vehicles can be further increased or facilitated using various mechanical techniques such as electroporation, sonoporation or “gene gun.”

- 29 -

As used herein, a heterologous nucleic acid (also referred to as exogenous nucleic acid or foreign nucleic acid) with reference to nucleic acid contained in the genome of a virus refers to a nucleic acid that is not normally produced *in vivo* by an organism or virus from which it is expressed or that is produced by an organism or a virus but is at a different locus, or that mediates or encodes mediators that alter expression of endogenous nucleic acid, such as DNA, by affecting transcription, translation, or other regulatable biochemical processes. Hence, heterologous nucleic acid is often not normally endogenous to an organism or a virus into which it is introduced. Heterologous nucleic acid can refer to a nucleic acid molecule from another virus in the same organism or another organism, including the same species or another species. Heterologous nucleic acid, however, can be endogenous, but is nucleic acid that is expressed from a different locus or altered in its expression or sequence (*e.g.*, a plasmid). Thus, heterologous nucleic acid includes a nucleic acid molecule not present in the exact orientation or position as the counterpart nucleic acid molecule, such as DNA, is found in a genome. Generally, although not necessarily, such nucleic acid encodes RNA and proteins that are not normally produced by the organism or virus or in the same way in the virus in which it is expressed. Any nucleic acid, such as DNA, that one of skill in the art recognizes or considers as heterologous, exogenous or foreign to the virus in which the nucleic acid is expressed is herein encompassed by heterologous nucleic acid. Examples of heterologous nucleic acid include, but are not limited to, nucleic acid that encodes exogenous peptides/proteins, including diagnostic and/or therapeutic agents. Proteins that are encoded by heterologous nucleic acid can be expressed within the virus, secreted, or expressed on the surface of the virus in which the heterologous nucleic acid has been introduced.

As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA constructs exist as a result of human manipulation, and include clones and other copies of manipulated molecules.

As used herein, vector (or plasmid) refers to discrete elements that are used to introduce a heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect

- 30 -

integration of a gene or portion thereof into a chromosome of the genome. Vectors include non-viral vectors, such as non-viral expression vectors. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial chromosomes and mammalian artificial chromosomes. Vectors also include "virus vectors" or "viral
5 vectors." Selection and use of such vehicles are well known to those of skill in the art.

As used herein, an expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional
10 segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage,
15 recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

As used herein, "virus," refers to any of a large group of infectious entities that cannot grow or replicate without a host cell. Viruses typically contain a protein coat surrounding an RNA or DNA core of genetic material, but no semipermeable membrane, and are capable of growth and multiplication only in living cells. Viruses include those that are formed when, such as when a vector containing all or a part of a
25 viral genome, is transduced into an appropriate cell or cell line for the generation of such particles. The resulting viral particles have a variety of uses, including, but not limited to, transferring nucleic acids into cells either *in vitro* or *in vivo*. Thus, a virus is a packaged viral genome. A virus can refer to a single particle, a stock of particles or a viral genome.

As used herein, viral vector refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle or virus. Reference to viral vector herein is used interchangeably with virus

- 31 -

when it is packaged inside a protein coat. The viral vector particles or virus can be used for the purpose of transferring DNA, RNA or other nucleic acids into cells either *in vitro* or *in vivo*. Viral vectors include, but are not limited to, retroviral vectors, vaccinia vectors, lentiviral vectors, herpes virus vectors (*e.g.*, HSV), baculoviral
5 vectors, cytomegalovirus (CMV) vectors, papillomavirus vectors, simian virus (SV40) vectors, Sindbis vectors, Semliki Forest virus vectors, phage vectors, adenoviral vectors, and adeno-associated viral (AAV) vectors. Suitable viral vectors are described, for example, in U.S. Patent Nos. 6,057,155, 5,543,328 and 5,756,086. Viral vectors typically include engineered viruses that are operatively linked to
10 exogenous genes to transfer (as vehicles or shuttles) the exogenous genes into cells.

As used herein, "adenovirus vector" and "adenoviral vector" are used interchangeably and are well understood in the art to mean a polynucleotide containing all or a portion of an adenovirus genome. An adenoviral vector, refers to nucleic acid encoding a complete genome or a modified genome or one that can be
15 used to introduce heterologous nucleic acid when transferred into a cell, particularly when packaged as a particle. An adenoviral vector can be in any of several forms, including, but not limited to, naked DNA, DNA encapsulated in an adenovirus capsid, DNA packaged in another viral or viral-like form (such as herpes simplex, and AAV), DNA encapsulated in liposomes, DNA complexed with polylysine, complexed with
20 synthetic polycationic molecules, conjugated with transferrin, complexed with compounds such as PEG to immunologically "mask" the molecule and/or increase half-life, or conjugated to a non-viral protein.

As used herein, the term "adenovirus" or "adenoviral particle" is used to include any and all viruses that can be categorized as an adenovirus, including any
25 adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Depending upon the context reference to "adenovirus" can include adenoviral vectors. There are at least 51 serotypes of adenovirus that are classified into several subgroups. For example, subgroup A includes adenovirus serotypes 12, 18, and 31. Subgroup B includes adenovirus serotypes 3, 7, 11a, 11p, 14, 16, 21, 34,
30 35 and 50. Subgroup C includes adenovirus serotypes 1, 2, 5, and 6. Subgroup D includes adenovirus serotypes 8, 9, 10, 13, 15, 17, 19, 19p, 20, 22-30, 32, 33, 36-39, 42-49 and 51. Subgroup E includes adenovirus serotype 4. Subgroup F includes

- 32 -

adenovirus serotypes 40 and 41. Thus, as used herein an adenovirus or adenovirus particle is a packaged vector or genome. For purposes herein, the viruses typically are recombinant adenoviruses containing a heterologous nucleic acid molecule in its genome and formed when an adenovirus vector is encapsulated in an adenovirus capsid.

Included among adenoviruses are any and all viruses that can be categorized as an adenovirus, including any adenovirus that infects a human or an animal, including all groups, subgroups, and serotypes. Thus, as used herein, "adenovirus" and "adenovirus particle" refer to the virus itself and derivatives thereof and cover all serotypes and subgroups and naturally occurring and recombinant forms, except where indicated otherwise. Included are adenoviruses that infect human cells. Adenoviruses can be wildtype or can be modified in various ways known in the art or as disclosed herein. Such modifications include, but are not limited to, modifications to the adenovirus genome that is packaged in the particle in order to make an infectious virus. Exemplary modifications include deletions known in the art, such as deletions in one or more of the E1a, E1b, E2a, E2b, E3, or E4 coding regions. Other exemplary modifications include deletions of all of the coding regions of the adenoviral genome. Such adenoviruses are known as "gutless" adenoviruses. The terms also include replication conditional adenoviruses, which are viruses that preferentially replicate in certain types of cells or tissues but to a lesser degree or not at all in other types.

As used herein, subject can be a vertebrate, more specifically a mammal (*e.g.*, a human, horse, cat, dog, cow, pig, sheep, goat, mouse, rabbit, rat, and guinea pig), birds, reptiles, amphibians, fish, and any other animal. The term does not denote a particular age or sex. Thus, adult and newborn subjects, whether male or female, are intended to be covered. As used herein, patient or subject may be used interchangeably and can refer to a subject in need of a therapeutic agent. The term patient or subject includes human and veterinary subjects. Both therapeutic, industrial, veterinary and agricultural (*e.g.*, meat production) uses are disclosed herein.

As used herein, a patient refers to a human subject.

- 33 -

As used herein, a combination refers to any association between or among two or more items. The combination can be two or more separate items, such as two compositions or two collections, can be a mixture thereof, such as a single mixture of the two or more items, or any variation thereof. The elements of a combination are
5 generally functionally associated or related.

As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

As used herein, the term “or” is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.

10 As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. Hence “about 5 grams” means “about 5 grams” and also “5 grams.” It also is understood that ranges expressed herein include whole numbers within the ranges and fractions thereof. For example, a range of between 5 grams and 20 grams includes whole number values such as 5, 6, 7,
15 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 grams, and fractions within the range including, but not limited to, 5.25, 6.72, 8.5 and 11.95 grams.

As used herein, “optional” or “optionally” means that the subsequently described event or circumstance does or does not occur and that the description includes instances where said event or circumstance occurs and instances where it
20 does not.

B. INJECTION DEVICE

Provided herein is are injection devices that can be used in minimally invasive procedures, such as laparoscopic procedures, for use in delivering fluids, such as therapeutics, by direct injection into a target locus, such as by direct injection into a
25 target tissue. The device has an elongated needle sheath with a small diameter, and can be inserted through an endoscopic port, such as a laparoscopic ports, trocars or cannulas, to reach the internal target site. The device provided herein can deliver small and accurate doses of the fluid directly into the target tissue, without the need of large standard syringes and open surgery. The device can optionally deliver multiple
30 doses to the same or different target sites.

The device can be used in any method that requires direct injection of an agent into a target site, in which access to the target site is limited, such as in minimally

- 34 -

invasive procedures. For example, in addition to laparoscopic surgeries, the device provided herein can also be used for direct injection of a fluid, such as a therapeutic, during other minimally invasive medical or surgical procedures, such as thoracoscopic surgery. As described elsewhere herein, any fluid, such as a
5 therapeutic, can be administered, including but not limited to, protein, nucleic acid, small molecule, virus, antibodies or other fluids. The device can be used in conjunction with other minimally invasive surgical devices using single-port or multi-port endoscopic (e.g. laparoscopic) surgery. The device can also be used to deliver multiple discrete doses to the same or different sites of injection without removing or
10 after removing the device from the laparoscopic port.

As described further below, in all embodiments of the device, the device contains a movable sheath enclosing a fixed needle. The sheath contains an opening to expose the needle, whereby movement of the sheath is controlled by stops in a controller that can be adjusted by a positioner that moves between stops in the
15 controller. The stops are positioned a predetermined distance so that movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose the injection needle inside the lumen of the sheath, and movement of the positioner rearward towards the proximal end engages the second stop to move the sheath to expose no more than a predetermined length of the distal tip of the injection
20 needle. Hence, the sheath moves around the fixed needle and is able to retract from its enclosed position to expose a desired length of needle for penetration of a tissue or organ. The particular length of the needle that is exposed is a function of the predetermined distance between the stops in the controller. The stops also can be
locked to prevent movement of the needle once it is placed.

25 The ability to control movement of the sheath to fully enclose the needle or to expose the needle only a desired length, are features of the injection device that permit its use for direct administration to a parenchymal tissue or other desired locus. For example, the ability to enclose the needle by the sheath prevents unwanted exposure of the needle where its penetration into target tissues is not desired, which
30 can occur when the device is being positioned for direct injection or when it is being removed from a subject. Also, the ability to control the extent or length of needle that

- 35 -

is exposed ensures that the needle is no longer than the thickness of the tissue or organ so that the needle cannot puncture through the tissue or organ when it is injected.

Further, because the needle is fixed and does not move relative to the needle sheath controller, the positioner only controls the movement of the needle sheath, while the injection needle and other components of the device are stationary regardless of the position of the positioner. Thus, control of the movable sheath, and hence needle retraction or extension, is independent from movement of the plunger. This ensures precise injection into the tissue by the plunger without disturbing the placement of the needle in the tissue. In addition, because the needle is fixed and independent of the plunger, movement of the plunger only controls the drawing up and dispelling of fluids. This means that the plunger can be pulled back at the site of injection to draw up fluids to test needle placement (*e.g.* to confirm injection is not into a blood vessel), without disturbing placement of the needle. As described herein, embodiments of the injection device also can contain a visibility window (*e.g.* a transparent syringe barrel or needle coupler) to visualize the fluid that is drawn up by the plunger.

The injection devices provided herein include devices that are configured to minimize dead volume and/or avoid problems in pressure drops, which are problems with injection devices for minimally invasive, such as laparoscopic, surgeries. Thus, the injection devices generally avoid loss of the fluid, such as a therapeutic, that is being injected by the device. Also, because the injection devices provided herein are configured so that any problems with pressure drop are minimized, the injection devices provided herein also do not require undue axial force to depress the plunger to compensate for pressure drops. Therefore, the devices are safe to use and efficient to use.

The device, including exemplary embodiments of the device, will be described with reference to the accompanying drawings. As indicated, the use of a prime (') designation with a number indicates that the element shown or described is the same as the non-prime element, except as shown or described differently.

The device generally has two ends, the needle tip end and the plunger end. For clarity of description, it should be noted that the exemplary devices are depicted with the needle tip end generally towards the right side in the drawings, and the

- 36 -

plunger end generally towards the left side of the drawing. The needle tip end will be generally described as the "distal end," and the plunger end will be generally described as the "proximal end." The term "distal end" is intended to refer to the end of the injection device furthest from the person holding the device, and the term

5 "proximal end" is intended to refer to the end of the device closest to the holder of the device. If a component is described to be more "proximal" to another component, the component is closer to the proximal (plunger) end. If a component is described to be more "distal" to another component, the component is closer to the distal (needle tip) end.

10 Some components of the injection device can move in two general directions along the longitudinal axis relative to other components. For example, components can generally move towards the proximal end or distal end, or move in the proximal direction or the distal direction. Components that move towards the distal direction (needle tip) are described as moving forward, and components that move toward the

15 proximal direction (plunger) are described as moving rearward/backward. The exemplary devices are also generally depicted with needle sheath controller positioned so that the positioner is pointing upward, with the exception of **FIGS. 4A-4C**, which are birds-eye views looking down on the device. Some of the components, such as the positioner, can move parallel to the vertical axis. The components can

20 move in the upward direction or the downward direction. Pressing of the positioner toward the needle sheath controller will be described as pressing "downward" and releasing the positioner will be described as the positioner moving "upward."

In a general embodiment, the injection device, or apparatus, provided herein, includes a needle sheath and needle sheath controller, an injection needle with a

25 needle tip that can be sheathed and unsheathed, a syringe barrel used as a reservoir for the fluid, such as a therapeutic, that is being delivered to the target tissue and a plunger that controls loading and release of the fluid. The needle sheath generally is a rigid shaft, but a flexible or steerable shaft can also be used depending on the purpose of use.

30 For example, with reference to **FIG. 1A** and **1B**, which illustrate a first exemplary embodiments provided herein, the syringe injection device is indicated generally by the reference numeral **60**, and includes the needle sheath **72** and needle

- 37 -

sheath controller **71**, the injection needle **81**, the syringe barrel **91** and the plunger **92**. Other embodiments of the syringe device are described in **FIG. 2** and **FIG. 3**, and other Figures as described below. For example, **FIG. 2** shows a further embodiment indicated generally by the reference numeral **60'**, and includes the needle sheath **72'**,
5 needle sheath controller **71'**, the injection needle **81**, the syringe barrel **91'** and the plunger **92'**. In this embodiment, the needle sheath **72'**, needle sheath controller **71'**, the syringe barrel **91'** and the plunger **92'** are substantially the same as the embodiment of **FIG. 1A** and **1B**, except that that the syringe barrel **91'** is located at the distal end of the device and is integrated with the needle sheath **72'** and therefore
10 the plunger **92'** traverses through the needle control sheath controller **71'**. **FIG. 3** shows a further embodiment indicated generally by the reference numeral **60''**, and includes the needle sheath **72''**, the needle sheath controller **71'**, the injection needle **81**, the syringe barrel **91''** and the plunger **92''**. In this embodiment, the needle sheath **72''**, needle sheath controller **71'**, syringe barrel **91''** and plunger **92''** are substantially
15 the same as the embodiment of **FIG. 1A** and **1B**, except that the syringe barrel **91''** is located at the distal end of the device and is adapted so that it is dockable into the needle sheath **72''**. Further, the plunger **92''** traverses the needle sheath controller **71'**, and is further adapted to associate with an auxiliary plunger **920** located distal to the needle sheath controller **71'** where the auxiliary plunger **920** is adapted to move
20 within the syringe barrel **91''**.

In all embodiments of the laparoscopic device provided herein, the dimensions of the laparoscopic device permits its use through typical ports for laparoscopic surgery or other minimally invasive surgical procedures. For example, typical ports for laparoscopic surgery, through which the instruments or devices enter the patient, is
25 about 5 to 10 mm in diameter. The device is used to reach and inject into the target tissue, which is typically an internal tissue or organ of the body, including the parenchyma of an organ. The length of the device is sufficiently long to permit access to the particular desired target tissue through a laparoscopic port, while not being so unwieldy that it is difficult to control. The choice of dimension of the device is
30 dependent on the particular user, the target tissue, the subject being treated, the agent being administered, and other factors within the level of a skilled artisan. Generally, the needle sheath **72**, **72'** or **72''** of the injection device is of a sufficient length to

- 38 -

permit laparoscopic access to the target of interest, and is generally a length of 200 mm to 600 mm, such as 250 to 400 mm, and generally at least or about at least or 300 mm.

In all aspects of the device provided herein, the syringe barrel **91**, **91'** or **91''** is cylindrical in shape with a hollow center that can fit the plunger **92**, **92'** or **92''** so that the plunger can move back and forth inside the syringe barrel. The syringe can be made out of plastic or glass or other suitable material. Generally, the syringe is made out of glass or plastic, such as polypropylene, polyethylene, or polycarbonate. Other types of biocompatible materials may also be used. The syringe barrel can contain calibrations or markings on the outer surface in order to measure or detect the volume of solution. The calibrations can be marked in any measurement such as in cubic centimeters (cc), milliliters (mL), tenths of a milliliter, hundredths of a milliliter or other measurement. The volume of the syringe barrel can be selected by the operator depending on the particular application, the agent being administered, the type of device that is being used and other similar factors. For example, the volume of the syringe barrel can depend on the desired amount of fluid, such as a therapeutic, to be delivered, which is generally between 200 μ L and 10 mL, more typically 500 μ L to 2.5 mL, such as at least 500 μ L, 1 milliliter (mL), 2 mL, 2.5 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, 10 mL or more. For example, the syringe barrel can be 0.5 mL to 20 mL (i.e. 0.5 cc to 20 cc), and generally is 0.5 mL to 3 mL (i.e. 0.5 cc to 3 cc), such as at least or about a 1 mL (i.e. 1 cc) syringe. The syringe barrel also can have unit calibrations, such as present on standard insulin syringes (e.g. 100 units correlates to 1 mL). Typically, 200 μ L to 600 μ L of the fluid, such as a therapeutic, is delivered to the target locus, and the volume of syringe barrel is 1 mL.

The syringe barrel **91**, **91'** or **91''** is always positioned on the proximal side of the injection needle, but can be positioned on either side of the needle sheath controller and in a manner that is on the proximal or distal side of the needle sheath controller. For example, the syringe barrel can be positioned on the proximal side of the needle sheath controller, or inside the needle sheath **72**, **72'** or **72''**. In particular aspects, with reference to the Figures and description below, **FIG. 1A** and **1B** depict a device **60** where the syringe barrel **91** is proximal to the needle sheath controller **71**. In contrast, **FIG. 2** depicts a device **60'** where the syringe barrel **91'** is distal to the

- 39 -

needle sheath controller **71'** and is integrated with the needle sheath at its distal end.

FIG. 3 depicts a device **60''** where the syringe barrel **91''** is distal to the needle sheath controller **71'** and is dockable, and hence removable from, the needle sheath at the distal end.

5 In cases where sterile injections are required, the syringe barrel can be loaded with the fluid, such as a therapeutic, in a sterile environment, such as a sterile operating room, or a sterile pre-loaded syringe can be used. For example, a sterile standard or dockable syringe can be connected to the device after loading with the fluid, such as a therapeutic, in a sterile environment. In other cases, the entire device
10 is loaded, manipulated and operated in a sterile environment.

 The plunger is located at the proximal end of the device and is movable so that it can be pulled and pushed along the inside the syringe barrel. Portions of the plunger travel within the syringe barrel along the longitudinal axis of the device. The plunger is cylindrical to move through the syringe barrel, and is made of a material
15 that permits ease of movement through the syringe barrel. For example, the plunger generally is made of a plastic, such as polypropylene or polyethylene. The plunger also contains a head at the proximal end of the device that can be conveniently grasped by the operator to manipulate the plunger. The plunger head can transmit axial force from the operator in both the distal or proximal directions, leading to
20 depression and drawing back, respectively, of the plunger. The plunger can be drawn back to load the syringe barrel with the fluid, such as a therapeutic, or depressed to inject the fluid, such as a therapeutic, in the target tissue. Pulling back on the plunger draws in the fluid, such as a therapeutic, or air into the syringe barrel. Pushing in the plunger forces air or the fluid or air out of the syringe barrel. The plunger can also be
25 pulled back at the site of injection to test needle placement.

 The length of the plunger is sufficiently long to permit its association with the inside of the syringe barrel directly or indirectly in order to effect dispelling of the fluid, such as a therapeutic, or composition or solution through the distal end of the syringe (and into a needle or tube if connected thereto). For example, in some aspects
30 herein, a control plunger that is accessible to the operator can be adapted to be used with an auxiliary plunger when the syringe barrel is distally located. The length of the plunger can be 5 mm to 500 mm, such as 10 mm to 300 mm, 10 mm to 200 mm or 10

- 40 -

mm to 100 mm. Depending on the positioning of the syringe barrel with reference to the needle sheath controller, in some aspects the plunger also traverses through the needle sheath controller. In particular aspects, with reference to the Figures and description below, **FIG. 1A** and **1B** depict a device **60** where the plunger **92** is a standard plunger that is sized to move only within the syringe barrel **91** located at the proximal end of the device relative to the needle sheath controller. In contrast, **FIG. 2** depicts a device **60'** where the plunger **92'** is elongated to traverse through the needle sheath controller **71'** and hollow lumen of the needle sheath before traveling through the syringe barrel **91'** at the distal end of the device. In another aspect, **FIG. 3** depicts a device **60''** where the plunger **92''** is elongated to traverse through the needle sheath controller **71'** and hollow lumen of the needle sheath, but does not travel through the syringe barrel **92''** at the distal end of the device. Instead, the plunger is adaptable with an auxiliary plunger **920** that is sized to move only with the syringe barrel located at the distal end of the device.

The plunger **92**, **92'** or **92''** can be manually depressed or pulled back, or an automatic controller can be used to control the plunger. An automatic or mechanical plunger mechanism can deliver several fixed or variable doses of the fluid, such as a therapeutic, with or without having to remove the injection device from the laparoscopic port. For example, a means of depressing the plunger **92**, **92'** or **92''** can include hydraulic components, such as mechanically or electronically actuated piston and cylinder assemblies operatively connected, via hydraulic fluid lines, to the respective plunger **92**, **92'** or **92''** elements. The device can be used to deliver a single dose of the fluid, such as a therapeutic, or multiple injections to the same patient without withdrawing the device from the laparoscopic port. Multiple doses can be delivered at different injection sites, if the multiple sites are reasonably close to each other that removal from the laparoscopic port is not necessary. The injection of several discrete doses can be achieved using different controls, such as mechanical controls and hydraulic mechanisms. For example, hydraulic components, such as mechanically and/or electronically actuated piston/cylinder assemblies or hydraulic plunger actuators can be used to control the plunger, which permits the use of a stroke or a force multiplier, and also permits a flexible shaft for the plunger mechanism, to transmit axial force. For multiple injections, an indexed injection trigger is used to

- 41 -

deliver discrete doses of the fluid, such as a therapeutic, for example 100 microliter (μL), upon each pull of the trigger. The doses for multiple injections can be fixed or variable, and a volume control or a feedback mechanism for dose control for multiple injections can be used. Multiple doses provide an advantage over a single large dose
5 in that they can be manipulated by parameters such as the location of the tissue, geometrical parameters and temporal parameters.

In all aspects of the devices provided herein, the device contains an injection needle **81** that is located inside the sheath at the proximal end of the needle and can be sheathed and unsheathed at its distal tip. The injection needle typically contains a
10 beveled tip sufficient to penetrate or pierce a tissue or an organ. The injection needle **81** can be directly or indirectly connected to the distal end of the syringe barrel in a manner that permits passage of a fluid or solution in the syringe barrel through the needle to its distal tip. For example, in some aspects, the injection needle **81** can be indirectly connected to the syringe barrel by an intermediary tube **83** that, together
15 with the injection needle, form a continuous sealed fluid pathway for solution to move through. The intermediary tube can be a plastic or metal tube that is coupled directly or indirectly to the injection needle **81** by welding, bonding or molding. The intermediary injection tube **83** can be indirectly coupled to the injection tube **81** by a needle coupler **85**. The needle coupler **85** can be made of any biocompatible and drug
20 compatible rigid material, including metals, plastics, and ceramics, and is typically made of plastics such as polycarbonate or Acrylonitrile butadiene styrene (ABS). An optional coupling member **82** can be present inside the cavity of the needle coupler **85**. The needle coupler **85** is coupled to each of the intermediary injection tube **83** and injection tube **81** by welding, bonding, molding or other procedure that creates a
25 secure and reliable seal.

In some variations, the distal end of the syringe barrel can contain an adaptor that is compatible with a needle hub on the proximal end of the injection needle **81** or other intermediary tube **83** that itself is coupled to the injection needle **81**. For example, with reference to **FIG. 1A**, and as described further below, the distal end of
30 the syringe barrel **91** can contain a Luer fit adaptor **93** that is compatible with a needle hub **84** on the proximal end of intermediary injection tube **83**, which itself is directly or indirectly connected to the injection needle **81**. In other variations of the devices

- 42 -

herein, the proximal portion of the injection needle **81** or other intermediary tube **83** that couples to the injection needle is directly affixed to the distal end of the syringe barrel and extends out of the syringe barrel. For example, with reference to **FIGS. 2** and **3**, the injection needle **81** is directly connected to the syringe barrel.

5 The size and diameter of the injection needle **81** is selected depending on the ease of insertion into tissue, damage to tissue that can be tolerated, shear/flow parameters of the fluid such as viscosity, injection force and injection rate required for the fluid, properties of the target tissue, amount of dead volume that remains in the device after injection, and other factors considered by persons skilled in the art.

10 Typically, a small diameter needle **81** is employed to reduce the force required to insert the needle into the target tissue or organ, and to reduce trauma to the target tissue or organ. Generally, injection needle **81** is between 25 and 34 gauge, such as 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge or 31 gauge, and typically is 27 gauge.

15 The length of the injection needle **81** is dependent on the configuration of the syringe barrel in the device (i.e. whether the syringe barrel is located at the proximal or distal end of the device). The length of the injection needle **81** also is dependent on whether the needle is coupled directly to an intermediary injection tube **83** or is indirectly coupled to an intermediary injection tube **83** by a needle coupler **85**. Such
20 parameters can be related to the pressure drop that can be tolerated, the viscosity of fluid, the dead volume that can be tolerated, and other similar factors. For example, factors that influence pressure drop include the length of the needle, the diameter of the needle, and the viscosity of the fluid. A certain amount of injection pressure can be needed to deliver a fluid, such as a therapeutic, to a specific tissue. A specific
25 injection pressure can be needed for delivery of certain fluid compositions. The injection pressure required can depend on factors such as parameters of the fluid being delivered such as viscosity, injection rate, and target tissue pressure.

 For example, in some variations of the device, the injection needle **81** can be long and extend from the distal tip of the device through the sheath controller **71**
30 where it is connected to syringe barrel **91** at the proximal end of the device. Hence, the length of the injection needle can range from 5 mm to 500 mm or more, such as 10 mm to 300 mm. Generally, in examples of the devices herein, the injection needle

- 43 -

is shorter, which avoids problems in pressure drop that can occur when a solution is injected through a long needle. For example, the length of the injection needle generally can range from 5 mm and 40 mm, such as 10 mm to 40 mm. For example, common needle lengths that are widely available include for example, 12.7 mm, 25.4 mm or 38.1 mm needles. If a longer path is required for solution or fluid to travel (i.e. the syringe barrel is located at the proximal end of the device, e.g. **FIGS. 1A** and **1B**), a smaller injection needle **81** can still be employed, but a pressure drop can be avoided by directly or indirectly coupling a smaller diameter injection needle **81** to an intermediary injection tube **83** of a greater diameter. For example, if the injection needle **81** is 27 gauge, the intermediary injection tube can be 15 gauge to 25 gauge, such as generally 20 gauge to 25 gauge, for example 21 gauge.

The injection needle **81** of the device is protected by a blunt, elongated needle sheath, which can sheathe and protect the needle prior to injection and unsheath the needle at the site of injection. Hence, in all embodiments of the laparoscopic injection device provided herein, such as devices set forth in **FIGS. 1A, 1B, 2** or **3**, the needle sheath **72, 72'** or **72''** is adapted so that the injection needle **81** can be sheathed and unsheathed. The ability to sheathe or unsheath the injection needle **81** permits the operator of the device to control when the injection needle is exposed or when the injection needle is protected. For example, sheathing of the needle can prevent accidental injections or penetrations, damages to the patient's tissue, including the target tissue and non-target tissues, damages to the laparoscopic surgical instruments, such as damages to the elastomeric seals and valves of the laparoscopic port, damage to the needle, and accidental drip of the fluid, such as a therapeutic, during the insertion of the device into the laparoscopic port or removal of the device from the laparoscopic port. At the site of injection, the needle can be unsheathed, exposing the injection needle **81** to allow the needle tip to penetrate the target site and deliver the agent to the target site, such as the parenchyma of a target organ. The injection needle **81** can be sheathed again after injection to prevent accidental needle puncture of tissue other than the injection site.

In particular, the needle sheath **72, 72'** or **72''** is adapted to be controlled by the needle sheath controller **71** or **71'**. The needle sheath controller **71** or **71'** contains the components that control movement of the needle sheath **72, 72'** or **72''**, connects

- 44 -

the proximal and distal ends of the device, and is the conduit by which inner tubings, plungers or other components can travel between the proximal and distal ends of the device. The needle sheath controller **71** or **71'** includes a controller housing **710** that encloses components internal to the needle sheath controller **71** or **71'**, and the proximal end of the needle sheath **72**, **72'** or **72''**. The needle sheath controller housing **710** can be made of any suitably resilient and rigid material, such as any polymeric material, including plastics, or rubber, metals, ceramics, composites, or other suitable material known to one of skill in the art. Typically, the needle sheath controller housing **710** is made from a plastic, including medical-grade plastics such as polypropylene, polystyrene, polyethylene, polyvinyl chloride, polyurethane, or silicone, rubber or acrylic. The needle sheath controller housing **710** can be molded using any technique known in the art, including compression-molding, thermoforming or injection-molding. The housing **710** can be made of one singular piece, using methods such as by an injection molding. Alternatively, the housing **710** can include multiple pieces that are separately manufactured and attached in a secondary process, such as with adhesive, locking joints, or other fasteners.

As shown in **FIGS. 1A, 1B, 2 and 3**, the needle sheath controller **71** or **71'** is positioned on the proximal side of the needle sheath **72**, **72'** or **72''**. The needle sheath controller **71** or **71'** is configured to be held and manipulated by an operator, such as a surgeon. The needle sheath controller **71** or **71'** can be any shape and size that is convenient to permit the operator to hold and manipulate the device.

Generally, the needle sheath controller **71** or **71'** is cylindrical and can fit into the palm of an average person. The diameter of the needle sheath controller **71** or **71'** is larger than the diameter of the needle sheath **72**, **72'** or **72''** in order to accommodate the proximal end of the needle sheath **72**, **72'** or **72''**. For example, the diameter can be 15 mm to 100 mm, and is generally 20 to 35 mm. The diameter can be uniform or variable. For example, the outside of the needle sheath controller **71** or **71'** can be graduated, contoured, beveled or grooved. The needle sheath controller **71** or **71'** generally has a length of 30 mm to 225 mm, such as 50 mm to 75 mm. On the outside of the needle sheath controller **71** or **71'**, an optional grip can be present to facilitate the manipulation and handling of the device.

- 45 -

The needle sheath controller **71** or **71'** contains an externally accessible positioner **711**, which controls the position of the needle sheath **72** relative to the injection needle **81**. As can be seen in **FIGS. 1A, 1B, 2** and **3**, the needle sheath controller **71** or **71'** is a cylindrical ring having a positioner **711** extending out of the needle sheath controller **71** or **71'** so that it is accessible to the operator. The positioner **711** can be integrally formed with the housing **710**, or alternatively can be a separate piece coupled to the housing during assembly.

The positioner **711** is configured in the needle sheath controller **71** or **71'** so that it is movable both forward and rearward relative to the needle sheath controller **71** or **71'**. Movement of the positioner **711** forward or rearward controls movement of the needle sheath **72, 72'** or **72''** between two fixed or locked positions, the sheathed position **72a** and unsheathed positions **72c**. When sheathed, the injection needle **81** is hidden inside the needle sheath, and when unsheathed, the injection needle **81** is exposed outside of the needle sheath. The injection needle **81**, however, is fixed and does not move relative to the needle sheath controller **71** or **71'**. Thus, the positioner **711** only controls the movement of the needle sheath **72, 72'** or **72''**, while the position of the injection needle **81** and other components of the device are stationary regardless of the position of the positioner **711**. The relative position of the injection needle **81**, however, changes with the movement of the needle sheath **72, 72'** or **72''**, as the needle sheath **71** or **71'** moves in the distal direction or the proximal direction, hiding or exposing the injection needle **81**.

As shown in **FIG. 4A**, positioning of the positioner in a forward **711a** position moves the needle sheath over the injection needle in the sheathed position **72a** so that the injection needle is hidden inside the shaft of the needle sheath. As shown in **FIG. 4B**, positioning or moving the positioner to an intermediate position **711b**, that is not fully locked forward or rearward, transitions the needle from outside of the needle sheath shaft to a transitional position **72b** that exposes less of the needle than its maximum extent or length. As shown in **FIG. 4C**, positioning of the positioner in the rearward **711c** position moves the needle sheath proximally towards the needle sheath controller to its fully unsheathed position **72c**, thereby permitting maximum exposure of the injection needle **81**.

- 46 -

The positioner **711** is engaged with the needle sheath and slides the needle sheath. As can be seen in **FIGS. 5-7**, the movement of the needle sheath **72**, **72'** or **72''** by the positioner **711** is facilitated by a connection member **713**. The connection member **713** is connected to the proximal end of the needle sheath **72**, **72'** or **72''** and the lower part of the positioner **711**. The positioner **711** and the needle sheath connector **713** can be connected to each other by welding, adhesive, locking joints, fasteners or other suitable means. The distal end of the connection member **713** is connected to the proximal end of the needle sheath **72**, **72'** or **72''**, such that the sheath is longitudinally movable relative to the controller housing **710** and the injection needle **81**. In particular, the distal end of the outside of the connection member **713** is engaged with the proximal inside lumen **723** of the needle sheath around its circumference. The needle sheath **72**, **72'** or **72''** can be connected to the connection member **713** by welding, adhesive, locking joints, fasteners or other suitable means.

The lower portion of the positioner **711**, the connection member **713** and proximal end of the needle sheath **72**, **72'** or **72''** are enclosed by the controller housing **710**. With reference to **FIGS. 5-7**, the needle sheath controller housing **710** is molded with an internal needle sheath controller lumen **717** that is a hollow cavity inside the needle sheath controller **71** or **71'** of a sufficient length and diameter to accommodate forward and rearward movement of the connection member **713**. The length and diameter of the controller lumen **717**, however, is always less than the total length and diameter of the needle sheath controller **71** or **71''**, thereby restricting movement of the needle sheath connector **713** within the inside of the needle sheath controller **71** or **71'**. The controller lumen **717** is generally longitudinal along the housing body. The shape of the internal or central lumen **717** of the controller can be any of a variety of shapes and configurations, so long as it provides a tracking means along which the connection member **713** slides. For example, the controller lumen **717** can be cylindrical or rectangular. The controller lumen **717** also can be uniform or non-uniform in shape, size or diameter. For example, the distal and proximal ends can be the same diameter or different diameters.

The needle sheath controller housing **710** also contains cut-out grooves to serve as sheath stops **715** and **716** that provide a means to engage with the positioner **711**. As shown in **FIGS. 5-7**, the positioner **711** contains a projected top portion or

- 47 -

head that juts out of the needle sheath controller **71** or **71'** where it can be moved forward or rearward by the operator. Internal to the needle sheath controller **71** or **71'**, the body of the positioner **711** is notched on its sides or is otherwise configured to engage with sheath stops. The sheath stops **715** and **716** are grooves in the needle
5 sheath controller housing **710** that fit the notched body of the positioner and trap the positioner **711** so that it cannot be moved without external force.

The positioner **711** is configured to be lockable and releasable in the sheath stops **715** and **716**, such that when the positioner is engaged in a sheath stop it is secure to prevent the sheath from moving, but can be conveniently repositioned to
10 control the movement of the sheath. For example, the sheath stops can be configured in a manner that creates a cradle for the positioner so that the positioner **711** is secured within the sheath stop and is not able to fall out of the cradle in the stop. To move the positioner **711** out of the cradle in the stop, the positioner must be physically moved outward from the cradle, so that the positioner **711** can be repositioned. To lock the
15 positioner, the positioner must be physically moved inward (towards the grooves or cradle in the stop) to engage with the cradle created in the stop. Thus, the positioner **711** can also be pivoted to move outward (away from the grooves or cradle in the stop) to unlock from the sheath stops **715** and **716**, then slid along the longitudinal axis to change positions, and pivoted again to move inward (towards the grooves or
20 cradle in the stop) to engage with and lock into the sheath stops **715** and **716** to lock the positioner **711** and the needle sheath **72**.

As an alternative, the positioner **711** can contain a lock and release element that facilitates lock and release of the positioner with the grooves of the sheath stops. **FIG. 5** depicts an optional lock and release element **712** that can be contained in the
25 positioner to facilitate lock and release of the positioner **711** with the grooves of the sheath stops. For example, the lock and release element **712** can be a spring or other resilient means. When the positioner **711** is moved or fit into the grooves of a stop it is locked into place by a vertically upward force against the positioner **711** and a downward force against the connection member **713**. Pressing the positioner **711**
30 vertically downwards releases the vertically upward force applied by the lock and release element **712**, and releases the positioner from the stops.

- 48 -

Because the positioner **711** and the connection member **713** are connected, the movement of the positioner **711** can control the movement of the connection member **713** and the connected needle sheath **72**, **72'** or **72''**. Therefore, movement of the positioner **711** between the sheath stops **715** and **716** moves the needle sheath **72**, **72'** or **72''** between the sheathed and unsheathed positions. In other variations, the lock and release mechanism can be a latch or switch that can be selectively engaged or disengaged according to its mechanical nature, for example, by sliding a latch or pivoting a lever attached to the head of the positioner **711**, thereby moving it out of the way of a notch or other fastening mechanisms in the groove of the sheath stops.

For example, with reference to **FIGS. 5-7**, the needle sheath controller housing **710** contains two sheath stops **715** and **716** that are arranged into the needle sheath controller housing **710** on the proximal and distal sides of the positioner **711**. With reference to **FIG. 5**, when the positioner **711** is engaged in either of the sheath stops **715** or **716**, the lock and release element **712**, such as a spring, can exert a force against the positioner **711** in the vertically upward direction, and the connection member **713** in the downward direction. Unless force is applied against the lock and release element **712** by pressing the positioner **711** down, the positioner **711** and connection member **713** have a tendency to be pushed away from each other in the vertical direction, due to the force exerted by the lock and release element **712**. The force that pushes the positioner **711** in the upward direction permits the positioner **711** to be locked in place in either the distal sheath stop **715** or the proximal sheath stop **716**. If the positioner **711** is pressed vertically downward, the positioner **711** is freed from the grooves and can move in the forward or rearward direction longitudinally.

FIGS. 5-7 demonstrate the alternative positions of the positioner **711** relative to the sheath stops. For example, **FIG. 5** depicts the positioner **711** in the forward position **711a** where it is engaged or fit into the distal sheath stop **715**. When the positioner **711** is engaged with distal stop **715**, the connection member **713** is longitudinally moved to the furthest distal position within the controller lumen **717** and the sheath is in the extended position hiding the needle tip. **FIG. 6** depicts the positioner **711** in the rearward position **711c** where it is engaged or fit into the proximal sheath stop **716**. When the positioner **711** is engaged with proximal stop **716**, the connection member is longitudinally moved towards the proximal end of the

- 49 -

needle sheath lumen, thereby exposing the injection needle. **FIG. 7** depicts the positioner **711** in an intermediate position **711b** after releasing the positioner from its locked position in either sheath stop and sliding the positioner along the longitudinal axis. In this position, the injection needle **81** is in an intermediate unsheathed
5 position, but is not fully exposed.

The extent or length of the injection needle **81** that can be exposed or unsheathed at the distal end of the device is related to the distance along the longitudinal axis between a first sheath stop and a second sheath stop, which is the distance that the positioner **711**, and hence connection member **713** controlling the
10 position of the sheath, moves between locked positions. For example, with reference to **FIGS. 5-7**, the extent or length of the injection needle **81** that can be exposed or unsheathed at the distal end of the device can be substantially the same as the distance between the distal sheath stop **715** and the proximal sheath stop **716**. It is understood, however, that the extent or length of the injection needle that is exposed can be
15 somewhat longer or shorter than the distance between the first and second groove stop due to a slight recess of the distal tip of the injection needle in the distal tip of the needle sheath when it is unsheathed. For example, if the distal tip of the injection needle **81** is recessed from the distal tip of the needle sheath **73** in the fully sheathed position **72c**, the extent or length the injection needle that can be exposed is shorter
20 than the distance between a first sheath stop and a second sheath stop. A needle that is exposed substantially the same as the distance between the sheath stops is recessed only slightly and no more than 1 mm, such that the difference in the distance of the sheath stop and the length that the injection needle that can be exposed is less than 1 mm or 0.5 mm or less. As an example, if the distal tip of the injection needle **81** is
25 slightly recessed from the distal tip of the needle sheath **73** in the fully sheathed position **72c**, the maximum extent or length of the injection needle that can be exposed or unsheathed at the distal end of the device is the distance between the distal sheath stop **715** and the proximal sheath stop **716**, minus the slight distance between the tip of the injection needle **81** and the distal tip of the needle sheath **73** in the fully
30 sheathed position.

In other examples, the length of the injection needle that is exposed or extended is appreciably shorter than the distance between the sheath stops. In this

- 50 -

case, the injection needle can be positioned so that it is recessed inside the distal tip of the needle sheath **73** in the unsheathed position **72c** more than 1 mm, and generally 2 mm to 5 mm, from the distal tip of the needle sheath **73** in the unsheathed position **72c**. Thus, if the distal tip of the injection needle **81** is recessed from the distal tip of the needle sheath **73** in the fully sheathed position **72c**, the maximum extent or length of the injection needle that can be exposed or unsheathed at the distal end of the device is the distance between the distal sheath stop **715** and the proximal sheath stop **716**, minus the distance between the tip of the injection needle **81** and the distal tip of the needle sheath **73** in the fully sheathed position.

10 The extent or length of the injection needle **81** that is exposed when unsheathed can be empirically determined, and is a function of the target tissue, the particular subject being treated, the agent being administered and other factors within the level of a skilled artisan. For example, the extent of the injection needle that is unsheathed is of a sufficient length so that the needle tip can penetrate the
15 parenchyma of the target tissue of interest, but not so long that it can easily pass through or puncture the target tissue through to the other side. Typically, the desired length of the exposed injection needle when unsheathed is from or from about 2 mm to 10 mm, such as generally 5 mm to 10 mm. For example, general adult tissues, such as the liver, have a thickness of 10 mm to 30 mm. The thickness of the tissue can vary
20 depending on the anatomical dimensions of the subject, such as age, height, weight, and/or the type of tissue or organ. Hence, the distance between the distal sheath stop **715** and the proximal sheath stop **716** is 2 mm to 15 mm, such as 2 mm to 12 mm, 2 mm to 10 mm, such as generally 5 mm to 10 mm.

 In variations of the injection devices herein, more than two sheath stops, such
25 as 3, 4, 5 or more sheath stops, can be configured into the needle sheath controlling housing **710** that can each engage separately with the positioner **711** to lock the sheath. Engagement of the positioner with the most distal sheath stop locks the sheath in its fullest extended position to completely hide the injection needle inside the needle sheath. Engagement of the positioner with the most proximal sheath stop locks
30 the sheath in its fullest retracted or opened position to maximally expose the injection needle outside of the needle sheath. The other sheath stops provide means to vary the length of the exposed injection needle from its fully sheathed or unsheathed positions.

- 51 -

Hence, the length of the exposed injection needle **81** can be varied with use of multiple needle sheath lock grooves. For example, in addition to the proximal **715** and distal **716** needle sheath stops, several additional sheath stops can be present, between the proximal and distal stops, permitting the positioner **711** and the needle sheath **72**, **72'** or **72''** to be locked in several different positions, with different lengths of the injection needle **81** exposed. As an example, the controller housing **710** can contain four sheath stops that are separated along the longitudinal axis by a distance of 2 mm. Thus, the positioner **711** can be locked in four different positions, resulting in positioning of the injection needle so that it can be sheathed, or exposed by 2 mm, 4 mm or 6 mm.

10 The connection member **713** contains a central cavity that is also longitudinal along the housing body and is of a sufficient size to slide around and independently from components of the device that traverse through the needle sheath controller **71**, **71'** or **71''**. For example in **FIGS. 5-7**, an injection tube or plunger can traverse through the inside of the needle sheath controller across its longitudinal axis. In particular, **FIG. 5** shows an intermediary injection tube **83** that traverses through the inside of the needle sheath controller, and the connection member **713** contains a central cavity that slides around and independently from the injection tube **83**. The injection tube **83** is fixed to the needle sheath controller **71** at its proximal end. As shown in **FIGS. 6-7**, the plunger **92'** or **92''**, respectively, longitudinally traverses through the inside of the needle sheath controller **71'**, and the connection member **713** contains a central cavity that accommodates and slides around and independently from the plunger **92'** or **92''**. The plunger is movable within the needle sheath controller **71'** and is not fixed thereto. The particular width or size of the cavity is dependent on the particular component that traverses through it. The connection member **713** is disengaged from and moves independently with respect to the components (e.g. injection tube or plunger) that run through its internal central cavity.

In aspects of the injection device provided herein, the needle sheath optionally has a visibility window, allowing visualization of the drawback fluids to test needle placement in target organs. For injections into the parenchyma of a target organ that has extensive vasculature, the drawback fluid can be used to confirm needle placement into the parenchyma, and avoid injections into the vasculature or the bile

- 52 -

duct. At the site of injection, the plunger can be pulled back slightly to draw a small amount of fluids, in order to determine whether the needle was placed at a blood vessel or the target organ. Once the needle **81** is positioned and has penetrated the target injection site, the plunger **92, 92' or 92''** can be depressed to deliver the fluid, such as a therapeutic, contained in the syringe barrel to the target site.

The syringe barrel **91, 91' or 91''** and/or the device can be disposable or reusable. For example, except if the syringe is integrated with the device, the syringe barrel can be removed after injection or exhaustion of the fluid, such as a therapeutic, replaced with a new loaded syringe, or reloaded and re-connected. If the syringe barrel is at the outside the laparoscopic port, such as described with device **60**, this can be achieved without the need to withdraw the device from the laparoscopic port. In some cases, the device can be withdrawn from the laparoscopic port and disposed of after one use. The method of loading and the type of syringe and syringe format employed can be empirically determined and is a function of factors considered by persons of skill in the art, such as the objective of the injection, target tissue or organ, dose and frequency of injections needed, properties of the fluid, such as a therapeutic, composition, and surgical environment.

For clarity of description, exemplary embodiments of the injection device are described below. It is understood that for the described embodiments, general aspects and components of the device are the same, and that different aspects or components are so described. Thus, except as noted, the description of the various exemplary embodiments and the structures of the embodiments described above apply to all embodiments of the injection device. Additionally, the methods of using the injection device, for example for injection of a fluid, such as a therapeutic, to a target tissue during a minimally invasive procedure, apply to all embodiments as well. The particular injection device employed can be empirically determined and is a function of factors considered by persons of skill in the art, such as the objective of the injection, target tissue or organ, dose and frequency of injections needed, properties of the fluid, such as a therapeutic, composition, and surgical environment.

1. STANDARD INJECTION DEVICE

FIGS. 1A-B, 5, 8A-B, and 9A-D depict the injection device **60** and components and features thereof. The injection device as shown in **FIGS. 1A and 1B**

- 53 -

includes needle sheath **72**, needle sheath controller **71**, injection needle **81**, syringe barrel **91** and plunger **92**. With reference to **FIG. 1A**, generally, the needle sheath **72** of the injection device is of a sufficient length to permit laparoscopic access to the target of interest, and is generally a length of 200 mm to 600 mm, such as 250 to 400 mm, and generally at least or about at least or 300 mm. The device is generally cylindrical around the longitudinal axis, generally having a smaller diameter in the needle sheath **72** region and the plunger **92** region, and a larger diameter in the needle controller **71** region. The needle sheath **72** portion of the device is typically inserted through the laparoscopic port. The diameter of the needle sheath **72** is typically between 3 mm to 12 mm in size, and typically from 5 mm to 10 mm. It is understood that the portions of the device external to the laparoscopic port can have a diameter greater than 10 mm. For example, the needle sheath controller body **71** can have a diameter sufficiently large, so long as it can be easily gripped or handled by the operator. The needle sheath controller body **71** is held by the operator, typically a surgeon, to manipulate and position the device **60**, control the needle sheath **72**, and support the device while manipulating the plunger **92**.

The syringe barrel **91** is cylindrical in shape with a hollow center that can fit plunger **92** so that the plunger can move back and forth inside the syringe barrel. The syringe barrel is generally clear and transparent. The syringe barrel **91** can be made out of plastic or glass or other suitable material, and in particular is made out of plastic such as polypropylene, polyethylene, polycarbonate or other clear material. As described above, the syringe barrel **91** can contain calibrations or marking on the outer surface to indicate the volume of the agent within the barrel. As described above, the syringe barrel **91** can have a volume capacity that is from the range of 0.5 mL to 20 mL (i.e. 0.5 cc to 20 cc), and generally is 0.5 mL to 3 mL (i.e. 0.5 cc to 3 cc), such as at least or about a 1 mL (i.e. 1 cc) syringe. Typically, 200 μ L to 600 μ L of the fluid, such as a therapeutic, is delivered to the target locus, and the volume of syringe barrel is 1 mL.

The syringe barrel **91** is positioned proximal to the injection needle **81**, and on the proximal side of the needle sheath controller **71**. As shown in **FIG. 1A**, the distal end of the syringe barrel **91** contains a Luer fit adaptor **93** that is compatible with a needle hub **84** on the proximal side of the needle sheath controller **71**. The syringe

- 54 -

barrel **91** is removable and attachable with the needle sheath controller **71** and the connected needle sheath **72** by manipulation of the Luer fit locking mechanisms. **FIG. 1A** shows the syringe in the detached position **900a**. Thus, a sterile syringe barrel **91** can conveniently be used when drawing up or loading the syringe with a fluid, such as a therapeutic, compositions or other solutions into the syringe barrel. If desired, a separately sterile needle can be fitted on the Luer fit adaptor **93** to permit loading of the syringe barrel **91** with a fluid, such as a therapeutic. After the agent is drawn up into the syringe, the syringe barrel **91** (without needle) can be secured to the needle sheath controller **71** through the Luer fit adaptor **93** on the distal end of the syringe barrel **91** and the needle hub **84** on the proximal end of the needle sheath controller **71**. In some cases, a pre-loaded syringe with standard Luer fit adaptor **93** can be connected. **FIG. 1B** shows injection device **60** with the syringe barrel **91** secured to the needle sheath controller, in the connected position **900b**. Advantages of device **60** having a removable and attachable syringe barrel **91** include the ease of loading the syringe barrel and exchange of loaded syringe. Since standard syringes can be used to connect to the needle sheath control **71**, a variety of syringe types can be used, and several different types of syringes can be used for one patient, if necessary. In cases where the syringe must be re-loaded or additional fluid is needed, new or re-loaded syringes can easily be connected.

The plunger **92** is located on the proximal end of the device **60** and is movable so that it can be pulled and pushed along the inside of the syringe barrel **91**. The plunger **92** can be drawn back to load the syringe barrel **91** with the fluid or depressed to inject the fluid in the target tissue. The plunger **92** can also be pulled back at the site of injection to test needle placement. The plunger is cylindrical to move through the syringe barrel **91**, and is made of a material that permits ease of movement through the syringe barrel, such as a plastic, for example polypropylene or polyethylene. The plunger contains a head **95** at the proximal end of the device that can be conveniently grasped by the operator to manipulate the plunger. The plunger head **95** also is generally made of plastic. The distal tip of the plunger **92** is generally made of silicone or other natural or synthetic rubber to provide a tight seal within the syringe barrel **91** when traveling within the syringe barrel **91**.

- 55 -

The plunger **92** is long enough in length to permit its association with the inside of the syringe barrel **91** in order to dispel the fluid through the distal end of the syringe (and into a needle or tube if connected thereto). For example, the plunger is 5 cm to 50 cm, such as 5 cm to 30 cm or 10 cm to 20 cm. Pulling back on the plunger **92** draws in the fluid, such as a therapeutic, or air, and pushing the plunger **92** forces the fluid, such as a therapeutic, or air out of the syringe barrel. Optionally, the plunger can contain syringe barrel base **94** that can aid manipulation of the syringe barrel **91** with respect to the plunger **92**.

The syringe barrel **91** and/or the device **60** can be disposable or reusable. For example, the syringe barrel **91** connected to the proximal side of the needle sheath controller **71** through a Luer fit adaptor **93**, can be removed after injection of the fluid, such as a therapeutic, replaced with a new loaded syringe, or reloaded and re-connected, with or without the need to withdraw the device from the laparoscopic port. The device **60** can be withdrawn from the laparoscopic port and disposed of after one use.

The device **60** contains an injection needle **81** that is located inside the needle sheath **72** that can be sheathed and unsheathed at the distal tip of the needle **81**. With reference to **FIG. 1A**, the distal tip of the needle sheath **73** contains a needle channel **733** that guides the needle outside of the needle sheath **72** when it is unsheathed as shown in **FIG. 1B**. As shown in **FIG. 1B**, the injection needle **81** contains a beveled tip sufficient to penetrate or pierce a tissue or an organ.

FIG. 5 depicts an enlarged cross section view of the distal end of the syringe barrel **91** and the needle sheath controller **71**. As shown in **FIG. 5**, the plunger **92** is contained within the syringe barrel **91**, which optionally can contain a syringe base **94**, where it can movably travel. The needle sheath controller **71** is positioned on the proximal side of the needle sheath **72**. The needle sheath controller **71** contains the components that control movement of the needle sheath **72**, connect the proximal and distal ends of the device, and is the conduit by which the injection needle **81**, directly or indirectly connected to an intermediary injection tube **83**, travel between the proximal and distal ends of the device. The needle sheath controller **71** is configured to be held and manipulated by an operator, such as a surgeon. As discussed above, the needle sheath controller **71** can be any shape and size that is convenient to permit

- 56 -

the operator to hold and manipulate the device, and typically is cylindrical in shape. The diameter of the needle sheath controller **71** is such that it can be held in the palm of an average adult, and is generally 20 mm to 100 mm in diameter with a length of 50 mm to 225 mm. The needle sheath controller **71** optionally can contain an outside
5 grip for handling.

As shown in **FIG. 1A-B** and **FIG. 5**, the needle sheath controller **71** includes a controller housing **710** that encloses components internal to the needle sheath controller **71**, and the proximal end of the needle sheath **72**. As discussed above, the needle sheath controller housing **710** can be made of any suitably resilient and rigid
10 material, such as any polymeric material, including plastics, or rubber, metals, ceramics, composites, or other suitable material known to one of skill in the art. The controller housing **710** is typically made of polypropylene, polystyrene, polyethylene, polyvinyl chloride, polyurethane, silicone, rubber or acrylic. As discussed above, the housing **710** can be made by any manufacturing known to a skilled artisan, and can be
15 made as one singular piece or can be made of two or more pieces that are attached together, such as with adhesive, locking joints or fasteners.

As shown in **FIG. 1A** and **1B**, the needle sheath controller **71** contains an externally accessible positioner **711**. As described above, the positioner **711** is configured in the needle sheath controller **71** so that it is movable both forward and
20 rearward relative to the needle sheath controller **71**. As described above, the positioner **711** is engaged with the needle sheath **72** through a connection member **713**, and can be used to slide the needle sheath **72**. This connection permits movement of the positioner **711** between the forward or rearward positions to control movement of the needle sheath between two fixed or locked positions, the sheathed
25 and unsheathed positions. The sheathed position protects or hides the injection needle, while the unsheathed position exposes the needle.

With reference to **FIG. 5**, the connection member **713** is connected to the proximal end of the needle sheath **72**, and the lower part of the positioner **711**. The connection of the connection member **713** with the proximal end of the needle sheath
30 is such that the needle sheath **72** is longitudinally movable relative to the controller housing **710** and the injection needle **81**. For example, the distal end of the outside of the connection member **713** is engaged with the proximal inside cavity of the needle

- 57 -

sheath **72** around its circumference. The connections of the control member **713** with the positioner **711** and needle sheath **72** can be by welding, adhesive, locking joints, fasteners or other suitable means.

As described above generally, the connection member **713** moves inside a
5 hollow cavity or lumen **717** contained inside the housing **710** of the needle sheath controller **71** that is closed at both ends relative to the housing **710**. The controller lumen **717** accommodates the connection member **713** such that the connection member **713** can easily glide or move forward or rearward in a restricted manner. For example, the connection member **713** can be cylindrical and fit inside a cylindrical
10 hollow lumen cavity **717**. As shown in **FIG. 5**, and discussed further below, the connection member **713** contains an internal hollow cavity to fit the injection tube **83** that passes through.

Movement of the connection member **713** is controlled by the positioner **711**. As shown in **FIGS. 1A, 1B** and **5**, the positioner **711** contains a projected top portion or head that juts out of the needle sheath controller **71** where it can be moved forward
15 or rearward by the operator. As shown in **FIG. 5**, internal to the needle sheath controller **71**, the body of the positioner **711** is notched on its sides or is otherwise configured to engage with sheath stops **715** or **716**. Sheath stops **715** and **716** are grooves in the needle sheath controller housing **710** that fit the notched body of the
20 positioner and trap the positioner **711** so that it cannot be moved.

FIG. 5 depicts the optional lock and release element **712** configured in the positioner **711** to facilitate lock and release of the positioner with the grooves of the sheath stop **715** or **716**. For example, the lock and release element **712** can be a spring or other resilient means. The mechanism controlling lock and release of the
25 positioner **711** with the grooves of the sheath stop **715** or **716** by the lock and release element **712** is as described above, whereby downward, vertical or lateral forces release or lock the positioner **711** from the sheath stops **715** or **716**. Pushing downward on the positioner **711** permits the positioner to slide and to fit it into either of sheath stops **715** or **716**.

30 Movement of the positioner **711** between the sheath stops **715** and **716** moves the connection member **713**, and thereby also moves the needle sheath **72** so that it can transition from the sheathed and unsheathed positions by control of the positioner

- 58 -

by the operator. When the positioner is in the forward position **711a** as exemplified in **FIG. 5**, proximal sheath stop **716** is free and the positioner **711** is fit into the distal sheath stop **715**, thereby sheathing the injection needle so that it is protected. While not shown in **FIG. 5**, the positioner **711** also can be in the rearward position **711c** as exemplified in **FIG. 6**, where the distal sheath stop **715** is free and the positioner **711** is fit into the proximal sheath stop **716**, thereby unsheathing the injection needle so that it is exposed. As a further position, the positioner **711** also can be in an intermediate position **711b** as exemplified in **FIG. 7**, where both the distal sheath stop **715** and the proximal sheath stop **716** are free and not engaged with the positioner **711**.

The injection needle **81** shown in **FIG. 1B** is indirectly connected to the syringe barrel **91** through an intermediary injection tube **83** as shown in **FIG. 1A** and **5**. The injection tube **83** contains a proximal needle hub **84** that is secured with the Luer fit adaptor **93** of the syringe barrel **91**. The injection tube **83** is fixed directly to the needle sheath controller housing **710** so that the injection tube, and hence injection needle coupled thereto at the distal end of the device, is not movable.

As shown in **FIG. 5**, the injection tube **83** passes through the inside lumen **717** of the needle sheath controller **71** and passes through a central cavity of the connection member **713**, but is not directly attached to the connection member. Hence, the connection member **713** can move independently around the fixed injection tube **83**. As discussed above, because the needle sheath **72** is directly connected to the connection member **713** contained in the controller lumen **717**, the injection tube **83** enters the lumen **723** of the needle sheath **72** inside the needle sheath controller **71**. The injection tube **83** exits the distal end of the needle sheath controller **71** where it is contained within the hollow cavity of the needle sheath **72**.

With reference to **FIGS. 8A** and **8B**, the injection tube **83** runs distally and longitudinally through the needle sheath **72** where it is connected to the injection needle **81**. The injection tube **83** and the injection needle **81** can be made of one piece, or made of more than one separate pieces. When the injection tube and injection needle **81** are made of one piece, the injection tube **83** can also be an elongated tapered needle, having a larger diameter in the proximal region, and a smaller diameter in the distal region near the injection needle **81**. Optionally, a needle

- 59 -

coupler **85**, made of the same or different material, can be used to indirectly connect the two parts. The injection tube **83** and injection needle **81** can be made of the same material, or of different material. The injection tube **83** and the injection needle **81** have the same diameter, or a different diameter.

5 As shown in **FIGS. 8A** and **8B**, the injection tube **83** is indirectly coupled to the injection needle **81** through a needle coupler **85**. The coupler **85** connects the injection tube **83** to the injection needle **81** to form a continuous sealed fluid pathway for solution to move through. The connection can be by welding, bonding, molding or other procedure that creates a secure and reliable seal. The coupler **85** can be made
10 of any biocompatible and drug compatible material suitable to provide a seal, and generally is made of a plastic. The coupler **85** can be clear or transparent or opaque. For example, the coupler **85** can be made of polycarbonate or other clear material. As discussed further below, in embodiments where the needle sheath **72** contains an optional visibility window **724** to view drawn up fluids, the needle coupler **85**
15 generally is clear or transparent to permit visualization of the fluid or solution through the window.

The injection needle **81** contains a beveled tip sufficient to penetrate or pierce a tissue or an organ. The injection needle **81** is typically made of metal or alloy, such as surgical stainless steel or other medical grade metal. The size and diameter of the
20 injection needle **81** is selected based on parameters described above. As described above, typically a small diameter needle **81** is employed to reduce the force required to insert the needle into the target tissue or organ, and to reduce trauma to the target tissue or organ. For example, the injection needle **81** is between 25 and 34 gauge, such as a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge or 31 gauge
25 needle, and typically is 27 gauge.

The gauge of the injection tube **83** can be the same or different than the injection needle **81**. The device provided herein is generally designed, however, to minimize pressure drop throughout the path that the fluid traverses. Factors that influence the pressure within the column of fluid includes the length of the needle,
30 viscosity of the fluid contained within, rate of delivery of the fluid, and the gauge of the needle. The device is designed to have reasonable axial force requirements to depress the plunger **92**, thereby permitting delivery of the fluid in a laparoscopic

- 60 -

manner with sufficient injection pressure. For example, the axial force required to depress the plunger **92** in order to inject the fluid to the target organ is typically less than 2 pounds of force (lbf), preferably less than 1 lbf. The axial force required to depress the plunger **92** can also depend on the desired rate of delivery of the fluid, and
5 the optimal pressure can also depend on the operator. In some cases, a significant injection force can be required to inject the fluid through a long needle of the laparoscopic device. To prevent an immediate significant pressure drop when the fluid traverses the injection tube **83**, a larger gauge injection tube can be used. Thus, in order to reduce pressure drops that can occur due to the long path created by the
10 continuous sealed fluid pathway made up of the injection tube **83**, coupler **85** and injection needle **81**, the injection tube **83** generally has a larger diameter than the injection needle **81**.

For example, if the syringe barrel **91** is positioned at least 300 mm proximal to the injection needle **81**, and the fluid, such as a therapeutic, must traverse a long path
15 through the needle sheath shaft **72**, a significant pressure drop can occur. In this case, an injection tube **83** of a larger diameter can be used, coupled to an injection needle **81** with a smaller diameter, to prevent the large pressure drop when traversing through a narrow needle **80**. An optional needle coupler **85** can be used to join the injection tube **83** with the injection needle **81**. The needle coupler **85** contains a recess by
20 which the injection tube **83** and the injection needle **81** can be press fit to stably hold the position of the needle components in place within the needle sheath lumen **723**. The needle coupler **85**, can optionally contain a coupling member **82** to facilitate coupling of the injection tube **83** and the injection needle **81** in the recess of the needle coupler **85**.

25 If the gauge of the injection tube **83** and injection needle **81** are different, the coupler **85** can be sized to fit the opposing diameters, for example, it can be beveled on its proximal or distal end. In particular examples, the injection tube **83** is 15 gauge to 25 gauge, and the injection needle **81** is 25 gauge to 34 gauge. For example, the injection tube **83** is 21 gauge and the injection needle **81** is 27 gauge. The injection
30 tube **83** can be made of metal or plastic, such as any surgical grade materials. The combined length of the injection tube **83**, coupler **85** and injection needle **81** is sufficiently long to pass from the distal end of the syringe barrel **91** to the distal end

- 61 -

of the needle sheath **72**, for example is 100 mm to 600 mm long, and generally at least or about at least 300 mm. The particular size of the injection tube **83**, coupler **85** and injection needle **81** can be chosen by the user and can depend, for example, on the convenience of available injection needles. For example, commonly used injection
5 needles are sized as 12.7 mm, 25.4 mm or 38.1 mm needles.

The continuous sealed fluid pathway formed by the injection tube **83**, coupler **85** and injection needle **81** pass through and traverse the central inside hollow cavity or lumen **723** of the needle sheath **72**. The needle coupler **85** also holds the injection tube **83**, and injection needle **81**, so that the needle sheath **72** can slide over the
10 injection tube **83**, needle coupler **85** and injection needle **81** when the sheath is moved between the sheathed position **72a** and unsheathed position **72c**. For example, the needle coupler **85** is loosely fit into the hollow circular sheath lumen **723**. Thus, the needle sheath **72** moves independently from the needle coupler **85**. The needle coupler **85** can be made of any biocompatible and drug compatible rigid material,
15 including metals, plastics, and ceramics, and is typically made of plastics such as polycarbonate or Acrylonitrile butadiene styrene (ABS). The injection tube **83** and injection needle **81** can be press fit into the recess of the needle coupler to create a stable fixed relationship with the needle coupler **85**, and hence also the housing **710**. An optional coupling member **82** can be present inside the recess of the needle
20 coupler **85** and can be connected to the injection tube **83** and injection needle **81**. The coupling member **82** is coupled to each of the intermediary injection tube **83** and injection tube **81** by welding, bonding, molding or other procedure that creates a secure and reliable seal. The coupling member **82** can be made of any biocompatible and drug compatible rigid material, including metals, plastics, and ceramics, and is
25 typically made of plastics such as polycarbonate or Acrylonitrile butadiene styrene (ABS).

At the distal end of the device **60**, the needle sheath **72** ends in a distal tip of the needle sheath **73** that contains a needle channel **733**. The needle channel **733** is sufficiently sized to fit the injection needle **81** so that the injection needle can extend
30 and retract through the needle channel **733** as the needle sheath **72** moves. In **FIG. 8A**, the injection needle **81** is covered by the needle sheath **72** and does not traverse through the distal portion of the needle channel **733**. With reference to **FIG. 4A**, the

- 62 -

device **60** in **FIG. 8A** is in the sheathed position **72a**. In **FIG. 8B**, the injection needle **81** is extended out of the needle sheath **72** and does traverse through the distal portion of the needle channel **733**. With reference to **FIG. 4C**, the device **60** in **FIG. 8B** is in the unsheathed position **72c**.

5 In the unsheathed position, the needle sheath **72** is pulled back, but the injection tube **83**, needle coupler **85** and injection needle **81** are fixed and do not move. For example, as shown in **FIG. 8B**, because the needle sheath **72** is pulled back, the size of the sheath lumen **723** between the distal end of the needle coupler **85** and the distal tip **73** of the device is shortened compared to the size of the
10 corresponding sheath lumen shown in **FIG. 8A**. This demonstrates that movement of the sheath, as described with reference to **FIG. 5** above using the positioner **711**, only controls the movement of the needle sheath **72**, while the position of the injection needle **81** and other components of the device are stationary regardless of the position of the positioner **711**.

15 As described above, in the unsheathed position, the extent by which the injection needle **81** is extended or exposed out of the device **60** is a function of the distance between the sheath stops **715** and **716** as shown in **FIG. 5**. This distance is a function of the particular application of the device, the particular target tissue, the subject being treated and other considerations. For example, unsheathed needle that is
20 exposed should not be so long that it can easily penetrate through to the other side of a target tissue. Generally, with reference to most target tissues (e.g. liver), the portion of the injection needle **81** shown in **FIGS. 8B, 9B** and **9D** that can be unsheathed or exposed is generally less than 1 cm, such as 2 mm to 10 mm, and generally no more than 5 mm. For a child, the length can be smaller, and is generally less than 4 mm.
25 For applications *in utero*, the length can be 2 mm to 3 mm.

 The needle sheath **72** can be solid or can be transparent or clear. In some cases, the needle sheath **72** contains an optional visibility window **724**. As described above, the presence of the visibility window **724** allows visualization of the administered agent or solution as well as the drawback fluids. For example, since
30 some applications require injection directly into the parenchyma, and not into a vessel or bile duct, the ability to drawback and visualize fluid from the area the needle has penetrated can be used to confirm needle placement into the parenchyma, while

- 63 -

avoiding injections into the vasculature or bile ducts. Since device **60** is long and the plunger **92** is outside of the body it is helpful to visualize the fluid path closer to the injection site and within the view of the laparoscope. To achieve this, a visibility window **724** can optionally be present in the needle sheath **72** to visualize the fluid path through a clear or transparent needle coupler **85**. **FIGS. 9A** and **9C** provide corresponding perspective views of the needle sheath shown in **FIG. 8A** in the sheathed position **72a**. In **FIG. 9A**, the needle sheath **72** is solid and the injection needle inside the sheath cannot be visualized. In **FIG. 9C**, the needle sheath **72** contains a visibility window **724** that permits visualization of the inside components of the needle sheath **72**, including the injection needle. Likewise, **FIGS. 9B** and **9D** provide corresponding perspective views of the needle sheath shown in **FIG. 8B** in the unsheathed position **72c**. In **FIG. 9B**, the needle sheath **72** is solid and the injection needle **81** inside the sheath is extended, but otherwise cannot be visualized inside the needle sheath **72**. In **FIG. 9D**, the needle sheath **72** contains a visibility window **724** that permits visualization of the inside components of the needle sheath **72**, including the portion of the injection needle **81** that is not extended out of the sheath. It is understood that the visualization window **724** in **FIGS. 9B** and **9D** is for exemplification only, and that the visualization window can be any desired size. For example, the visualization window can extend the entire sheath. It also can extend distally and include portions of the distal tip of the needle sheath **73**. Other variations also are contemplated and can be easily envisioned by a skilled artisan in view of this description.

The syringe barrel and/or the device can be disposable or reusable. For example, the syringe barrel **91** connected to the proximal side of the needle sheath controller **71** through a Luer fit adaptor **93**, can be removed after injection or exhaustion of the fluid, such as a therapeutic, replaced with a new loaded syringe, or reloaded and re-connected, without the need to withdraw the device from the laparoscopic port. In some cases, the device **60** can be withdrawn from the laparoscopic port and disposed of after one use, or can be re-used.

With reference to the above Figures, exemplary of the mode of operation of the injection device **60** involves loading a standard syringe (e.g. 1 mL insulin syringe) containing a syringe barrel **91** and plunger **92** with a fluid, such as a

- 64 -

therapeutic, prior to connecting the syringe to the needle sheath controller **71** via the Luer fit adaptor **93** of the syringe barrel **91** and the needle hub **84** connected to the injection tube **83**. Once the syringe barrel **91** is loaded and connected to the needle sheath controller **71**, the needle sheath **72** can be positioned in the sheathed position **72a**, and the device can be inserted into a laparoscopic port to be placed near the site of injection. At the site of injection (target tissue), the needle sheath **72** can be unsheathed **72c**, and the injection needle **81** can be exposed for injection. If necessary, the plunger **92** can be pulled back to draw fluids from the site of injection, to test the placement of the injection needle **81** at the injection site. The optional visibility window **724** can be used to visualize the drawback fluid from the injection site. Once the site of needle placement is determined, the plunger **92** can be depressed, to inject the fluid, such as a therapeutic, at the target tissue. After injection, the needle sheath **72** can be positioned in the sheathed position **72a**, to protect the non-target organs and prevent accidental needle puncture, prior to removing the laparoscopic device from the injection site and through the laparoscopic port.

2. INTEGRATED INJECTION DEVICE

FIGS. 2, 6 and 10A-D depict the injection device **60'** and components and features thereof. The injection device as shown in **FIG. 2** includes needle sheath **72'**, needle sheath controller **71'**, injection needle **81**, syringe barrel **91'** and plunger **92'**. The needle sheath **72'** of the injection device is of a sufficient length to permit laparoscopic access to the target of interest, and is generally a length of 200 mm to 600 mm, such as 250 to 400 mm, and generally at least or about at least or 300 mm. The device is generally cylindrical around the longitudinal axis, generally having a smaller diameter in the needle sheath **72'** region and the plunger **92'** region and a larger diameter in the sheath controller **71'** region. The needle sheath **72'** of the device is typically inserted through the port (e.g. laparoscopic port). The diameter of the needle sheath **72'** is typically from 3 mm to 12 mm in size, and typically from 5 mm to 10 mm. It is understood that portions of the device external to the laparoscopic port can have a diameter greater than 10 mm. For example, the needle sheath controller body **71'** can have a diameter sufficiently large, so long as it can be easily gripped or handled by the operator. The needle sheath controller body **71'** is held by

- 65 -

the operator, typically a surgeon, to manipulate and position the device **60'**, control the needle sheath **72'** and support the device while manipulating the plunger **92'**.

The syringe barrel **91'** is cylindrical in shape with a hollow center that can fit plunger **92'** so that the plunger can move back and forth inside the syringe barrel. The syringe barrel is generally clear and transparent. The syringe barrel can be made out of plastic or glass or other suitable material, and in particular is made of plastic such as polypropylene, polyethylene, polycarbonate or other clear material. As described generally above, the syringe barrel **91'** can contain calibrations or markings on the outer surface to indicate the volume of the agent within the barrel. As described above, the syringe barrel **91'** can have a volume capacity that is from the range of 0.5 mL to 20 mL (i.e. 0.5 cc to 20 cc), and generally is 0.5 mL to 3 mL (i.e. 0.5 cc to 3 cc), such as at least or about a 1 mL (i.e. 1 cc) syringe. Typically, 200 μ L to 600 μ L of the fluid, such as a therapeutic, is delivered to the target locus, and the volume of syringe barrel is 1 mL.

The syringe barrel **91'** is positioned on the distal side of the needle sheath controller **71'**. As shown in **FIG. 2**, the syringe barrel **91'** is integrated and contained within the distal most lumen end of the needle sheath **72'**. Thus, the syringe barrel is enclosed by the needle sheath **72'**. As shown in **FIG. 10A** and **10B**, described in more detail below, the syringe barrel **91'** is not directly connected to the lumen **723** of the sheath cavity, but is positioned so that it is immovable in relation to the needle sheath controller **71'**. Thus, in this embodiment, the syringe barrel **91'** is not removable from the needle sheath **72'**.

The needle sheath **72'** can be opaque or can be transparent or clear. Generally, the needle sheath **72'** is opaque, but contains a visibility window **725** for visualization of the integrated syringe barrel **91'**. Since device **60'** contains a syringe barrel **91'** that is enclosed within the needle sheath **72'**, and that would not otherwise be visible, the presence of the visibility window **725** permits visualization of the graduated markings on the syringe barrel to aid in drawing up agents or solutions. In addition to permitting visualization of the administered agent or solutions, the presence of the visibility window **725** allows visualization of drawback fluids. For example, since some applications require injection directly into the parenchyma, and not into a vessel or bile duct, the ability to drawback and visualize fluid from the area the needle has

- 66 -

penetrated can be used to confirm needle placement into the parenchyma, while avoiding injections into the vasculature or bile ducts. The visibility window **725** can be made of glass or clear plastic such as polycarbonate. The visibility window **725** is integrated directly into the body of the needle sheath **72'**. The visibility window can surround the entire circumference of the needle sheath **72'** or can partially surround the circumference of needle sheath **72'**. The visibility window **725** can be any desired length, and located anywhere along the needle sheath **72'** so long as a portion of the syringe barrel **91'** is exposed under the visibility window **725**. Generally, the visibility window **725** exposes the distal portion of the syringe barrel **91'**, but can expose the entire syringe barrel **91**. The visibility window **725** can be 10 cm to 300 mm, and generally is 20 mm to 100 mm in length.

The plunger **92'** is located on the proximal end of the device **60'** and passes through the needle sheath controller **71'** and the needle sheath **72'** where it can engage with and pass into the syringe barrel **91'**. The plunger **92'** is movable through the needle sheath controller **71'**, needle sheath **72'** and syringe barrel **91'** so that it can be pulled and pushed along inside the syringe barrel **91'**. The plunger **92'** can be drawn back to load the syringe barrel **91'** with the fluid, such as a therapeutic, or depressed to inject the fluid, such as a therapeutic, in the target tissue. The plunger **92'** also can be pulled back at the site of injection to test needle placement. The plunger is cylindrical to move through the syringe barrel **91'**, and is made of material that permits ease of movement through the needle sheath controller **71'**, needle sheath **72'** and syringe barrel **91'**. Typically, the plunger **92'** is made of plastic, for example polypropylene or polyethylene. The plunger contains a head **95** at the proximal end of the device that can be conveniently grasped by the operator to manipulate the plunger. The plunger head **95** also is generally made of plastic. The distal tip of the plunger **92'** is generally made of silicone or other natural or synthetic rubber to provide a tight seal within the syringe barrel **91'** when traveling within the syringe barrel **91'**.

The plunger **92'** is long enough in length to permit its association with the inside of the syringe barrel **91'** in order to dispel the fluid, such as a therapeutic through the distal end of the syringe and into the needle **81** connected thereto. Since the plunger essentially extends the length of the device, the plunger is generally at

- 67 -

least as long as the sheath, and generally longer since it extends outside of the laparoscopic port. For example, the plunger **92'** can be 200 mm to 800 mm, such as 300 to 600 mm, and generally at least or about at least or 300 to 400 mm. Pulling back on the plunger **92'** draws in the fluid, such as a therapeutic, or air, and pushing the plunger **92'** forces the fluid, such as a therapeutic, or air out of the syringe barrel.

The device **60'** contains an injection needle **81** that is located inside the needle sheath **72'** that can be sheathed and unsheathed at the distal tip of the needle **81**. With reference to **FIG. 10A**, described in more detail below, the distal tip of the needle sheath **73** contains a needle channel **733** that guides the needle outside of the needle sheath **72'** when it is unsheathed as shown in **FIG. 2**. As shown in **FIG. 2**, the injection needle contains a beveled tip sufficient to penetrate or pierce a tissue or an organ.

As discussed further below, because the injection needle **81** is directly attached to the syringe barrel **91'** at the distal end of the device, the injection needle is relatively short. This avoids problems in pressure drop that can occur with longer needles. This also means that the dead volume in the device **60'**, which is the volume of fluid that is loaded into the syringe barrel **91'**, but cannot be expelled from the device and injected into the tissue, is generally small. Since therapeutics are often costly or limited, an injection device that minimizes amount of dead volume is advantageous. Factors that influence the amount of dead volume include the length of the needle, the diameter of the needle, and the diameter of the syringe barrel. In case of a long needle, the amount of air in the needle often is not tolerable in the patient and the target tissue and/or organ. Hence, the air needs to be removed from the needle and the needle is sometimes "primed." After the injection, the amount of fluid remaining in the fluid path between the tip of the plunger and the tip of the injection needle **81** cannot be expelled completely, and thus results in dead volume. In case of a long needle, the amount of dead volume is thus larger. In device **60'**, the syringe barrel **91'** is located close to the tip of the needle sheath **72'**, and the dead volume occurs only in the tip of the syringe barrel **91'** and the injection needle **81**.

FIG. 6 depicts an enlarged cross section view of the needle sheath controller **71'** and the plunger **92'** extended through the needle sheath controller **71'**. The needle sheath controller **71'** is positioned on the proximal side of the needle sheath **72'**. The

- 68 -

needle sheath controller **71'** contains the components that control movement of the needle sheath **72'**, connect the proximal and distal end of the device, and is the conduit by which the plunger **92'** travels between the proximal and distal ends of the device. The needle sheath controller **71'** is configured to be held and manipulated by
5 an operator, such as a surgeon. As discussed above, the needle sheath controller **71'** can be any shape and size that is convenient to permit the operator to hold and manipulate the device, and typically is cylindrical in shape. The diameter of the needle sheath controller **71'** is such that it can be held in the palm of an average adult, and is generally 20 mm to 100 mm in diameter with a length of 50 mm to 225 mm.
10 The needle sheath controller optionally can contain an outside grip for handling.

As shown in **FIG. 2** and **FIG. 6**, the needle sheath controller **71'** includes a controller housing **710** that encloses components internal to the needle sheath controller **71'**, and the proximal end of the needle sheath **72'**. As discussed above, the needle sheath controller housing **710** can be made of any suitably resilient and rigid
15 material, such as any polymeric material, including plastics, or rubber, metals, ceramics, composites, or other suitable material known to one of skill in the art. The controller housing **710** is typically made of polypropylene, polystyrene, polyethylene, polyvinyl chloride, polyurethane, silicone, rubber or acrylic. As discussed above, the housing **710** can be made by any manufacturing known to a skilled artisan, and can be
20 made as one singular piece or can be made of two or more pieces that are attached together, such as with adhesive, locking joints or fasteners.

As shown in **FIG. 2** and **FIG. 6**, the needle sheath controller **71'** contains an externally accessible positioner **711**. As described above, the positioner **711** is configured in the needle sheath controller **71'** so that it is movable both forward and
25 rearward relative to the needle sheath controller **71'**. As described above, the positioner **711** is engaged with the needle sheath **72'** through a connection member **713**, and can be used to slide the needle sheath **72'**. This connection permits movement of the positioner **711** between the forward or rearward positions to control movement of the needle sheath between two fixed or locked positions, the sheathed
30 and unsheathed positions. The sheathed position protects or hides the injection needle, while the unsheathed position exposes the needle.

- 69 -

With reference to **FIG. 6**, the connection member **713** is connected to the proximal end of the needle sheath **72'**, and the lower part of the positioner **711**. The connection of the connection member **713** with the proximal end of the needle sheath is such that the needle sheath **72'** is longitudinally movable relative to the controller housing **710** and the injection needle **81**. . For example, the distal end of the outside of the connection member **713** is engaged with the proximal inside cavity of the needle sheath **72'** around its circumference. The connections of the control member with the positioner **711** and needle sheath **72'** can be by welding, adhesive, locking joints, fasteners or other suitable means.

As described above generally, the connection member **713** moves inside a hollow cavity or lumen **717** contained inside the housing **710** of the needle sheath controller **71'** that is closed at both ends relative to the housing **710**. The controller lumen **717** accommodates the connection member **713** such that the connection member **713** can easily glide or move forward or rearward in a restricted manner. For example, the connection member **713** can be cylindrical and fit inside a cylindrical hollow lumen cavity **717**. As shown in **FIG. 6**, and discussed further below, the connection member **713** contains an internal hollow cavity sized to fit the plunger **92'** that passes through.

Movement of the connection member **713** is controlled by the positioner **711**. As shown in **FIGS. 2** and **6**, the positioner **711** contains a projected top portion or head that juts out of the needle sheath controller **71'** where it can be moved forward or rearward by the operator. As shown in **FIG. 6**, internal to the needle sheath controller **71'**, the body of the positioner **711** is notched on its sides or is otherwise configured to engage with sheath stops **715** or **716**. Sheath stops **715** and **716** are grooves in the needle sheath controller housing **710** that fit the notched body of the positioner and trap the positioner **711** so that it cannot be moved.

As exemplified in **FIG. 5** with the exemplary device **60**, device **60'** also contains an optional lock and release element **712** configured in the positioner **711** to facilitate lock and release of the positioner with the grooves of the sheath stop **715** or **716**. For example, the lock and release element **712** can be a spring or other resilient means. The mechanism controlling lock and release of the positioner **711** with the grooves of the sheath stop **715** or **716** by the lock and release element **712** is as

- 70 -

described above, whereby downward, vertical or lateral forces release or lock the positioner **711** from the sheath stops **715** or **716**. Pushing downward on the positioner **711** permits the positioner to slide and to fit it into either of sheath stops **715** or **716**.

Movement of the positioner **711** between the sheath stops **715** and **716** moves
5 the connection member **713**, and thereby also moves the needle sheath **72'** so that it can transition from the sheathed and unsheathed positions by control of the positioner by the operator. When the positioner is in the rearward position **711c** as exemplified in **FIG. 6**, distal sheath stop **715** is free and the positioner **711** is fit into the proximal sheath stop **716**, thereby unsheathing the injection needle so that it is exposed. While
10 not shown in **FIG. 6**, the positioner **711** also can be in the forward position **711a** as exemplified in **FIG. 5**, where the proximal sheath stop **716** is free and the positioner **711** is fit into the distal sheath stop **715**, thereby sheathing the injection needle so that it is protected. As a further position, the positioner **711** also can be in an intermediate position **711b** as exemplified in **FIG. 7**, where both the distal sheath stop **715** and the
15 proximal sheath stop **716** are free and not engaged with the positioner **711**.

As shown in **FIG. 6**, the plunger **92'** passes through the inside lumen **717** of the needle sheath controller **71'** and passes through a central cavity of the connection member **713**, but is not directly attached to the needle sheath controller **71'** or connection member **713**. Hence, the connection member **713** can move
20 independently around the plunger **92'**, and the plunger **92'** can move independently through the connection member **713**. As discussed above, because the needle sheath **72'** is directly connected to the connection member **713** contained in the controller lumen **717**, the plunger **92'** enters the inside cavity of the needle sheath **72'** inside the needle sheath controller **71'**. The plunger **92'** exists the distal end of the needle sheath
25 controller **71'** where it is contained within the lumen **723** of the needle sheath **72'**.

With reference to **FIG. 10A** and **10B**, the plunger **92'** runs distally and longitudinally through the needle sheath **72'** where it engages with the proximal end of the syringe barrel **91'**. The injection needle **81** is directly connected to the inside of the syringe barrel **91'** at the distal end of the syringe barrel **91'**. The injection needle
30 **81** contains a beveled tip sufficient to penetrate or pierce a tissue or an organ. The injection needle **81** is typically made of metal or alloy, such as surgical stainless steel or other medical grade metal. The size and diameter of the injection needle **81** is

- 71 -

selected based on parameters generally describe above. As described above, typically a small diameter needle **81** is employed to reduce the force required to insert the needle into the target tissue or organ, and to reduce trauma to the target tissue or organ. For example, the injection needle **81** is between 25 and 34 gauge, such as a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge or 31 gauge needle, and typically is 27 gauge.

At the distal end of the device **60'**, the needle sheath **72'** ends in a distal tip **73** that contains a needle channel **733**. The needle channel **733** is sufficiently sized to fit the injection needle **81** so the injection needle can extend and retract through the needle channel **733** as the needle sheath **72'** moves. In **FIG. 10A**, the injection needle **81** is covered by the needle sheath **72'** and does not traverse through needle channel **733**. With reference to **FIG. 4A**, the device **60'** in **FIG. 10A** is in the sheathed position **72a**. In **FIG. 10B**, the injection needle **81** is extended out of the needle sheath **72'** and does traverse through needle channel **733**. With reference to **FIG. 4C**, the device **60'** in **FIG. 10B** is in the unsheathed position **72c**.

As shown in **FIGS. 10A** and **10B**, because the syringe barrel **91'** is not connected to the needle sheath **72'**, the needle sheath **72'** moves independently around the syringe **91'**. In the unsheathed position, the needle sheath **72'** is pulled back, but the syringe barrel **91'** and injection needle **81** are fixed and do not move. For example, as shown in **FIG. 10B**, because the needle sheath **72'** is pulled back, the size of the sheath lumen **723** is shortened compared to **FIG. 10A** when the needle sheath **72'** is not pulled back. In the unsheathed position shown in **FIG. 10B**, the distal end of the syringe barrel **91'** touches the distal tip of the sheath **73**. A notch can be configured in the distal tip **73** in order to accommodate the syringe barrel **91'** as it is positioned in the unsheathed position **72c**. This demonstrates that movement of the sheath, as described with reference to **FIG. 6** above using the positioner **711**, only controls the movement of the needle sheath **72'**, while the position of the syringe barrel **91'** and injection needle **81** of the device are stationary regardless of the position of the positioner **711**.

As described above, in the unsheathed position, the extent by which the injection needle **81** is extended or exposed out of the device **60'** is a function of the distance between the sheath stops **715** and **716** as shown in **FIG. 6**. This distance is a

- 72 -

function of the particular application of the device, the particular target tissue, the subject being treated and other considerations. For example, unsheathed needle that is exposed should not be so long that it can easily penetrate through to the other side of a target tissue. Generally, with reference to most target tissues (e.g. liver), the portion
 5 of the injection needle **81** shown in **FIG. 10B** that can be unsheathed or exposed is generally less than 1 cm, such as 2 mm to 10 mm, and generally no more than 5 mm. For a child, the length can be smaller, and is generally less than 4 mm. For applications *in utero*, the length can be 2 mm to 3 mm. Generally, the total length of the injection needle **81** in device **60'** is slightly longer than the unsheathed needle tip
 10 that extends out of the device. As shown in **FIG. 10B**, the extent of the extra length is sufficient to account for the distance of the distal sheath tip **73** and the extent to which the proximal end of the needle is connected to syringe barrel **91'**. For example, the total length of the injection needle **81** can range from 5 mm to 40 mm, such as 10 mm to 40 mm, such as a 12.7 mm, 25.4 mm or 38.1 mm needle.

15 **FIG. 10C** provides a corresponding perspective view of the needle sheath shown in **FIG. 10A** in the sheathed position **72a**. **FIG. 10D** provides a corresponding perspective view of the needle sheath shown in **FIG. 10B** in the unsheathed position **72c**. In **FIG. 10A** and **D**, the needle sheath **72'** is opaque, but contains a visibility window **725** in order to view the syringe barrel **91'** and injection needle **81** whether
 20 sheathed or unsheathed.

The device **60'** can be disposable or reusable. For example, the device **60'** can be withdrawn from the laparoscopic port and disposed of, or reloaded and reused. The device **60'** also can be a sterile device. For example, the device **60'** can be loaded through the injection needle **81** in a sterile environment, such as a sterile operating
 25 room. The device **60'** can be pre-loaded with the fluid, such as a therapeutic, and provided as a sterile pre-loaded syringe. Furthermore, distribution of sterile disposable pre-loaded devices is easily achieved using this device **60'** due to the complete integration of the syringe barrel into the needle shaft, thereby minimizing contamination that can occur when the syringe barrel and device must be packaged or
 30 stored separately. Alternatively, the injection needle **81** can be inserted into a container with the fluid, such as a therapeutic, composition, and the plunger **92'** can be pulled back to load the fluid, such as a therapeutic, in the syringe barrel **91'**.

- 73 -

With reference to the above Figures and description, exemplary of the mode of operation of the injection device **60'** involves first loading the device **60'** with a fluid, such as a therapeutic. With the needle sheath **72'** in the unsheathed position **72c**, the injection needle **81** can be inserted into a vial or a container of fluid, such as a therapeutic, and the integrated syringe plunger **92'** can be pulled back to load the syringe with the fluid, such as a therapeutic. Optionally, a vial adaptor can be used when loading the syringe with the therapeutic compound, such that the long device can be stabilized over a vial or container of fluid, such as a therapeutic, loading the syringe barrel **92'**. Once the syringe is loaded, the needle sheath **72'** can be positioned in the sheathed position **72a**, and the device can be inserted into a laparoscopic port to place the device near the site of injection. At the site of injection (target tissue), the needle sheath **72'** can be unsheathed **72c**, and the injection needle **81** can be exposed for injection. If necessary, the integrated syringe plunger **92'** can be pulled back to draw fluids from the site of injection, to test the placement of the injection needle **81** at the injection site. The syringe visibility window **725** can be used to visualize the drawback and the movement of the plunger **92'**. Once the site of needle placement is determined, the plunger **92'** can be depressed, to inject the fluid, such as a therapeutic, at the target tissue. After injection, the needle sheath **72'** can be positioned in the sheathed position **72a**, to protect the non-target organs and prevent accidental needle puncture, prior to removing the laparoscopic device from the injection site and through the laparoscopic port.

3. DOCKABLE INJECTION DEVICE

FIGS. 3, 7 and 11A-D depict the injection device **60''** and components and features thereof. The injection device as shown in **FIG. 3** includes needle sheath **72''**, needle sheath controller **71'**, plunger **92''** and a dockable syringe **910** containing injection needle **81**, syringe barrel **91''**, and associated auxiliary plunger **920**. The needle sheath **72''** of the injection device is of a sufficient length to permit laparoscopic access to the target of interest, and is generally a length of 200 mm to 600 mm, such as 250 to 400 mm, and generally at least or about at least or 300 mm. The device is generally cylindrical around the longitudinal axis, generally having a smaller diameter in the needle sheath region **72''** and the plunger region **92''** and a larger diameter in the needle controller region **71'**. The needle sheath **72''** of the

- 74 -

device is typically inserted through the port (e.g. laparoscopic port). The diameter of the needle sheath **72''** is typically between 3 mm to 12 mm in size, and typically from 5 mm to 10 mm. It is understood that portions of the device external to the laparoscopic port can have a diameter greater than 10 mm. For example, the needle sheath controller body **71'** can have a diameter sufficiently large, so long as it can be easily gripped or handled by the operator. The needle sheath controller body **71'** is held by the operator, typically a surgeon, to manipulate and position the device **60''**, control the needle sheath **72''** and support the device while manipulating the plunger **92''**.

Injection device **60''** is adapted so that a dockable syringe **910** containing injection needle **81**, syringe barrel **91''** and associated auxiliary plunger **920** can be temporarily docked therewith. As shown in **FIG. 3**, the syringe barrel **91''** is cylindrical in shape with a hollow center that can fit auxiliary plunger **920** so that the plunger can move back and forth inside the syringe barrel. The auxiliary plunger **920** is located on the proximal side of the syringe barrel **91''** and is movable so that it can be pulled and pushed along inside of the syringe barrel **91''**. The auxiliary plunger **920** can be drawn back to load the syringe barrel **91''** with the fluid, such as a therapeutic, or depressed to dispel or inject the fluid in the target tissue. The auxiliary plunger **920** can also be pulled back at the site of injection to test needle placement. As discussed below, movement of the auxiliary plunger **920** when docked in the device is controlled by the plunger **92''**. The auxiliary plunger **920** is cylindrical to move through the syringe barrel **91''**, and is made of material that permits ease of movement through the syringe barrel, such as a plastic, for example, polypropylene or polyethylene.

The auxiliary plunger **920** contains a plunger head **95** at the proximal end of the plunger that can be conveniently grasped by the operator to manipulate the plunger, or otherwise configured to control movement of auxiliary plunger **920**. For example, the auxiliary plunger **920** can be independently moved and controlled, for example, when the dockable syringe **910** is in the undocked position (discussed further below). In other instances, when the dockable syringe **910** is docked in device **60''**, movement of the auxiliary plunger **920** is controlled by plunger **92''** at the proximal end of device **60''** through a plunger adaptor **951** (discussed further below).

- 75 -

The plunger head **95** also is generally made of plastic. The distal tip of the auxiliary plunger **920** is generally made of silicone or other natural or synthetic rubber to provide a tight seal within the syringe barrel **91''** when traveling within the syringe barrel **91''**.

5 The auxiliary plunger **920** is long enough in length to permit its association with the inside of syringe barrel **91''** in order to dispel the fluid, such as a therapeutic, through the distal end of the syringe barrel **91''** and into injection needle **81** connected thereto. For example, the auxiliary plunger **920** can have a length between 50 mm and 100 mm, typically 70 mm to 90 mm. Pulling back on the auxiliary plunger **920**
10 draws in the fluid or air, and pushing the auxiliary plunger **920** forces the fluid or air out of the syringe barrel.

 The syringe barrel **91''** is generally clear and transparent. The syringe barrel **91''** can be made out of plastic or glass or other suitable material, and in particular is made out of plastic such as polypropylene, polyethylene, polycarbonate or other clear
15 material. As described above, the syringe barrel **91''** can contain calibrations or marking on the outer surface to indicate the volume of the agent within the barrel. As described above, the syringe barrel **91''** can have a volume capacity that is from the range of 0.5 mL to 20 mL (i.e. 0.5 cc to 20 cc), and generally is 0.5 mL to 3 mL (i.e. 0.5 cc to 3 cc), such as at least or about a 1 mL (i.e. 1 cc) syringe. Typically, 200 μ L
20 to 600 μ L of the fluid, such as a therapeutic, is delivered to the target locus, and the volume of syringe barrel is 1 mL.

 The dockable syringe **910** of device **60''** contains an injection needle **81** that is located on the distal end of the syringe barrel **91''**, and hence the distal end of the device **60''** when the dockable syringe **910** is docked into device **60''** (discussed
25 further below). The injection needle **81** can be connected directly or indirectly to syringe barrel **91''**. For example, the injection needle **81** can be directly affixed, such as by an adhesive, bonding or molding, to the inside of syringe barrel **91''** at the distal end of syringe barrel **91''**. In other examples, the distal end of syringe barrel **91''** can contain a Luer fit or other adaptor that is compatible with a hub on the proximal end
30 of injection needle **81**.

 As shown **FIG. 3**, the injection needle contains a beveled tip sufficient to penetrate or pierce a tissue or an organ. The injection needle **81** is typically made of

- 76 -

metal or alloy, such as surgical stainless steel or other medical grade metal. The size and diameter of the injection needle **81** is selected based on parameters generally describe above. As described above, typically a small diameter needle **81** is employed to reduce the force required to insert the needle into the target tissue or organ, and to reduce trauma to the target tissue or organ. For example, the injection needle **81** is between 25 and 34 gauge, such as a 25 gauge, 26 gauge, 27 gauge, 28 gauge, 29 gauge, 30 gauge or 31 gauge needle, and typically is 27 gauge.

Because the injection needle **81** is directly attached to the syringe barrel **91''**, the injection needle is relatively short. This avoids problems in pressure drop that can occur with longer needles. Similar to device **60'** discussed above, this also means that there is generally a small dead volume created by device **60''**. For example, the total length of the injection needle **81** can range from 5 mm to 40 mm, such as 10 mm to 40 mm, such as a 12.7 mm, 25.4 mm or 38.1 mm needle. Generally, the use of shorter needle is desired in order to avoid problems related to dead volume and pressure drops.

The needle sheath **72''** can be opaque or can be transparent or clear. The needle sheath **72''** is generally solid at the proximal portion of the needle sheath **720**, but contains an open cavity **726** at its distal portion. The dockable syringe **910** containing auxiliary plunger **920**, syringe barrel **91''** and injection needle **81** is configured so that it can be docked and undocked in the open cavity of the sheath, and in a manner in which the needle sheath **72''** is movable around the dockable syringe **910**. As shown in **FIG. 3** and **FIG. 11A**, the open cavity **726** is a cut out in the top half of the needle sheath **72''**. The inner side of the open cavity **726** of the sheath can be lined with a syringe adaptor lining **96** in a manner so that the sheath moves independently from the syringe adaptor lining **96**. The syringe adaptor lining **96** also has an open cavity of substantially similar size.

For example, as shown in **FIGS. 11A** and **11B**, a syringe adaptor lining **96** can run through the sheath, such that the sheath moves independently around the syringe adaptor lining **96**. The syringe adaptor lining **96** can be connected or fixed at its proximal end to the needle sheath controller **71'** and have an open cavity at its distal end to form a nest for the dockable syringe. For example, the syringe adaptor lining **96** can be a hypodermic tubing that has a distal section removed to form a nest for the

- 77 -

dockable syringe. The tubing can have a diameter smaller than the inside portion of the needle sheath 72" so that the tubing can run into and through the sheath where it can be connected to the needle sheath controller 71' in a fixed position.

The open cavity of the syringe adaptor lining 96 can contain a plunger rest cavity 960, a barrel rest cavity 962, and two barrel docks 961 and 963. The barrel rest cavity 962 is flanked by two barrel docks 961 and 963, which are clasps or fitting that are adapted to seat or secure the syringe barrel 91" at its proximal and distal end, respectively. The size of the barrel rest cavity 962 and the distance between the two barrel docks 961 and 963 permit engagement with the syringe barrel 91". If the syringe barrel 91" contains grooves to fit into the barrel docks 961 and 963, the length between the two barrel docks 961 and 963 is the same as the length between the corresponding grooves in the syringe barrel 91". The portion of the syringe barrel 91" that can dock with barrel docks 961 and 963 can be restricted by configuring syringe barrel 91" with narrow grooves at its proximal and distal ends that fit dock 961 and 963, respectively. This ensures that the syringe barrel 91", when fitted in the open cavity 726, is properly lined up for sheathing and unsheathing injection needle 81. The barrel docks 961 and 963 can be similarly sized, or can be different sizes depending on the particular size and configuration of syringe barrel 91". The barrel docks 961 or 963 can be rigid or flexible, and can be made out of metal or polymeric materials such as plastics. The barrel docks 961 and 963 can be features extruding from the syringe adaptor lining 96, or can be separate parts that are attached to the exposed part of the syringe adaptor lining 96. The barrel rest cavity 962 and the docks 961 and 963 are not directly connected to the needle sheath so that the needle sheath 72" moves around and independently from the syringe adaptor lining 96, including the barrel rest cavity and docks.

A plunger adaptor 951 that is part of the distal end of plunger 92" is located at the proximal end of the cavity 726. The plunger adaptor 951 rests inside open cavity of the syringe adaptor lining 96 when the plunger 92" is pulled back in an extended position. As discussed below, the plunger 92" is movable within the lumen of the syringe adaptor lining 96 in order to control movement of auxiliary plunger 920. The distance between barrel dock 961 and plunger adaptor 951 when the plunger 92" is in its extended position (i.e. pulled out to maximum length outside of syringe barrel)

- 78 -

creates a plunger rest cavity **960** within the syringe adaptor lining **96** sufficiently sized to fit the auxiliary plunger **920** in its extended position.

Hence, the length of the open cavity **726** of the needle sheath **72''** and the open cavity of the syringe adaptor lining **96** is sufficient to fit dockable syringe **910**. In some instances, the cavity can span the entire length of the needle sheath **72''**, except for the distal tip of the needle sheath **73'** discussed below. Typically, the open cavity **726** is 50 mm to 250 mm in length. Accordingly, the open cavity of the syringe adaptor lining **96**, which has a substantially similar length to the open cavity **726** of the needle sheath, is 50 mm to 250 mm in length. The length of the open cavities also depends on the diameter of the needle sheath **72''**, the volume, length and diameter of the dockable syringe **910**. If a larger volume of syringe barrel **91''** is needed for a specific injection, the length of the syringe barrel **91''** and the open cavities can be made larger. However, the stroke length of the auxiliary plunger **920** is limited to less than half of the entire length of the needle sheath **72''**, as both the fully extended auxiliary plunger **920** and the syringe barrel **91''** must fit in the length of the needle sheath **72''** and the open cavities. The stroke length of the plunger **92''** is also limited to the maximum stroke length of the auxiliary plunger **920**. Hence, if a larger volume of syringe barrel **91''** is needed, the diameter of the needle sheath **72''** can be larger. The optimal length and diameter of the syringe barrel **91''** in relation to the stroke length and the length of the needle sheath **72''**, including the length of the proximal portion of the needle sheath **720**, can be empirically determined based on the diameter of the laparoscopic ports, type of surgery, and the volume of syringe barrel required.

The open cavities terminate at the distal tip of the needle sheath **73'**. The distal tip of the needle sheath **73'** is solid, except that it contains an open needle groove **76** on its top side. The needle groove **76** is a narrow opening sufficient for injection needle **81** to drop into the distal tip of needle sheath **73'** where it can line up with needle channel **733** to guide the injection needle **81** outside when unsheathed. The length and diameter of the groove **76** is sufficient to fit injection needle **81**. For example, the needle groove **76** is 5 mm to 40 mm long, such as 10 mm to 40 mm. The width of the needle groove is 0.2 to 2 mm, such as 0.3 to 1 mm.

FIGS. 11A and 11B depict the dockable and undocked configurations of dockable syringe **910** with the syringe adaptor lining **96** and the needle sheath **72''**.

- 79 -

For example, **FIG. 11A** shows the dockable syringe **910** in the undocked position **910a**. As shown in **FIG. 11A**, a syringe adaptor lining **96** is inside the needle sheath **72''**. An open cavity of the syringe adaptor lining **96** configured into the open cavity **726** of the needle sheath **72''** is configured to fit the dockable syringe **910** as described above. **FIG. 11B** shows the dockable syringe **910** in the docked position **910b**. In the docked position **910b**, the dockable syringe **910** is positioned on the distal side of the needle sheath controller **71'**. When in the docked position **910b**, the injection needle **81** is located inside the needle sheath **72''** and can be sheathed and unsheathed at the distal tip of the needle **81** as discussed below.

10 The ability to dock into syringe dock accessible by the open cavity **726** of the needle sheath **72''** and the open cavity of the syringe adaptor lining **96** permits visualization of the syringe barrel in device **60''** so that the administered agent or drawback fluids can be visualized. For example, as discussed above, since some applications require injection directly into the parenchyma, and not into a vessel or
15 bile duct, the ability to drawback and visualize fluid from the area the needle has penetrated can be used to confirm needle placement into the parenchyma, while avoiding injections into the vasculature or bile ducts.

 In addition, the ability to remove or dock the syringe **910** in injection device **60''** also provides advantages, including the ease of loading the syringe barrel,
20 exchange of loaded syringe, and sterility of syringe. For example, a sterile syringe barrel **91''** can conveniently be used when drawing up or loading the syringe with a fluid, such as a therapeutic, compositions or other solutions into the syringe barrel. If desired, a separately sterile needle **81** can be fitted to the syringe barrel **91''**, such as by a Luer fit adaptor, to permit loading of the syringe barrel **91''** with a fluid, such as
25 a therapeutic. Syringe barrel **91''** also can be separately loaded prior to use of device **60''**, or a pre-loaded syringe barrel **91''** can be used. Also, a variety of syringe types and sizes can be used so long as they are dockable with the device **60''**. In some cases, several different types of syringes can be used for one patient, if necessary. In cases where the syringe must be re-loaded or additional fluid, such as a therapeutic, is
30 needed, new or re-loaded syringes can be docked.

 As shown in **FIG. 3**, plunger **92''** is located on the proximal end of the device **60''** where it can be controlled and operated by the operator outside of the

- 80 -

laparoscopic port. Plunger **92''** passes through the needle sheath controller **71'** and the proximal portion of the needle sheath **72''**. The plunger **92''** is generally cylindrical and movable within needle sheath controller **71'** and needle sheath **72''**. The plunger **92''** is made of material that permits ease of movement through the needle sheath controller **71'** and needle sheath **72''**. Typically, the plunger **92''** is made of plastic, for example polypropylene or polyethylene. The distal end of the plunger **92''** contains a plunger adaptor **951** that is exposed through open cavity **726** in the needle sheath **72''** where it associates with auxiliary plunger **920**. The plunger **92''** is long enough in length to permits its association with auxiliary plunger **920** in needle sheath **72''** when auxiliary plunger **920** is docked in cavity **726**. For example, the length of plunger **92''** can range from 50 mm to 500 mm, such as 100 mm to 400 mm or 100 mm to 200 mm. Plunger **92''** is generally longer than auxiliary plunger **920**.

The plunger adaptor **951** contains a groove or notch to connect with auxiliary plunger **920** through plunger head **95'** of auxiliary plunger **920**. The plunger adaptor **951** is of a sufficient size and shape so that plunger head **95'** of auxiliary plunger **920** can be seated or secured in the plunger rest cavity **960**. As shown in **FIG. 11B**, when plunger head **95'** of auxiliary plunger **920** is fitted or secured in plunger adaptor **951**, the auxiliary plunger **920** and the plunger **92''** are connected, such that movement of the plunger **92''** controls movement of auxiliary plunger **920**. The plunger **92''** also contains a plunger head **95** at the proximal end of the device that can be conveniently grasped by the operator to manipulate plunger **92''**, and thus also auxiliary plunger **920**. For example, pushing the plunger **92''** also pushes the auxiliary plunger **920** and forces the fluid or air out of the syringe barrel **91''**.

FIG. 7 depicts an enlarged cross section view of the needle sheath controller **71'** and the plunger **92''** extended through the needle sheath controller **71'**. The needle sheath controller **71'** is positioned on the proximal side of the needle sheath **72''**. The needle sheath controller **71'** contains the components that control movement of the needle sheath **72''**, connect the proximal and distal end of the device, and is the conduit by which the plunger **92''** travels between the proximal and distal ends of the device. The needle sheath controller **71'** is configured to be held and manipulated by an operator, such as a surgeon. As discussed above, the needle

- 81 -

sheath controller **71'** can be any shape and size that is convenient to permit the operator to hold and manipulate the device, and typically is cylindrical in shape. The diameter of the needle sheath controller **71'** is such that it can be held in the palm of an average adult, and is generally 20 mm to 100 mm in diameter with a length of 50 mm to 225 mm. The needle sheath controller optionally can contain an outside grip for handling.

As shown in **FIG. 3** and **FIG. 7**, the needle sheath controller **71'** includes a controller housing **710** that encloses components internal to the needle sheath controller **71'**, and the proximal end of the needle sheath **72''**. As discussed above, the needle sheath controller housing **710** can be made of any suitably resilient and rigid material, such as any polymeric material, including plastics, or rubber, metals, ceramics, composites, or other suitable material known to one of skill in the art. The controller housing **710** is typically made of polypropylene, polystyrene, polyethylene, polyvinyl chloride, polyurethane, silicone, rubber or acrylic. As discussed above, the housing **710** can be made by any manufacturing known to a skilled artisan, and can be made as one singular piece or can be made of two or more pieces that are attached together, such as with adhesive, locking joints or fasteners.

As shown in **FIG. 3** and **FIG. 7**, the needle sheath controller **71'** contains an externally accessible positioner **711**. As described above, the positioner **711** is configured in the needle sheath controller **71'** so that it is movable both forward and rearward relative to the needle sheath controller **71'**. As described above, the positioner **711** is engaged with the needle sheath **72''** through a connection member **713**, and can be used to slide the needle sheath **72''**. This connection permits movement of the positioner **711** between the forward or rearward positions to control movement of the needle sheath **72''** between two fixed or locked positions, the sheathed and unsheathed positions. The sheathed position protects or hides the injection needle, while the unsheathed position exposes the needle.

With reference to **FIG. 7**, the connection member **713** is connected to the proximal end of the needle sheath **72''**, and the lower part of the positioner **711**. The connection of the connection member **713** with the proximal end of the needle sheath is such that the needle sheath **72''** is longitudinally movable relative to the controller housing **710** and the injection needle **81**. For example, the distal end of the outside of

- 82 -

the connection member **713** is engaged with the proximal inside lumen **723** of the needle sheath **72''** around its circumference. The connections of the control member with the positioner **711** and needle sheath **72''** can be by welding, adhesive, locking joints, fasteners or other suitable means.

5 As described above generally, the connection member **713** moves inside a hollow cavity or lumen **717** contained inside the housing **710** of the needle sheath controller **71'** that is closed at both ends relative to the housing **710**. The controller lumen **717** accommodates the connection member **713** such that the connection member **713** can easily glide or move forward or rearward in a restricted manner. For
10 example, the connection member **713** can be cylindrical and fit inside a cylindrical hollow lumen cavity **717**. As shown in **FIG. 7**, and discussed further below, the connection member **713** contains an internal hollow cavity sized to fit the plunger **92''** that passes through.

 Movement of the connection member **713** is controlled by the positioner **711**.
15 As shown in **FIGS. 3** and **7**, the positioner **711** contains a projected top portion or head that juts out of the needle sheath controller **71'** where it can be moved forward or rearward by the operator. As shown in **FIG. 7**, internal to the needle sheath controller **71'**, the body of the positioner **711** is notched on its sides or is otherwise configured to engage with sheath stops **715** or **716**. Sheath stops **715** and **716** are grooves in the
20 needle sheath controller housing **710** that fit the notched body of the positioner and trap the positioner **711** so that it cannot be moved.

 As exemplified in **FIG. 5** with the exemplary device **60**, device **60''** also contains an optional lock and release element **712** configured in the positioner **711** to facilitate lock and release of the positioner with the grooves of the sheath stops **715** or
25 **716**. For example, the lock and release element **712** can be a spring or other resilient means. The mechanism controlling lock and release of the positioner **711** with the grooves of the sheath stops **715** or **716** by the lock and release element **712** is as described above, whereby downward, vertical or lateral forces release or lock the positioner **711** from the sheath stops **715** or **716**. Pushing downward on the positioner
30 **711** permits the positioner to slide and to fit it into either of sheath stops **715** or **716**.

 Movement of the positioner **711** between the sheath stops **715** and **716** moves the connection member **713**, and thereby also moves the needle sheath **72''** so that it

- 83 -

can transition from the sheathed and unsheathed positions by control of the positioner by the operator. When the positioner is in the intermediate position as exemplified in **FIG. 7**, both distal sheath stop **715** and the proximal sheath stop **716** are free and not engaged with the positioner **711**. While not shown in **FIG. 7**, the positioner **711** also
 5 can be in the forward position **711a** as exemplified in **FIG. 5**, where the proximal sheath stop **716** is free and the positioner **711** is fit into the distal sheath stop **715**, thereby sheathing the injection needle so that it is protected. As a further position, while not shown in **FIG. 7**, the positioner also can be in the rearward position **711c** as shown in **FIG. 6**, where distal sheath stop **715** is free and the positioner **711** is fit into
 10 the proximal sheath stop **716**, thereby unsheathing the injection needle so that it is exposed.

As shown in **FIG. 7**, the plunger **92''** passes through the inside lumen **717** of the needle sheath controller **71'** and passes through a central cavity of the connection member **713**, but is not directly attached to the needle sheath controller **71'** or
 15 connection member **713**. Hence, the connection member **713** can move independently around the plunger **92''**, and the plunger **92''** can move independently through the connection member **713**. As discussed above, because the needle sheath **72''** is directly connected to the connection member **713** contained in the controller lumen **717**, the plunger **92''** enters the inside cavity of the needle sheath **72''** inside
 20 the needle sheath controller **71'**. The plunger **92''** exits the distal end of the needle sheath controller **71'** where it is contained within the hollow cavity of the needle sheath **72''**.

At the distal end of the device **60''**, the needle sheath **72''** ends in a distal tip of the needle sheath **73'** that contains a needle channel **733** that is sufficiently sized to fit
 25 injection needle **81**. When the dockable syringe **910** is docked in the device in the docked position **910b** as shown in **FIGS. 11B-D**, injection needle **81** fits through groove **76** where it is lined up to pass through needle channel **733** so that injection needle **81** can extend and retract through needle channel **733** as the needle sheath **72''** moves. In **FIG. 11B**, injection needle **81** is fit into the groove **76** and contained in
 30 needle sheath **72''**, but does not traverse through the distal portion of needle channel **733**. With reference to **FIG. 4A**, the device **60''** in **FIG. 11B** is in the sheathed position **72a**. In **FIG. 11C**, injection needle **81** is extended out of needle sheath **72''**

- 84 -

and does traverse through the distal portion through needle channel **733**. With reference to **FIG. 4C**, the device **60''** in **FIG. 11C** is in the unsheathed position.

As shown in **FIGS. 11B** and **11C**, because syringe barrel **91''** is not connected to needle sheath **72''**, the needle sheath **72''** moves independently around syringe barrel **91''**. In the unsheathed position **72c** as shown in **FIG. 11C**, the needle sheath **72''** is pulled back, but the syringe barrel **91''** and injection needle **81** are fixed and do not move. For example, as shown in **FIG. 11C**, because the needle sheath **72''** is pulled back, the distal portion of the syringe barrel **91''** is covered up by the distal tip of the needle sheath **73**. In contrast, in the sheathed position **72a** as shown in **FIG. 11B**, the sheath is not pulled back, such that the distal end of the syringe barrel **91''** is not covered up by the distal tip of needle sheath **73**. Hence, movement of the needle sheath **72''** between sheathed and unsheathed positions, shortens the amount of syringe barrel **91''** that is exposed in the docked cavity of device **60''**.

As described above, in the unsheathed position **72c** as shown in **FIG. 11C**, the extent by which injection needle **81** is extended or exposed out of the device **60''** is a function of the distance between sheath stops **715** and **716** as shown in **FIG. 7** (and related **FIG. 5** and **6**). This distance is a function of the particular application of the device, the particular target tissue, the subject being treated and other considerations. For example, unsheathed needle that is exposed should not be so long that it can easily penetrate through to the other side of a target tissue. Generally, with reference to most target tissues (e.g. liver), the portion of the injection needle **81** shown in **FIG. 11C** that can be unsheathed or exposed is generally less than 1 cm, such as 2 mm to 10 mm, and generally no more than 5 mm. For a child, the length can be smaller, and is generally less than 4 mm. For applications in utero, the length can be 2 mm to 3 mm. Generally, the total length of the injection needle **81** in device **60''** is slightly longer than the unsheathed needle tip that can extend out of the device in the fully unsheathed position. As shown in **FIG. 11C**, the extent of the extra length is sufficient to account for the portion of the proximal end of the injection needle **81** still contained in the distal tip of sheath **73'** and distal end of syringe barrel **91''** when device is in the unsheathed position. For example, as described above, the total length of the injection needle **81** can range from 5 mm to 40 mm, such as 10 mm to 40 mm, such as a 12.7 mm, 25.4 mm or 38.1 mm needle.

- 85 -

Dispelling or ejecting a fluid, such as a therapeutic, or other solution through the injection needle is controlled by depressing plunger **92''**, which effects depression of auxiliary plunger **920** because of the connection achieved by plunger adaptor **951**. With reference to **FIG. 11C**, plunger **92''** is in an extended position, such that
 5 auxiliary plunger **920** also is in an extended position. In contrast, **FIG. 11D** illustrates plunger **92''** in the depressed position, such that auxiliary plunger **920** also is in the depressed position. This allows the delivery of the fluid, such as a therapeutic, to the target tissue. The plunger **92''** also can be used to control draw back of fluids from the injection site if drawback is required to test the needle placement. This is
 10 achieved by pulling or drawing back on plunger **92''**, which, through its connection with auxiliary plunger **920**, also draws back auxiliary plunger **920**. The drawback fluid can be visible in syringe barrel **91''** where it is not covered by needle sheath **72''**.

The dockable syringe **910** (containing auxiliary plunger **920**, syringe barrel **91''** and injection needle **81**) and/or the device **60''** can be disposable or reusable. For
 15 example, after injection or exhaustion of the fluid, such as a therapeutic, from the syringe barrel **91''**, or when otherwise desirable, dockable syringe **910** can be withdrawn from the laparoscopic port. A newly loaded dockable syringe **910** can be docked into device **60''**. The newly loaded dockable syringe **910** can contain the previously used dockable syringe barrel **91''** that can be re-loaded, or it can be new
 20 pre-loaded dockable syringe **910**. Alternatively, the device **60''** can be withdrawn from the laparoscopic port and disposed of after one use. In cases where sterile injections are required, the syringe barrel **91''** can be loaded with the fluid, such as a therapeutic, in a sterile environment, such as a sterile operating room, and then docked into device **60''**. Alternatively, a sterile pre-loaded dockable syringe **910** can
 25 be used, which can be docked into device **60''**.

With reference to the above Figures and description, exemplary of the mode of operation of the injection device **60''** involves first loading dockable syringe **910** with fluid, such as a therapeutic, prior to docking the syringe into the syringe adaptor in the syringe adaptor lining **96** located inside the needle sheath **72''**. Once the dockable
 30 syringe **910** is loaded, the syringe is docked into the syringe dock by engagement with barrel docks **961** and **963** and plunger adaptor **951**. The needle sheath **72''** can be positioned in the sheathed position **72a**, and the device can be inserted into a

- 86 -

laparoscopic port to be positioned close to the target site. At the site of injection (target tissue), the needle sheath **72"** can be unsheathed **72c**, and the injection needle **81** can be exposed for injection. If necessary, the control plunger **92"** can be pulled back to draw fluids from the site of injection, for example, to test the placement of injection needle **81** at the injection site. The drawback fluid is visible at the distal end of syringe barrel **91"** in needle sheath **72"**. The control plunger **92"** can be depressed, to inject the fluid, such as a therapeutic, at the target tissue. After injection, the needle sheath **72"** can be positioned in the sheathed position **72a**, to protect the non-target organs and prevent accidental needle puncture, prior to removing the laparoscopic device from the injection site and through the laparoscopic port.

C. APPLICATIONS AND USES

The injection devices provided herein permits direct delivery of fluids, such as a therapeutic, into a specific target site, such as the parenchyma of an organ internal to the body of the subject, in minimally invasive procedures, such as surgeries, for example as laparoscopic surgeries. Accordingly, the injection device can be used in diverse applications, including, but not limited to, medical applications, including applications to exogenously administer a fluid, such as a therapeutic, for the treatment of a disease or condition, or other applications such as agricultural, veterinary and industrial applications that require direct delivery of a fluid to a target site in minimally invasive procedures. For example, the device can be used to deliver chemotherapeutic agents to a specific target organ, or the device can be used to deliver nucleic acids or viral agents to a specific organ targeted for gene therapy, without the need of invasive open surgery. In some examples, the injection device can be useful in delivering fluids, such as a therapeutic in settings where the fluid treats or ameliorates a disorder or condition in a subject or otherwise improves the quality of life in a subject. In other examples, the injection device can be useful in agricultural settings, for example, for applications that improve the quality or quantity of meat production.

The injection device can be used in any subject or patient that is in need of direct delivery of a fluid, such as a therapeutic, into a target site in a minimally invasive manner. Exemplary of such subjects include, but are not limited to, mice,

- 87 -

rats, cows, pigs, sheep, goats, horses and humans. In particular examples, children under age 18, including infants, toddlers or young children, are contemplated herein for the delivery of fluids, such as therapeutics, for the treatment of diseases or conditions. In particular examples, *in utero* delivery of a fluid, such as a therapeutic, to the fetus is contemplated herein, for the treatment of diseases or conditions.

Exemplary applications of the method herein are provided below. It is understood that other applications exist depending on the particular fluid delivered, setting or subject. It is within the level of a person skilled in the art choose a fluid, setting, or subject of interest based on any desired application. The description herein below is for exemplification only.

1. TREATING DISEASES AND DISORDERS

Provided herein are applications of treating a disease, disorder or condition by delivering a fluid, such as a therapeutic, directly into a target injection site in a subject using the injection device provided herein. The disease, disorder or condition that is treated is any that is amenable to treatment by an exogenously delivered fluid, such as a therapeutic, directly to the target site, such as the parenchyma of an internal organ of a subject. In any of such examples herein, the fluid, such as a therapeutic, is delivered directly and specifically to the target injection site during a minimally invasive procedure. Thus, provided herein is an injection device that is used to deliver an accurate amount of fluid to the target injection site of the subject in a minimally invasive procedure without accidental puncture of non-target sites or damage to the apparatuses used for minimally invasive procedures. The particular device used has an injection needle that when unsheathed also cannot puncture through the tissue or organ in which the direct injection is effected.

The fluid used for injection can be any fluid used for injection. In particular examples, the fluid contains a therapeutic used for treating a disease, disorder or a condition. The therapeutic can include a fluid comprising small molecule drugs, prodrugs, proteins, peptides, DNA, RNA, viruses, antibodies, organic molecules, saccharides, polysaccharides, lipids and combinations or conjugates thereof. In particular examples, the fluid can comprise a therapeutic including, but not limited to, a gene therapy agent, a chemotherapeutic agent, an analgesic agent, an anti-inflammatory agent, an antimicrobial agent, an amoebicidal agent, a trichomonocidal

- 88 -

agent, an anti-parkinson agent, an anti-malarial agent, an anticonvulsant agent, an anti-depressant agent, an antiarthritics agent, an anti-fungal agent, an antihypertensive agent, antipyretic agent, an anti-parasite agent, an antihistamine agent, an alpha-adrenargic agonist agent, an alpha blocker agent, an anesthetic agent, a bronchi dilator agent, a biocide agent, a bactericide agent, a bacteriostat agent, a betadrenergic blocker agent, a calcium channel blocker agent, a cardiovascular drug agent, a contraceptive agent, a decongestant agent, a diuretic agent, a depressant agent, a diagnostic agent, an electrolyte agent, a hypnotic agent, a hormone agent, a hyperglycemic agent, a muscle relaxant agent, a muscle contractant agent, an ophthalmic agent, a parasympathomimetic agent, a psychic energizer agent, a sedative agent, a sympathomimetic agent, a tranquilizer agent, a urinary agent, a vaginal agent, a viricide agent, a vitamin agent, a non-steroidal anti-inflammatory agent, an angiotensin converting enzyme inhibitor agent, an alcohol and a sleep inducer.

For example, the therapeutic can be a polypeptide, such as an enzyme, a hormone, a coagulation or clotting factor, a cytokine, a growth factor or active portion thereof, an antibody or antigen binding portions of antibodies, an angiogenesis modulator, an immunomodulator, a pain modulator, a receptor or active portion thereof, a transport protein, a regulatory protein, an antigen and an allergen.

In another example, the therapeutic can be a nucleic acid molecule for gene therapy, wherein the nucleic acid molecule encodes a polypeptide. The encoded polypeptide can include an enzyme, a hormone, a coagulation or clotting factor, a cytokine, a growth factor or active portion thereof, an antibody or antigen binding portions of antibodies, an angiogenesis modulator, an immunomodulator, a pain modulator, a receptor or active portion thereof, a transport protein, a regulatory protein, an antigen or an allergen. In a particular example, the polypeptides encoded can include adenosine deaminase, cystic fibrosis transmembrane conductance regulator (CTFR), galsulfase, laronidase, N-acetylgalactosamine 6-sulfatase, phenylalanine ammonia lyase, acid alpha glucosidase, imiglucerase, alglucosidase alpha, thyrotropin, growth hormone, insulin, thyroid hormone, erythropoietin (EPO), interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-7, interferon- α (IFN- α), IFN- β , IFN- γ , tumor necrosis factor (TNF), IL-12, IL-18, Fms-Related Tyrosine Kinase 3 (flt3), neuropilin-2 (NP2), bone morphogenic protein (BMPs), epidermal growth factor

- 89 -

(EGF), erythropoietin (EPO), fibroblast growth factor (FGF), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), platelet derived growth factor (PDGF), transforming growth factor α or β , vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), FGFR antagonist (sFGFR) transforming growth factor receptor (TGFR), vascular endothelial growth factor receptor (VEGFR), plasminogen activator, urokinase, Factor VIII, Factor IX, von Willebrand factor, growth hormone, metalloproteinase thrombospondin motifs 1 (METH-1), METH -2, tryptophanyl-tRNA synthetase (TrpRS) fragments, proliferin-related protein, prolactin fragment, pigment epithelium-derived factor (PEDF), vasostatin, angiostatin, endostatin, kininostatin, fibrinogen-E fragment, thrombospondin, tumstatin, canstatin, restin, soluble fms-like tyrosine kinase-1 (sFlt-1), soluble vascular endothelial growth factor receptors (sFlk), soluble Neuropilin 1 (sNRP1), Interferon gamma-induced protein 10 (IP-10), Platelet factor 4 (PF-4), Gro-beta, soluble Ephrin type-B receptor 4 (sEphB4), sEphrinB2, IGF-1, herpes simplex virus thymidine kinase (HSV-TK), carboxypeptidase G2 (CPG2), carboxylesterase (CA), cytosine deaminase (CD), cytochrome P450 (cyt-450), deoxycytidine kinase (dCK), nitroreductase (NR), purine nucleoside phosphorylase (PNP), thymidine phosphorylase (TP), varicella zoster virus thymidine kinase (VZV-TK), xanthine-guanine phosphoribosyl transferase (XGPRT), Aspartylglucosaminidase, α -Galactosidase A, Palmitoyl Protein Thioesterase, Tripeptidyl Peptidase, Lysosomal transmembrane protein, cysteine transporter, Acid ceramidase, acid α -L-fucosidase, protective protein/cathepsin A, acid β -glucosidase or glucocerebrosidase, acid β -galactosidase, iduronate-2-sulfatase, α -L-Iduronidase, galactocerebrosidase, acid α -mannosidase, acid β -mannosidase, arylsulfatase B, arylsulfatase A, N-Acetylgalactosamine-6-sulfate sulfatase, N-Acetylglucosamine-1-phosphotransferase, Acid sphingomyelinase, Niemann-Pick disease, type C1 (NPC-1), β -Hexosaminidase B, Heparan N-sulfatase, α -N-Acetylglucosaminidase (NaGlu), Acetyl-CoA: α glucosaminide N-acetyltransferase, N-Acetylglucosamine-6-sulfate sulfatase, β -Glucuronidase, acid lipase, neprilysin, the insulin-degrading enzyme insulysin, thimet oligopeptidase, calbindin D28, parvalbumin, hypoxia induced factor 1-alpha (HIF1-alpha), sirtuin-2 (SIRT-2),

- 90 -

survival motor neuron protein-1 (SMN-1), SMN-2, glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNF), low density lipoprotein receptor (LDLR), lipoprotein lipase (LPL), Alpha-1-Antitrypsin (AAT), UDP-glucuronyl-transferase (UGT), UGT1A1, glucose-6 phosphatase, phosphoenolpyruvate-
5 carboxykinase, galactose-1 phosphate uridyl transferase, phenylalanine hydroxylase, branched chain alpha-ketoacid dehydrogenase, fumarylacetoacetate hydrolase, methylmalonyl-CoA mutase, ornithine transcarbamylase, argininosuccinic acid synthetase, adenosine deaminase, hyposanthine guanine phosphoribosyl transferase, biotinidase, beta-glucocerebrosidase, beta-glucuronidase, porphobilinogen deaminase
10 (PBGD) and p53.

For example, diseases or conditions for which the injection device provided herein can be used include any in which treatment is effected by increasing or decreasing the activity of a specific protein or other cellular targets, decreasing or increasing expression of a gene associated with the condition, decreasing or
15 increasing the activity of a gene product associated with the condition or otherwise countering the alteration associated with the condition (*e.g.* signs, symptoms or effects associated with the disease or condition), by direct delivery of the therapeutic to a target organ. For example, nonspecific or targeted chemotherapeutic agents can be delivered directly and specifically to the parenchyma of a solid tumor to kill
20 rapidly dividing cells. The diseases or conditions for which the injection device provided can be used for include an arthritis, chronic pain, HIV-related AIDS, atherosclerosis, restenosis, inherited enzyme deficiency, inherited immune deficiency, cancer, a retrovirus infection, hemophilia, diabetes, a muscular dystrophy, a cardiovascular disorder, cystic fibrosis, a neurodegenerative disorder, trauma, pain,
25 sickle cell anemia, autoimmune disease, inflammatory disease, and hypertension.

In another example, the device can be used to deliver fluids that include gene therapy agents, such as nucleic acids, vectors or viruses. Gene therapy can be used to treat diseases or conditions associated with genetic deficiencies, including monogenic diseases, (*e.g.* hemophilia A and B, type I diabetes mellitus, alpha-1-antitrypsin
30 (AAT), cystic fibrosis, muscular dystrophy and numerous others) or can be used to treat diseases or conditions by encoding a therapeutic protein associated with ameliorating the disease or condition (*e.g.* cancers).

- 91 -

The injection device provided herein can be used in methods to inject a wide variety of fluids in medical applications. The delivered fluid, and the therapeutic agent therein, is selected based on the disorder or disease to be addressed, and the particular organ affected. As described elsewhere herein, one of skill in the art can
5 determine the type of therapeutic agent depending on the particular disease or disorder that is being treated. As further exemplification, the injection device can be used to deliver anti-angiogenesis agents, such as angiostatin or endostatin for the treatment of cancer, insulin for the treatment of diabetes mellitus, soluble tumor necrosis factor (TNF) receptor for the treatment of rheumatoid arthritis, angiostatin for the treatment
10 of renal failure, anti-human immunodeficiency virus (HIV) agents for the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS), ethanol for the treatment of papillary thyroid carcinoma (PTC), and Factor VIII or Factor IX for hemophilia. The therapeutic agents can also be in the form of nucleic acids that encode a protein required to ameliorate the disease symptoms or treat the disease. In
15 other examples, the injection device can be used to deliver a nucleic acid encoding a Factor VIII for the treatment of hemophilia A; a Factor IX for the treatment of hemophilia B; an insulin gene for treatment of type I diabetes mellitus; an alpha-1-antitrypsin (AAT) for the treatment of alpha-1-antitrypsin (AAT) deficiency; a hemochromatosis protein (HFE) for treatment of hemochromatosis; a copper-
20 transporting ATPase 2 for treatment of Wilson's disease; UDP glucuronosyltransferase 1A1 (UGT1A1) for the treatment of Crigler-Najjar syndrome type I; ornithine transcarbamylase (OTC) for the treatment of ornithine transcarbamylase deficiency, type II; low density lipoprotein receptor (LDLR) for the treatment of familial hypercholesterolemia; fibrinogen alpha (FGA), beta (FGB) or
25 gamma (FGB) for the treatment of afibrinogenemia; glucose-6-phosphate- α for the treatment of glycogen storage disease (GSD) type Ia; G6PT for the treatment of GSD type Ib; acid- α -glucosidase for the treatment of GSD type II (Pompe); α -L-iduronidase for the treatment of mucopolysaccharidosis (MPSI); sulphamidase for the treatment of MPS IIIA; α -N-acetylglucosaminidase (NaGlu) for the treatment of MPS
30 IIIB; β -glucuronidase for the treatment of MPS VII; α -galactosidase A for the treatment of Fabry disease; glucocerebrosidase for the treatment of Gaucher's disease; acid sphingomyelinase for the treatment of Niemann-Pick syndrome; phenylalanine

- 92 -

hydroxylase for the treatment of phenylketonuria; TIMP antagonist or anti-HSC molecules for the treatment of liver fibrosis; anti-ROS molecules for the treatment of liver ischemia reperfusion injury; amyloid-beta degrading enzyme neprilysin, the insulin-degrading enzyme insulysin, or thimet oligopeptidase for the treatment of

5 Alzheimer's disease; insulin growth factor-1 (IGF-1), calbindin D28, parvalbumin, HIF1-alpha, SIRT-2, VEGF, SMN-1, SMN-2, GDNF or ciliary neurotrophic factor (CNF) for the treatment of Amyotrophic Lateral Sclerosis (ALS); galactose-1 phosphate uridyl transferase for the treatment of galactosemia; branched chain alpha-ketoacid dehydrogenase for the treatment of maple syrup urine disease;

10 fumarylacetoacetate hydrolase for the treatment of tyrosinemia type 1; methylmalonyl-CoA mutase for the treatment of methylmalonic acidemia; argininosuccinic acid synthetase for the treatment of citrullinemia; hyposanthine guanine phosphoribosyl transferase for the treatment of Gout and Lesch Nyan syndrome; beta-glucuronidase for the treatment of Sly syndrome; peroxisome

15 membrane protein 70 kDa for the treatment of Zellweger syndrome, enfuvirtide for the treatment of Human immunodeficiency virus (HIV) infection; adenosine deaminase (ADA) for the treatment of combined immunodeficiency disease (SCID); cystic fibrosis transmembrane conductance regulator (CFTR) for the treatment of cystic fibrosis; porphobilinogen deaminase (PBDG) for the treatment of acute

20 intermittent porphyria; interferon-beta for the treatment of multiple sclerosis; lipoprotein lipase for the treatment of lipoprotein lipase deficiency (LPLD), p53 for the treatment of cancer; glutamic acid decarboxylase (GAD) for the treatment of Parkinson's Disease; neuropilin-2 (NP2) for treatment of pain; a nucleic acid encoding an angiogenesis inhibitor or tumor suppressor for the treatment of cancer;

25 and a nucleic acid encoding an insulin or exendin-4 for treatment of diabetes.

Further, it is known to one of skill in the art the particular target tissue or organ for direct injection of the fluid based on the disease or disorder to be treated, and the particular delivered therapeutic agent that is administered. In some cases, the delivered fluid such as a therapeutic does not exhibit specific tissue targeting when

30 systemically administered, and thus is delivered directly to the affected target site, such as a tissue or an organ.

- 93 -

For specific target tissues or organs for delivery of fluids, such as a therapeutic, the lung is an important target organ for direct injection of therapeutics to treat or ameliorate many acute and chronic diseases, including cancer, asthma, cystic fibrosis, alpha-1-antitrypsin deficiency and respiratory distress syndrome, among
 5 others. The muscle is a target organ for direct injection of therapeutics for treatment of muscular or motor disorders like muscular dystrophy or charcot-Marie-Tooth (CMT) disease. The brain is an important target organ for direct injection of therapeutics of motor neuron diseases (*e.g.* spinal muscular atrophy (AMA), amyotrophic lateral sclerosis (ALS), X-linked adrenoleukodystrophy (ALD)),
 10 Parkinson's Disease, or diseases and conditions associated with a missing or defective gene, including metabolic or lysosomal disorders such as Sanfilippo (mucopolysaccharidosis type III; MPSIII) or Canavan disease. The skin is a target organ for direct injection of therapeutics for chronic wounds, hypertrophic scars, keloids, cancer, genetic diseases and systemic diseases. The liver is a target organ for
 15 direct injection of therapeutics of numerous liver diseases and disorders including, but not limited to, hemochromatosis, hemophilia A and B, alpha 1 antitrypsin deficiency, Wilson's disease, Crigler-Najjar syndrome type I, ornithine transcarbamylase deficiency, type IIa familial hypercholesterolemia, afibrinogenemia, lysosomal storage diseases, glycogen storage diseases, phenylketonuria, Tay-Sachs disease,
 20 induced hepatitis.

This list is not intended to be limiting, as any disease or condition that can be addressed with a therapeutic agent that is directly and specifically delivered to a target injection site could be addressed. Exemplary methods of treating various diseases and conditions are described below.

25 D. EXAMPLES

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Example 1

Construction of Syringe Injection Device

30 A syringe injection device **60** of the type depicted in FIGS. 1A, 1B, 5, 8A-B and 9A-D and as described in the detailed description was constructed. The device contains a plunger **92** and syringe barrel **91**, a needle sheath controller **71**, a needle

- 94 -

sheath **72**, and an injection needle **81**. The device was configured so that a standard 1 cc syringe barrel **91** containing plunger **92**, but without needle, is able to be separately attached to needle sheath controller **71**. To permit laparoscopic access to a portion of the liver, the diameter of the needle sheath **72** was 5 mm and the length of the needle sheath **72** was 300 mm (see e.g. FIG. 1A showing syringe barrel removed from needle sheath controller, position **900a**, and FIG. 1B showing syringe barrel attached to needle sheath controller, position **900b**).

As constructed, when the syringe barrel **91** is connected to the needle sheath controller **71**, the injection needle **81** is connected to syringe barrel **91** via an injection tube **83**. The injection needle was a standard 27 gauge of 10 mm in length and was connected directly to a 27 gauge injection tube **83**. The injection tube **83** and injection needle **81** were made of stainless steel. The injection tube **83** contained a needle hub **84** at proximal end, and the injection tube **83** and needle hub **84** were directly affixed to needle sheath controller **71** at the proximal end of the inside of the needle sheath controller **71** (see e.g. FIG. 1A and 1B).

A standard 1 cc insulin syringe containing a syringe barrel **91** and plunger **92**, but without a needle, was filled with 0.7 mL solution and purged. The syringe was attached to the proximal end of the needle hub **84** outside of the needle sheath controller **71** using a Luer fit adaptor **93** (see FIG. 1A and 1B). The injection needle **81** was sheathed and locked by sliding the positioner **711** forward.

Example 2

Compartmentalized Transduction of The Liver in a Laparoscopic Simulator

A clamp device and the injection device **60** described in Example 1 were utilized in a laparoscopic simulator by a skilled surgeon/physician to effect clamping of a portion of the left median lobe of a liver to compartmentalize the region for delivery of an injectable solution. The laparoscopic simulator (*Lapa-Pro, Mexico*) was positioned at a 35° to 45° angle inclination to simulate the Semi-Fowlers position of a subject. The Semi-Fowlers position facilitates the access to the distal portion of the left lobe of the human liver using gravity to distally displace the abdominal organs. With respect to a subject, the entry ports of the simulator were positioned as

- 95 -

follows: one entry port in the epigastric abdominal region; one entry port in the umbilical abdominal region; and two entry ports in the left lumbar abdominal region.

A freshly obtained cadaveric pig liver was positioned inside the laparoscopic simulator. The laparoscope was inserted through the umbilical entry port. A
5 laparoscopic clamp was inserted through the epigastric entry port and was used to clamp a 5 cm portion of the distal portion of the left median lobe of the cadaveric pig liver.

A standard 1 cc insulin syringe was filled with 0.7 mL tap water solution and purged. The filled syringe containing a syringe barrel **91** and plunger **92** was attached
10 to a needle hub **84** on the proximal end of the needle sheath controller **71** as depicted in **FIG. 1B**. The positioner **711** on the needle sheath controller **71** was slid backward to unlock the positioner **711** and to unsheathe the injection needle **81**. The entire syringe injection device was purged by pressing the plunger until fluid was observed at the tip of the needle (approximately 200 μ L). The positioner **711** on the needle
15 sheath controller **71** was then slid forward to lock the positioner **711** in the forward position **711a** and to sheathe the injection needle **81**. The injection device with the needle sheathed was introduced into the simulator through the proximal left lumbar entry port. Using the laparoscope monitor, the tip of the injection device was positioned close to the site of injection. The injection needle **81** on the injection
20 device was unsheathed by sliding the positioner **711** backward and locking the positioner in the rearward position **711c**. The tip of the injection needle **81** was introduced into the parenchymal tissue making sure that it did not go through the tissue. Once the tip of the injection needle **81** was carefully positioned inside the parenchyma, the plunger **92** was pressed until 500 μ L of fluid was injected.

25 The positioner **711** on the needle sheath controller **71** was slid forward to lock the positioner **711** in the forward position **711a** and to sheathe the needle. The injection device **60** was removed from the simulator. The clamp also was released from the liver. Once released, the procedure was over, and the clamp also was removed from the simulator.

30

Since modifications will be apparent to those of skill in the art, it is intended that this invention be limited only by the scope of the appended claims.

51205-159

- 96 -

CLAIMS:

1. An injection device, comprising:

a) a syringe barrel, wherein the syringe barrel provides a fluid reservoir;

5 b) a plunger configured to be controlled by the operator of the device and to move within the syringe barrel for loading and releasing fluid from the fluid reservoir in the syringe barrel;

10 c) an injection needle that is fixed and operably coupled to the syringe barrel providing a fluid pathway for fluid contained in the syringe barrel to be injected into a target tissue when the plunger is depressed, wherein extraction or retraction of the needle is independent of movement of the plunger;

d) an elongate sheath, comprising an internal lumen that contains the injection needle and having a distal tip that contains an opening for the injection needle, wherein:

the sheath is movable around the injection needle; and

control of the sheath is independent from movement of the plunger; and

15 e) a controller for positioning the sheath, comprising:

a housing, comprising at least a first and second stop to control exposure of the injection needle and that are provided within the housing at a predetermined distance from each other, wherein the stops can be locked;

20 a central lumen in the housing comprising a connection member, wherein the connection member is configured to be movable in the central lumen in the housing and is coupled to the sheath, wherein the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath; and

25 a positioner mounted within the housing configured to move forward towards the distal end of the controller and rearward towards the proximal end of the

51205-159

- 97 -

controller, between the stops in the housing, wherein the positioner is operatively connected to the connection member to guide movement of the connection member in the same direction, whereby movement of the positioner forward towards the distal end engages the first stop and moves the sheath to enclose the injection needle inside the lumen of the sheath, and
 5 movement of the positioner rearward towards the proximal end engages the second stop and moves the sheath to expose no more than a predetermined length of the distal tip of the injection needle through the opening in the injection needle for injection into the tissue.

2. The injection device of claim 1, wherein the elongate sheath is of a sufficient length and width to reach an organ through an endoscopic port.

10 3. The injection device of claim 1 or claim 2, wherein the elongate sheath has a length from its proximal to distal end of from or from about 200 mm to 600 mm and a diameter of from or from about 2 mm to 15 mm.

4. The injection device of any one of claims 1-3, wherein the elongate sheath has a length from its proximal to distal end of from or from about 250 mm to 400 mm and a
 15 diameter of from 4 mm to 12 mm.

5. The injection device of any one of claims 1-4, wherein the elongate sheath has a length from its proximal to distal end of at least or about at least 300 mm and a diameter of at least or about at least 5 mm, 6 mm, 7 mm, 8 mm, 9 mm or 10 mm.

6. The injection device of any one of claims 1-5, wherein the predetermined
 20 length of the distal tip of the injection needle that is exposed is 1 mm to 10 mm, 2 mm to 8 mm, 4 mm to 6 mm or 2 mm to 3 mm.

7. The injection device of any one of claims 1-6, wherein the predetermined length of the distal tip of the injection needle that is exposed is less than 10 mm.

8. The injection device of any one of claims 1-7, wherein the predetermined
 25 length is less than 5 mm.

51205-159

- 98 -

9. The injection device of any one of claims 1-8, comprising at least 3 stops, 4 stops or 5 stops, wherein:

the second stop is the most proximal stop and the first stop is the most distal stop and the other stop or stops are positioned between the first stop and the second stop; and

5 each stop is positioned at a predetermined distance from adjacent stop or stops to control exposure of the needle to different predetermined lengths, wherein the second stop controls exposure of the needle its longest predetermined length, whereby the positioner can move between the adjacent stops to engage with the stop to expose different predetermined lengths of the injection needle.

10 10. The injection device of any one of claims 1-9, wherein the predetermined distance between stops is substantially the same as the predetermined length of the exposed injection needle.

11. The injection device of any one of claims 1-10, wherein the positioner comprises a lock and release element that is configured in the positioner to engage the
15 positioner with the stops.

12. The injection device of claim 11, wherein the lock and release element is a spring that provides an upward force against the positioner and a downward force against the connection member to lock the positioner into the stop, and is capable of being compressed to release the positioner from the stop.

20 13. The injection device of any one of claims 1-12, wherein the injection needle is 5 mm to 40 mm in length.

14. The injection device of any one of claims 1-13, wherein the syringe barrel is proximal or distal to the controller.

15. The injection device of any one of claims 1-14, wherein the syringe barrel is
25 proximal to the controller and is operably coupled to the injection needle by an injection tube, wherein:

51205-159

- 99 -

the injection tube comprises a proximal and a distal end, the proximal end connected to the syringe barrel and the distal end connected to the injection needle; and

the controller is configured to hold the injection tube and comprises an opening at the proximal end so that the injection tube is operably connected to the syringe barrel.

5 16. The injection device of claim 7, wherein the syringe barrel is configured to be connected to the injection tube so that the syringe barrel is detachable from the device.

17. The injection device of claim 7 or claim 8, wherein the injection tube comprises a hub on its proximal end that is compatible with an adaptor on the distal end of the syringe barrel and the hub of the injection tube connects to the adaptor of the syringe barrel.

10 18. The injection device of any one of claims 7-17, wherein:

the injection tube is fixed in the controller;

the connection member in the controller comprises a recess by which the injection tube is routed to pass from the controller into the sheath at the junction where the connection member is coupled to the sheath; and

15 the connection member is movable around the injection tube.

19. The injection device of any one of claims 7-18, wherein the injection tube is connected directly to the injection needle.

20. The injection device of any one of claims 7-18, wherein the injection tube is connected indirectly to the injection needle via a coupler, the coupler having a proximal and
20 distal end, the proximal end connected to the distal end of the injection tube and the distal end connected to the proximal end of the injection needle.

21. The injection device of any one of claims 7-20, wherein the injection tube and injection needle are the same gauge or different gauges.

22. The injection device of any one of claims 1-21, further comprising an injection
25 tube by which the injection needle is operably coupled to the syringe barrel, wherein:

51205-159

- 100 -

the injection tube comprises a proximal and a distal end, the proximal end connected to the syringe barrel and the distal end directly or indirectly connected to the injection needle;

5 the injection needle is 25 gauge or less or is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm; and

the injection tube has a larger diameter than the injection needle, wherein the injection needle is connected to the syringe barrel;

the controller is distal to the syringe barrel and plunger and comprises:

10 a cavity for the injection tube and an opening at the proximal end so that the injection tube extends out of the controller to connect to the syringe barrel, wherein the injection tube is fixed in the controller; and

a central lumen in the housing comprising a connection member,

wherein:

15 the connection member in the controller comprises a recess by which the injection tube is routed to pass from the controller into the distal lumen of the sheath at the junction where the connection member is coupled to the sheath; and

20 the connection member is configured to be movable in the central lumen in the housing around the injection tube and is coupled to the sheath, wherein the proximal end of the sheath is coupled to the distal end of the connection member so that movement of the connection member controls movement of the sheath.

23. The injection device of any one of claims 7-22, wherein the total length of the injection tube and injection needle is as long as the controller and sheath.

24. The injection device of any one of claims 1-6, wherein:

51205-159

- 101 -

the syringe barrel is positioned distal to the controller and the internal lumen of the sheath comprises the syringe barrel in its distal end; and

the syringe barrel is configured in the lumen so that the sheath is movable around the syringe barrel.

5 25. The injection device of claim 24, wherein:

the open cavity of the sheath comprises a lining that is configured in the sheath so that the sheath is movable around the lining; and

the syringe barrel is mounted into the lining in the open cavity.

10 26. The injection device of claim 25, wherein the open cavity extends the length of the sheath.

27. The injection device of any one of claims 24-26, wherein the plunger is operably connected to the syringe barrel in the distal end of the lumen of the sheath and arranged so that the plunger is movable through the controller and within the lumen of the sheath.

15 28. The injection device of any one of claims 24-27, wherein:

the plunger is operably connected to the syringe barrel by an auxiliary plunger provided in the lumen of the sheath; and

20 the plunger is adapted to couple with the auxiliary plunger in the lumen of the sheath and arranged so that the plunger is movable through the controller and sheath and the auxiliary plunger is movable through the sheath and configured to move within the syringe barrel, whereby depressing the plunger depresses the auxiliary plunger into the syringe barrel releasing fluid from the fluid reservoir in the syringe barrel and pulling back on the plunger pulls back on the auxiliary plunger to load fluid into the fluid reservoir in the syringe barrel.

29. The injection device of claim 28, wherein:

25 the sheath comprises an open cavity comprising a detachable syringe; and

51205-159

- 102 -

the detachable syringe comprises the syringe barrel, the auxiliary plunger having a distal end configured to be movable in the syringe barrel and a proximal end coupled to the plunger, and the injection needle that is operably coupled to the syringe.

30. The injection device of any one of claims 24-29, wherein the controller is
5 configured to hold the plunger so that the plunger is movable within the controller, the controller comprising:

an opening at its proximal end to receive the plunger; and

a recess in the connection member of the controller by which the plunger is
routed to pass from the controller into the lumen of the sheath at the junction where the
10 connection member is coupled to the sheath, wherein the plunger and connection member
move independently with respect to each other.

31. The injection device of any one of claims 24-29, further comprising:

an auxiliary plunger attached to the plunger to form an extended plunger
configured to be controlled by the operator of the device to move within the syringe barrel for
15 loading and releasing fluid from the fluid reservoir in the syringe barrel, whereby depressing
the plunger depresses the auxiliary plunger into the syringe barrel releasing fluid from the
fluid reservoir in the syringe barrel and pulling back on the plunger pulls back on the auxiliary
plunger to load fluid into the fluid reservoir in the syringe barrel;

an opening at the proximal end of the controller to receive the plunger and
20 comprising a cavity configured to hold the plunger so that the plunger is movable within the
controller; and

a recess in the connection member by which the plunger is routed to pass from
the controller into the distal lumen of the sheath at the junction where the connection member
is coupled to the sheath, wherein the plunger and connection member move independently
25 with respect to each other;

wherein:

51205-159

- 103 -

the injection needle is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm; and

the elongate sheath comprises an internal lumen that contains the plunger, the auxiliary plunger, the syringe barrel and the injection needle and having a distal tip that
5 contains an opening for the injection needle, wherein:

the sheath is enclosed at its proximal end and provides a conduit for the plunger, wherein the plunger is movable through the sheath;

the sheath comprises an open cavity at the distal end, the open cavity comprising the auxiliary plunger, syringe barrel and injection needle, wherein:

10 the open cavity of the sheath comprises a lining that is configured in the sheath so that the sheath is movable around the lining;

the auxiliary plunger, syringe barrel and injection needle are mounted into the lining in the open cavity; and

15 the auxiliary plunger, syringe barrel and injection needle are detachable as a unit from the open cavity; and

the sheath is movable around the plunger, auxiliary plunger, syringe barrel and injection needle.

32. The injection device of any one of claims 24-31, wherein:

20 the injection needle is 25 gauge to 34 gauge and has a length in the range from 5 mm to 40 mm;

the elongate sheath comprises an internal lumen that contains the plunger, the syringe barrel and the injection needle and has a distal tip that contains an opening for the injection needle;

25 the sheath is enclosed to provide a conduit for the plunger, wherein the plunger is movable through the sheath;

51205-159

- 104 -

the sheath comprises a window to view the syringe barrel;

the sheath is movable around the plunger, syringe barrel and injection needle;

the controller comprises an opening at its proximal end to receive the plunger and comprises a cavity configured to hold the plunger so that the plunger is movable within
5 the controller; and

the connection member comprises a recess by which the plunger is routed to pass from the controller into the distal lumen of the sheath at the junction where the connection member is coupled to the sheath, wherein the plunger and connection member move independently with respect to each other.

10 33. Use of an injection device of any one of claims 1-32 for delivering a therapeutic to the parenchyma of an organ or tissue for treatment of a disease.

34. The use according to claim 33, wherein the therapeutic is a nucleic acid.

35. Use of an injection device of any one of claims 1-32 for delivering a therapeutic to an organ or tissue during a surgery.

15 36. The use according to claim 35, wherein the surgery is minimally invasive surgery.


37. The use according to claim 35 or 36, wherein:


the therapeutic is a nucleic acid; and

the surgery effects delivery of the nucleic acid for gene therapy.

20 38. The injection device of any one of claims 1-32, comprising a therapeutic agent.

39. The injection device of claim 38, wherein the therapeutic is a biologic, chemotherapeutic or gene therapy agent.









FIG. 2

**FIG. 3**




FIG. 4A




FIG. 4B




FIG. 4C

6/16





FIG. 5



8/16






FIG. 7

9/16



10/16




FIG. 9A

FIG. 9B




FIG. 9C

FIG. 9D




FIG. 10A




FIG. 10B

12/16




FIG. 10C




FIG. 10D




FIG. 11A

14/16




FIG. 11B




FIG. 11C




FIG. 11D

